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Most  inﬂuenza  vaccines  are  generally  safe,  but inﬂuenza  vaccines  can  cause  rare  serious  adverse  events.
Some  adverse  events,  such  as fever  and  febrile  seizures,  are  more  common  in children  than  adults.  There
can  be  differences  in the  safety  of vaccines  in  different  populations  due  to underlying  differences  in
genetic  predisposition  to  the  adverse  event.  Live  attenuated  vaccines  have  not  been  studied  adequately
in  children  under  2 years  of age  to determine  the  risks  of  adverse  events;  more  studies  are  needed  to
address  this  and  several  other  priority  safety  issues  with  all inﬂuenza  vaccines  in  children.  All  vaccines
intended  for  use  in  children  require  safety  testing  in the  target  age  group,  especially  in  young  children.
Safety  of one  inﬂuenza  vaccine  in  children  should  not  be extrapolated  to  assumed  safety  of  all  inﬂuenza
vaccines  in  children.  The  low  rates  of adverse  events  from  inﬂuenza  vaccines  should  not be a  deterrent
to  the  use  of  inﬂuenza  vaccines  because  of the  overwhelming  evidence  of the  burden  of  disease  due  tonﬂammatory arthritis
uillain-Barre syndrome
inﬂuenza  in children.
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. Executive summary
Vaccines to prevent inﬂuenza have been administered to
undreds of millions of individuals throughout the world during
he past 70 years and use of inﬂuenza vaccines is increasing in many
reas. The purpose of this review is to summarize the available
ublished English-language literature on the safety of inﬂuenza
accines in children to assist decision-making regarding recom-
endations for use of these vaccines in children. The review does
ot include information regarding the burden of disease, vaccine
ffectiveness, cost, cost-effectiveness, supply, delivery and other
actors that are included in decision-making regarding the use of
accines. Inﬂuenza results in severe disease including pneumonia
nd other complications, hospitalization, and mortality in all age
roups. Children, especially young children, are at increased risk of
omplications. The beneﬁts from inﬂuenza vaccines, including pre-
ention of the enormous burden of inﬂuenza disease, far outweigh
he risks of adverse events summarized in this review.
Our literature searches identiﬁed 15,878 published articles
bout inﬂuenza vaccine safety for screening; 6001 were found to
ave information of potential value in the assessment of causal rela-
ionships between inﬂuenza vaccines and adverse events. For many
f the adverse events reviewed, case reports based only on tempo-
al associations have not provided valuable information regarding
ausal assessments and only a few are referenced in this review
o illustrate speciﬁc points. Data from controlled clinical trials,
opulation-based epidemiologic studies, and studies that provide
bjective data on biologic mechanistic evidence have been selec-
ively included because these studies provided stronger evidence
han temporal associations only in case reports, case series, or
eports from passive surveillance of adverse events.
We identiﬁed 108 inﬂuenza vaccines with unique names pro-
uced in the past decade in 27 countries by 47 manufacturers
Appendix 3). Some of these vaccines may  be the same prod-
cts marketed under different names, but we were unable to
dentify duplicates from the published literature and other online
ources. Types of inﬂuenza vaccines recently produced include live
nd inactivated, monovalent, bivalent, trivalent, or quadrivalent
reparations, whole virion, split-virus (with or without adjuvants),
urface antigen, and virosomal. Inﬂuenza vaccines based on new
roduction methods may  result in different safety proﬁles. Caution
s needed when drawing general conclusions about all inﬂuenza
accines based on studies of only one or a few vaccines because
here have been differences in the safety proﬁles of the many dif-
erent vaccine available.
Inﬂuenza vaccines produced in recent years in Europe and North
merica are much safer for children than vaccines produced 30–40
ears ago due to improvements in production methods. Some
nexpected adverse events causally associated with inactivated
nﬂuenza vaccines have been attributed to differences in pro-
uction methods; for examples, see sections on febrile seizures,
culorespiratory syndrome, and narcolepsy. Some past safety prob-
ems could be repeated and/or new safety problems could occur
s new manufacturers undertake the preparation of inﬂuenza
accines. This review does not include a systematic review of dif-
erences in vaccine production methods.
In 2003, the Global Advisory Committee on Vaccine Safety
GACVS) recognized the need for robust post-licensure vaccine
afety monitoring in all countries. Experiences with inﬂuenza
accines reinforce this need as important differences in vaccine
afety have been observed in different countries. Given the limited
esources to conduct large population-based studies of vaccine
afety in many countries, there is a need for enhanced global
accine safety monitoring and cooperation between countries by
haring data in a timely manner to address safety questions. In
013, GACVS published a manual for review of individual reports 33 (2015) F1–F67
of adverse events, but only brieﬂy mentioned criteria for assessing
general causality on a population basis. Comprehensive review and
detailed criteria for general causality assessment is needed on a
population level. More effort is needed to deﬁne what evidence
is sufﬁcient to conclude that there is no increased risk of adverse
events associated with vaccines, and the precise language used to
report causality conclusions to avoid misunderstandings should
be reﬁned. Revised criteria for assessing general causality are pro-
posed in this white paper (see Section 3.2).
Most inﬂuenza vaccines are very safe and the great majority
of individuals receiving these vaccines have minimal side effects
that are generally mild and self-limited. The most common adverse
events reported after injectable inactivated inﬂuenza vaccines are
local reactions and/or mild systemic reactions. Rare instances of
large local reactions that resemble cellulitis occur for unexplained
reasons. Most adjuvants are associated with increased rates of local
reactions and some may  be associated with increased rates of fever
and other systemic reactions.
Fever was  very common in young children following whole-
virus inﬂuenza vaccines produced several decades ago, and febrile
seizures occurred at unacceptable rates. Adverse events with these
vaccines were dose related. Information on rates of fever and febrile
seizures in young children is limited to only a few of the many mod-
ern vaccines that have been recently produced. Improvements in
vaccine production methods have resulted in some split-virus vac-
cines that induce little or no fever when administered alone. Some
currently available split-virus or virosomal vaccines are associated
with minimal or no increased rates of adverse events at full adult
doses as compared to half-doses in children 6–35 months of age.
Simultaneous administration of one inﬂuenza vaccine (Fluzone)
with pneumococcal conjugate (and possibly DTaP) has resulted
in increased rates of fever and febrile seizures. Additional studies
are needed with other vaccine preparations. One  inactivated split-
virus inﬂuenza vaccine produced in Australia resulted in unusually
high rates of fever and febrile seizures in 2010 and is no longer
recommended for use in young children in several countries, but
this vaccine is in use for older children and adults. Differences in
the methods used for viral disruption and changes in viral strains
selected for vaccine production resulted in viral particles that
appear to have caused the high rates of fever and febrile seizures.
This experience indicates the need for continued monitoring of
vaccine safety in children even when no substantial changes in
manufacturing process are introduced as well as a careful review of
production methods for all inﬂuenza vaccines that might be used
in children.
Modern whole-virus vaccines are generally more immunogenic
than equivalent doses of split-virus vaccines and appear to be well
tolerated by adults. In the small numbers of children studied, the
adverse event rates are higher following whole-virus vaccines than
with split-virus vaccines. Larger trials of inactivated whole-virus
vaccines need to be performed in children to better deﬁne the risks
of fever, febrile seizures and other severe adverse events.
Hypersensitivity, or allergic reactions, occur following both live
and inactivated inﬂuenza vaccines; anaphylaxis occurs at a rate
of approximately one per million doses. Milder allergic reactions,
including urticaria and respiratory symptoms, occur more com-
monly. Some allergic reactions have been due to residual egg
protein from the manufacturing process, but there are other aller-
gens in these vaccines that may  be responsible for some allergic
reactions. Changes in manufacturing processes have resulted in
vaccines with only trace amounts of residual egg protein that can be
safely administered to people who have allergy to eggs. Several new
vaccines have been developed that do not use eggs in the manufac-
turing process but allergic reactions have been reported following
these products; at the time of this writing, none have been approved
for use in children. Oculorespiratory syndrome (ORS) is a disorder
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hat resembles allergic reactions, but is not due to an IgE antibody
ediated process. Changes in manufacturing processes to reduce
ggregations of viral proteins have resulted in signiﬁcant decreases
n the risk of ORS.
Inﬂuenza vaccines have been associated with some other seri-
us adverse events. Vaccines produced in 1976 resulted in an
ncreased risk of Guillain-Barré syndrome (GBS) in adults at a rate
f approximately 1 in 100,000. Pandemic 2009 H1N1 vaccines were
ssociated with an increased risk of GBS in adults at a rate of 1–3
er million within the six weeks following immunization. The inci-
ence of GBS increases with age, and there is insufﬁcient evidence
o determine if there is an increased risk of GBS in children follow-
ng any inﬂuenza vaccine.
In 2000–2001, an intranasally administered inactivated
nﬂuenza vaccine containing an Escherichia coli heat-labile toxin
djuvant caused Bell’s palsy, apparently from toxin mediated
ocal inﬂammatory changes. Neither live nor inactivated inﬂuenza
accines recently in use have been shown to cause Bell’s palsy.
Two pandemic 2009–10 H1N1 inﬂuenza vaccines (produced by
he same manufacturer) were associated with increased risks of
arcolepsy in several countries. Underlying genetic predisposition
o narcolepsy explains some of the variability noted in different
ountries. The biologic mechanism for the increased risk has not
een completely determined but differences in vaccine antigens
nd/or the AS03 adjuvant may  partially explain the association.
ther inﬂuenza vaccines did not result in any increased risk of nar-
olepsy. The evidence is unclear regarding the possible increased
isk of narcolepsy following infection with the pandemic H1N1
nﬂuenza virus. Although a possible increase in diagnosed nar-
olepsy was noted in one area of China associated with infection
y the pandemic 2009 H1N1 inﬂuenza virus, other countries have
ot reported any increased risk in spite of widespread infections.
The available evidence does not establish a causal rela-
ionship between inﬂuenza vaccines and acute disseminated
ncephalomyelitis (ADEM) or transverse myelitis, but the available
vidence cannot rule out the possibility of a small increased risk fol-
owing inﬂuenza vaccines. If there is any risk following inﬂuenza
accines, this risk is very low.
Although each epidemiological study of associations between
nﬂuenza vaccines and multiple sclerosis (MS) reported to date has
ad relatively low power to rule out an increased risk, these studies
s a group provide consistent evidence against a causal association
ith MS  onset or relapse and inﬂuenza vaccine in adults. Studies
re more limited in children, due in part to the lower risk of disease,
ut there is no signal to indicate evidence of concern.
There is no increased risk of immune thrombocytopenia (ITP)
r inﬂammatory arthritis associated with inﬂuenza vaccines. How-
ver, incorrect injection of inﬂuenza vaccines too high in the deltoid
uscle can cause acute and chronic bursitis as well as inﬂammation
n the shoulder joint and head of the humerus.
Intranasally administered live attenuated inﬂuenza vaccines
ased on the Ann Arbor parent virus (LAIV) and the Leningrad based
ive vaccine (LAIV-L) produce transient rhinorrhea and congestion.
oth vaccines are associated with a small increase in the risk of
ow-grade fever in young children and a possible increased rate of
igh fever in less than 1% of children. One study indicated that chil-
ren 18–35 months of age in the United States with a past history
f wheezing had an increased risk of wheezing following LAIV, but
 study in Bangladesh with LAIV-L found no increase in wheezing
n children with or without a past history of wheezing. One study
n children under one year of age indicated an increased rate of
heezing in all children following LAIV and a possible increasedate of hospitalization from all causes in the 6 months following
accination. Additional safety data are needed before these live vac-
ines are licensed for use in children younger than 24 months of
ge. 33 (2015) F1–F67 F3
In summary, inﬂuenza vaccines are generally very safe in adults
and several inﬂuenza vaccines have been shown to be very safe
in children, but inﬂuenza vaccines can cause rare serious adverse
events. There are differences in susceptibility to adverse events
by age. Some adverse events, such as fever (and associated febrile
seizures), are more common in children than adults, while other
adverse events occur more commonly in adults. Safety data for chil-
dren in English-language publications are available for only a small
number of the inﬂuenza vaccines that are being produced. Safety
studies including enough participants to detect known or possible
adverse events identiﬁed following other vaccines should be con-
ducted in the age groups of intended users,. There can be differences
in the safety of vaccines in different populations due to underlying
differences in genetic predisposition to the adverse event (Table 1).
2. Introduction
The purpose of this review is to provide information on the
safety of inﬂuenza vaccines administered to children to assist
decision-making regarding immunization of children. The review
does not include information regarding the burden of disease, vac-
cine effectiveness, cost, cost effectiveness, supply, delivery and
other factors that are included in decision-making regarding the
use of vaccines. Inﬂuenza results in severe disease including pneu-
monia and other complications, hospitalization, and mortality in
all age groups. Children, especially young children, are at increased
risk for complications [1]. Inﬂuenza vaccines can prevent much of
the large burden of disease caused by inﬂuenza; the beneﬁts from
vaccination far outweigh the risks of adverse events summarized
in this review.
We have conducted a systematic review of the available English-
language peer-reviewed literature on inﬂuenza vaccine safety
using comprehensive search terms to identify all relevant articles
and objective and reproducible methods to systematically review
these publications. However, new articles are being published daily
and some important publications may  be in non-English language
literature. Also, we do not have access to unpublished informa-
tion that manufacturers or investigators may have generated. We
have attempted to be thorough in our search for information about
inﬂuenza vaccine safety, but any such effort may  miss some arti-
cles. We  have not included all references identiﬁed for all adverse
events studied because the list would be very long. In some reviews,
we have chosen representative articles to illustrate key points or
identify the range of adverse event rates associated with inﬂuenza
vaccines in children. We have not tried to make a comprehensive
list of all theoretical concerns that have been raised. There is insuf-
ﬁcient time and space to review all such concerns and undoubtedly
new ones will rise in the future.
3. Systematic approach to reviews
Adverse events were selected for review if there was  evi-
dence of possible causal relationships with one or more inﬂuenza
vaccines included in guidelines for the use of inﬂuenza vac-
cines, package inserts, reviews by the Institute of Medicine (IOM),
published reviews on inﬂuenza vaccine safety, and a literature
review for vaccine safety and inﬂuenza vaccines. Recently produced
vaccines were identiﬁed from the WHO, the WHO  Prequaliﬁed
Vaccines website (http://www.who.int/immunization standards/
vaccine quality/PQ vaccine list en/en/), searches of websites for
regulatory authorities including the Food and Drug Administration
(FDA), the European Medicines Agency (EMA), and manufacturers
identiﬁed through Google searches. The list of vaccines (Appendix
3) includes information from the WHO  table of pandemic and sea-
sonal inﬂuenza vaccines accessed October 30, 2014, but the WHO
F4 N.A. Halsey et al. / Vaccine 33 (2015) F1–F67
Table 1
Adverse events associated with one or more inﬂuenza vaccines.
Adverse event Age group at risk Estimated riska Vaccines Comment Risk from
natural disease
Local reactions All Very common All IIV Higher rates with
adjuvanted
None
Severe Rare
Shoulder injury/bursitis Primarily adults Very rare All IIV Often due to
incorrect injection
None
Myalgia All Common All Very common
Fever  (Febrile seizures)b Children (0.5–5 yrs) Very common (Rare) Higher rates with
simultaneous PCV
vaccine
Variable rates by
vaccine
Very common
Hypersensitivity (Anaphylaxis) All (All) Rare (∼1/million) All None
Oculorespiratory syndrome All Rare Some IIV Variable rates None
Guillain-Barré syndrome Adults Very rare H1N1 IIV Rates increase with
age
Very rare, but
higher than
from vaccines
Children Uncertain Probable all IIV
Narcolepsy Adults Uncertain Only with 2
vaccinesa
Rates vary by
genetic
predisposition
Uncertain
Children Very rare
Rhinorrhea and Congestion Primarily children Common LAIV only Very common
Wheezing Under 2 yrs Common LAIV only Very common
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aa CIOMS descriptions: Very common >10%; Common (frequent) >1% to <10%; Unc
b More severe/rare forms of AE and rates noted in parenthesis.
able does not include comprehensive information on approved
ges for administration, virus strains or name of the vaccine. When
nformation was found for the same vaccine produced in differ-
nt years, only information for the most recently produced vaccine
as included. Links to package inserts and manufacturers of the
accines were included when was available.
.1. Literature reviews
The search terms for the primary reviews of individual adverse
vents are included in Appendix 1. PubMed and EMBASE databases
ere searched separately for each adverse event category. A third
atabase, Scopus, was searched for GBS and febrile seizures, but was
hen removed from the search protocol due to overlap with EMBASE
esults. Search terms were edited for greater accuracy as we reﬁned
he search process. Within each search, results were ﬁltered to
xclude articles not available in English as well as comments, edi-
orials, letters, news and notes. When appropriate, searches were
urther ﬁltered to exclude articles not pertaining to humans and,
n topics for which there were ample studies, we limited our focus
o children. The numbers of published articles returned for each
earch was recorded and reported in Appendix 2. Publications were
orted by types and separated by review articles, case reports, con-
erence materials and clinical trials to allow for prioritization of data
xtraction. Clinical trials were given highest preference, followed
y epidemiologic studies, and publications in reviews. Case reports
r conference materials were extracted when there was lack of
pidemiologic and/or biological mechanism data. Some individual
ase reports were referenced in some reviews to highlight speciﬁc
ssues and/or to illustrate the logic used by authors for concluding
hat diseases were causally related to one or more inﬂuenza vac-
ines. Studies utilizing inappropriate epidemiological or statistical
ethods were not included. Search results were exported to End-
ote, and duplicate articles were deleted. The remaining articles
ere screened by the primary authors for each section for relevance
nd chosen for data extraction. Additional articles that provided
nsight into biological mechanisms of adverse events were selec-
ively identiﬁed during this screening process. Selective additional
earches were conducted in PubMed to help address speciﬁc ques-
ions that were identiﬁed during the reviews. The search results
re limited to articles available from PubMed or EMBASE as ofon (infrequent) >0.1% to <1%; Rare >0.01% and <0.1%; Very rare <0.01% [11].
September 30 and/or early October 2014 that included search terms
in the title, abstract or index categories. Examples of relevant arti-
cles missed by our Narcolepsy search are ‘Harris 2014’, which had
no abstract or indexing available and did not include “inﬂuenza”
or an equivalent term in the title. Also missed was the European
Centre for Disease Prevention and Control (ECDC) Technical Report
entitled, “Narcolepsy in association with pandemic inﬂuenza vacci-
nation: A multi-country European epidemiological investigation”,
which was available at http://www.ecdc.europa.eu/ but not from
PubMed or EMBASE. As each adverse event section was reviewed,
some additional brief literature reviews were conducted in order
to identify possible pathogenic mechanisms and evidence for bio-
logic plausibility for possible causal associations with inﬂuenza
vaccines. Also, outside expert reviewers provided some supple-
mental information and references, including review articles, and
speciﬁc studies on biological mechanisms that were relevant to the
assessment of causal relationships.
3.2. Assessment of casual associations
For this review, the following criteria have been accepted as evi-
dence of a causal relationship: (1) evidence of an increased risk in
vaccine recipients as compared to controls; or (2) evidence of an
increased risk in biologically plausible time windows as compared
to control windows in self-controlled studies; or (3) local reactions
at the site of the injection when there is no evidence of other pos-
sible causes such as other vaccines administered at the same site
or trauma; or (4) with live attenuated vaccines, evidence of the
vaccine virus or bacterium conﬁrmed by genetic sequencing in the
affected tissue of patients with a serious adverse event can some-
times establish a causal relationship even with a single case report
[3]; or (5) immediate hypersensitivity reactions occurring within
4 h after immunization when there is no evidence of other possible
exposures that could have resulted in a hypersensitivity reaction.
Other illnesses with longer time intervals that can mimic  imme-
diate hypersensitivity reactions require epidemiologic evidence to
support a causal relationship.The WHO  Global Advisory Committee on Vaccine Safety
(GACVS) has published guidelines for assessment of causality
for vaccine safety (http://www.who.int/vaccine safety/initiative/
investigation/New aide mem  causal assmt.pdf?ua=1). In 2013,
accine
G
i
o
f
f
p
i
c
i
c
s
a
a
t
i
t
p
d
p
s
r
u
w
v
c
h
a
a
t
[
i
p
s
w
a
a
d
d
t
e
r
b
a
f
l
t
b
C
M
a
t
r
c
a
m
[
g
s
i
a
p
v
e
provide data on possible causal associations and rates of adverseN.A. Halsey et al. / V
ACVS published a manual with revised guidelines for review of
ndividual adverse events and assessment of causal associations
f these cases [4,5]. The manual includes a brief outline of criteria
or assessing causality on a population basis, but there is a need
or a comprehensive review of the assessment of causality on a
opulation basis and to establish criteria for concluding that there
s no increased risk of speciﬁc adverse events associated with vac-
ines. Robust vaccine safety studies are capable of detecting small
ncreases in risk that do not meet previous strength of association
riteria. Also, the old criteria for speciﬁcity are outdated. Recent
tudies have identiﬁed small increases in risk of adverse events
ssociated with vaccines that are also caused by other factors, such
s febrile seizures and GBS. Self-controlled studies can preclude
he need for comparisons of vaccinated persons with unvaccinated
ndividuals. The investigations of narcolepsy associated with
he AS03-adjuvanted pandemic H1N1 vaccine have shown that
lausibility based upon existing knowledge is not essential for
etermining a true causal relationship.
The strongest evidence for causality assessment comes from
lacebo-controlled randomized trials. However, the relatively
mall sample sizes often result in inadequate power to detect or
ule out rare adverse events. Also, the limited duration of follow-
p in most clinical trials limits the ability to detect adverse events
ith vague timing of onset and adverse events with long inter-
als between vaccine receipt and symptom onset. Retrospective
ohort, case–control and self-controlled case series studies provide
igh quality evidence when conducted properly. Self-controlled
nd case-only studies where the vaccine recipients or persons with
 disorder serve as their own controls have emerged to be one of
he most useful epidemiologic methods for assessing vaccine safety
6]. These studies provide evidence for or against an increased risk
n biologically plausible time windows without the need for com-
arisons with unvaccinated or control populations. Self-controlled
tudies eliminate many potential biases and problems associated
ith identiﬁcation of appropriate controls in case–control studies
nd comparison populations in retrospective cohort studies.
Before concluding that an adverse event is causally related to
 vaccine, most experts require evidence from multiple studies in
ifferent populations by different investigators, sometimes using
ifferent study methods. However, there can be true differences in
he rates of adverse events in different populations due to differ-
nces in genetic or environmental factors that might inﬂuence the
isk of developing the adverse event. Some adverse events have
een identiﬁed in selected populations at increased risk, but the
dverse event is not observed in other populations.
Establishing a biologic mechanism alone is sometimes accepted
or determining a causal relationship such as anaphylaxis and iso-
ation of a live vaccine agent in tissues or body ﬂuids affected by
he adverse event [3]. A thorough discussion of the assessment of
iologic mechanisms can be found in the 2012 report from the
ommittee to Review Adverse Effects of Vaccines of the Institute of
edicine ([7], pp. 57–101). An understanding of the biologic mech-
nism is not essential to determining a causal association when
here are convincing epidemiologic data establishing an increased
isk of the adverse event in vaccine recipients. Animal studies
an provide useful information with regard to the pathogenesis of
dverse events, but there also are examples where studies in ani-
als have led to false conclusions with regard to effects in humans
8]. Animal studies have provided valuable insight into the patho-
enesis of adverse events following vaccines after epidemiological
tudies have established an increased risk of the adverse event
n humans [9]. Mechanistic evidence in the reviews of individual
dverse events is included when the evidence helps explain the
athogenesis. For most adverse events associated with inﬂuenza
accines, epidemiological evidence has proven to be the primary
vidence establishing or ruling out causal relationships. 33 (2015) F1–F67 F5
Repeat challenge is a valuable tool for the assessment of causal
relationships for immediate hypersensitivity reactions, but care
must be taken to be certain that the challenge does not result in
nonspeciﬁc reactions that can mimic  the local reactions associ-
ated with hypersensitivity reactions [10]. For other types of adverse
events, repeat challenge can provide some evidence supporting a
causal association, but most reports do not fulﬁll the criteria estab-
lished by the IOM including reasonable latency for each event in
the same individual following the same vaccine, documentation of
vaccine receipt, and clinician diagnosis of the health outcome [7].
Reviews of adverse events were sought for evidence of causal
associations with inﬂuenza vaccines, but conclusions from these
reviews were not used for determining causal relationships in this
white paper. The IOM has reviewed evidence of causal associations
between inﬂuenza vaccines and adverse events [7]. This commit-
tee started from a neutral position and weighed the evidence for or
against a causal relationship. For 23 of the 27 adverse events evalu-
ated, the committee concluded that “The evidence is inadequate to
accept or reject the causal relationship. . .”  ([7], pp. 402–404). These
conclusions have limited value in helping public health experts
and clinicians with decision-making. Also, these conclusions are
sometimes misunderstood as there is evidence supporting a causal
relationship, but the evidence is “inadequate”. For example, the
IOM reviewed three large studies where the investigators were
unable to ﬁnd any cases of encephalitis or encephalopathy follow-
ing inﬂuenza vaccines, and concluded that “no conclusions could be
drawn from these analyses” ([7], p. 296). The absence of identiﬁed
cases in biologically plausible time windows following inﬂuenza
vaccines in active surveillance programs where all health outcomes
are captured in large populations provides evidence against a causal
association, and if there is a possible causal association, the absolute
risk of the speciﬁc adverse event must be very small.
When precise rates of adverse events were not identiﬁed, we
followed the Council for International Organizations of Medical
Sciences (CIOMS) guidelines for describing rates of adverse drug
reactions [11]. Brieﬂy, the guidelines use the following categories:
Very common >10%, Common (frequent) >1% and <10%, Uncom-
mon  (infrequent) >0.1% and <1%, Rare >0.01% and <0.1%, Very rare
<0.01%.
Case reports based on temporal relationships only do not con-
tribute to the assessment of causal relationships. However, there
is some value to assessment of reports from passive surveillance
systems even when there is no control or comparison group. Some
information from these reports is included in the reviews of a few
adverse events that follow.
3.2.1. Causal association with one or all vaccines
There are reports of adverse events after only one or some
inﬂuenza vaccines but the evidence is not available for all inﬂuenza
vaccines. Some adverse events have been reported only with his-
torical vaccines. Changes in vaccine production have reduced or
eliminated these adverse events. Limited information is included
in this review about such adverse events because we were asked to
focus on currently available vaccines, although new manufactur-
ers could produce vaccines that might result in repeat experiences
with these adverse events.
3.2.2. Age
Some adverse events that are causally associated with inﬂuenza
vaccines occur only or primarily in adults, and some occur more
frequently or only in children. Whenever possible, we have tried toevents that have been causally associated in children. In instances
where the data on safety have been generated primarily in adults,
we have provided an assessment of the likelihood that the adult
data are applicable to the pediatric population.
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.3. Adverse events associated with injection technique
We  have included a review of deltoid or subacromial bursi-
is which is associated with inappropriate injection techniques
ecause this is a preventable and relatively common adverse event
nd the evidence is strong for a causal relationship. We  are not
ncluding information about other adverse events that may  be
ssociated with programmatic errors, such as contamination of
ulti-dose vials and inappropriate reuse of needles and syringes.
. Inﬂuenza vaccines recently produced
Information was obtained on 133 vaccines that have been
roduced recently. After deleting entries that did not contain infor-
ation on type of vaccine, 108 vaccines were identiﬁed produced
y 47 manufacturers in 27 countries (Appendix 3). The numbers
f different types of inﬂuenza vaccines produced per manufacturer
anged from one to 15. Of the 59 seasonal inﬂuenza vaccines (tri-
nd quadrivalent), 34 are approved for persons younger than 18
ears; of the 63 H1N1 pandemic vaccines, 15 were approved for
ersons younger than 18 years of age. None of the pre-pandemic
5N1 vaccines have been approved for pediatric populations. Of
he 108 vaccines, 98 were inactivated and 10 were live vaccines; 7
accines were quadrivalent.
This list does not include non-English language information and
ome manufacturers’ websites included neither prescribing infor-
ation nor contact information; other manufacturers did not have
 web presence that we could identify. Difﬁculty distinguishing
nique vaccines arises when manufacturers sell vaccines in multi-
le countries. For example, Abbot has employees and operations in
ore than 130 countries, Baxter in 44, and GSK in 32. Some com-
anies distribute the same vaccine under different brand names
n different countries and some manufacturers have production
lants in more than one country, or they manufacture in one coun-
ry and distribute the vaccine in other countries. The manufacturer
ountry on the list refers to the country identiﬁed in the package
nsert (or equivalent) as the place of manufacture. The list includes a
ew vaccines that are not currently available such as some vaccines
n clinical phase 3 trials and some vaccines that are in stockpiles for
andemic situations [12].
.1. Whole-virus vaccines in children
Whole-virus inactivated vaccines were the mainstay of immu-
ization against inﬂuenza from their development in 1945 until
hey were generally replaced with split-virus or subunit vaccines
uring the 1970s and 1980s, in large part due to the increased
eactogenicity (see Section 5.4) [13]. In Hungary, an aluminum-
djuvanted whole-virus vaccine, Fluval, has been in use since 1997.
early licensing trials in adults have shown few adverse reactions
14]. In recent years, renewed interest in the increased immuno-
enicity of whole-virus vaccines has led to the development of new
hole-virus pandemic vaccines.
A study of a Vero-cell derived whole-virus inactivated pandemic
009 H1N1 vaccine compared 2 doses of either 3.75 g or 7.5 g
f vaccine (Celvapan, Baxter) in 341 children 6 months to 17 years
f age in Austria and Germany without a placebo arm [15]. Tem-
eratures were monitored for 7 days after vaccine administration;
ther adverse events were monitored for 21 days after each vac-
ination. Fever assessed to be related to vaccine was  not reported
n children 9–17 years old, but occurred in 5.9% of children 1–8
ears old and 18.8% of children 6–11 months. Most fevers were
8–39 ◦C, no febrile convulsions occurred. Other systemic reactions
irritability, sleep disorder, headache, fatigue, muscle pain, etc.)
ccurred in 14.3% or less of children 1–17 years old, and 16.7–50% 33 (2015) F1–F67
of infants 6–11 months of age. Injection site reactions occurred in
less than 20% of children of all ages and tended to be reported more
commonly in the older children. Another study in the UK assessed
Vero cell-culture derived whole-virus H1N1 vaccine (Baxter) vs. an
AS03B adjuvanted H1N1 split-virus vaccine (GlaxoSmithKline) in
943 children 6 months to 12 years [16]. The adjuvanted vaccine
was more reactogenic and more immunogenic than the whole-
virus vaccine, mirroring what was seen in a similar trial in adults
[17]. After either the ﬁrst or second dose, 1.1% of whole-virus vac-
cine recipients over 5 years of age had severe local reactions [16]. In
children 6 months to <5 years, 9.3% of ﬁrst dose recipients and 12.5%
of second dose recipients had fever ≥38 ◦C, whereas children 5–12
years had lower fever rates (3.3% after ﬁrst dose, 2.9% after second).
One child who received the whole-virus vaccine had a focal seizure,
but it was assessed as unrelated to the vaccine. In addition to fever,
children 6 months to 5 years of age who  received the whole-virus
vaccine experienced the following adverse events after the ﬁrst and
second vaccination in rates higher than 20%: redness after vacci-
nation (22.9% and 19.2% after ﬁrst and second doses); decreased
feeding (33.7% and 29.9%); increased irritability (35.5% and 28.4%)
and need for analgesics or antipyretics (27.6% and 23.6%). Children
over 5 years experienced higher rates of pain at the injection site
(39.8% after ﬁrst dose, 42.3% after the second), redness at the injec-
tions site (22.7% and 21.7%), generally feeling unwell (24.9% and
14.9%) and headache (33.7% and 26.3%) [16].
In India, an aluminum-adjuvanted whole-virus monovalent
H1N1 vaccine was tested in 2010 at 10 mcg  or 15 mcg  single doses in
children and adults 3–76 years of age [18]. Adverse events were not
reported separately for children and adults. Of  the 161 recipients
of the 10 mcg  dose, and the 157 recipients of the 15 mcg dose, less
than 1% developed a fever. 13.7% and 18.5% had pain at the injection
site, the most frequently reported adverse event. Headache was
reported in 6.8% of 10 mcg  recipients and 4.5% in those who received
15 mcg  of the adjuvanted vaccine. The reported reactogenicity
events were generally mild and of short duration [18]. In a large
placebo-controlled trial in China, eight formulations of the H1N1
vaccine (varying doses of split-virus, whole-virus, adjuvanted and
unadjuvanted) were tested in 12,691 people 3 years and older in a
2-dose regimen [19]. Children received only the split-virus regimen
(with or without aluminum adjuvant). Adults received split-virus
and whole-virus vaccines. The whole-virus vaccines were given
at 5 mcg  and 10 mcg  doses and were adjuvanted with aluminum.
Adverse events in adults reported after the whole-virus vaccines (in
9.5% of those who  received 5 mcg  and 11.8% who received 10 mcg)
were comparable to those experienced by adults who received
placebo or 15 mcg  or 30 mcg of the unadjuvanted split-virus vac-
cine (9.6%, 10.2% and 12.4%), and were less than those experienced
by those receiving the adjuvanted vaccine (17.5–23.3%) [19].
Whole-virus vaccines for potential future avian pandemic
inﬂuenza strains have been developed because inactivated H5N1
subvirion vaccines were poorly immunogenic without an adju-
vant [20]. Attempts to make an immunogenic inactivated H5N1
vaccine have included adjuvants, vectored vaccines, and a prime-
boost strategy with two  different vaccines. One trial involving 675
children 6 months to 17 years of age using 3 doses of 2 different
unadjuvanted Vero cell derived whole-virus H5N1 vaccines was
conducted in Finland, Australia, Spain and Singapore in 2009–2012
[21]. Children 6 months to 8 years were given either 3.75 mcg  or
7.5 mcg  doses, those 9–17 years were given 7.5 mcg. After the ﬁrst
dose, injection site reactions, mostly mild in nature, occurred in
19.4–32% of the children, with older children reporting more reac-
tions, mostly pain. Fever in the 7 days after vaccination occurred
primarily in the younger children: 3.5% of children 3–17 years expe-
rienced fever compared to 18.1% of those 6–35 months. Headache,
at 18.7%, was  the most common systemic complaint in those 9–17
years old. Irritability was  the most common systemic symptom in
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he youngest children, occurring in 22.2% of those of 6–35 months.
ever rates were lower in the second and booster immunizations.
ther approaches to whole-virus H5N1 vaccines are being devel-
ped. In Hungary, a whole-virus H5N1 vaccine (Fluval) was tested
n 12 children ages 9–17 years with no side effects reported [14].
n aluminum hydroxide adjuvanted clade 2.2 vaccine was  shown
o be well tolerated in 80 adults in Russia [22]. Vietnam is devel-
ping capacity to produce pandemic avian inﬂuenza whole-virus
accines [23].
.1.1. Summary
In summary, modern whole-virus vaccines are more immuno-
enic than equivalent doses of split-virus vaccines and appear to be
ell tolerated by adults. In the small numbers of children studied,
he adverse event rates are higher than with split-virus vaccines.
arger trials of inactivated whole-virus vaccines need to be per-
ormed, especially in children, in order to determine the risks of
ebrile seizures and other severe adverse events.
. Evidence for or against causal relationships between
nﬂuenza vaccines and adverse events
.1. Local reactions following IIV
Most inactivated inﬂuenza vaccines are given by intramuscular
njection. An intradermal formulation available for use in adults
nly will not be reviewed here. In clinical trials the reported rates
f pain, tenderness, swelling have ranged from a low of 0.0% [24] to
0–60% [25], but most studies have reported intermediate rates of
0–20% following vaccines without adjuvants. The wide variability
n the reported rates of local adverse reactions can be attributed
rimarily to differences in the methods of data collection.
The most reliable data come from blinded clinical trials com-
aring inﬂuenza vaccines with a placebo, or one vaccine with
nother using daily monitoring of signs and symptoms. In direct
omparisons, inactivated vaccines induce higher rates of local
eactions than placebo [26,27]. TIV preparations produced using
ell culture technology have induced local reactions that are simi-
ar to egg-based vaccines [25]. In recent years, most studies have
ompared standard seasonal inﬂuenza vaccines with monovalent
andemic vaccines or adjuvanted pandemic or pre-pandemic
accines. Most local adverse events are mild and transient [26,27].
owever, some local reactions can interfere with daily activities
nd rare instances of extensive local reactions that resemble
ellulitis have been reported following several different vaccines
see below). In adults, the rates of reported pain have been higher
n females than males [28].
ose
The rates of local reactions following several TIV preparations
ere not increased by giving the standard 0.5 mL  dose administered
o adults and older children as compared to the 0.25 mL  dose that
as been recommended for children 6–35 months of age [29].
djuvants
In direct comparisons, vaccines containing AS03 or MF59
djuvants induced higher rates of pain/tenderness, erythema,
nduration, and swelling in most studies in adults and children than
accines without an adjuvant [30–33,379–381]. Local reactions
ncreased with increasing amounts of adjuvant for most adjuvants.
o consistent differences were noted between the ﬁrst and second
ose for young children. Almost all of these reactions were mild or
oderate in severity and the vaccines were considered to be well
olerated. 33 (2015) F1–F67 F7
5.2. Cellulitis-like reactions
Inactivated inﬂuenza vaccines and other vaccines can induce
reactions that can be mistaken for bacterial cellulitis [34]. The
median time following immunization to onset is approximately
one day [34]. Duration is 1–3 days in most instances. In a review
of medical claims, no increased rate of claims was noted in
the seven days following inﬂuenza vaccine for cellulitis, but an
increase in claims for cellulitis was detected following pneumo-
coccal polysaccharide vaccines [35]. Many affected individuals are
treated with antibiotics. The vast majority of such reactions are
not local infections however cellulitis due to bacteria can occur,
possibly associated with contamination of multi-dose vials [36].
Criteria are needed to help clinicians distinguish between cellulitis
caused by bacterial infections and cellulitis-like reactions due to
vaccines. The pathogenesis of cellulitis-like reactions has not yet
been determined, but is presumed to be a form of delayed type
hypersensitivity reaction.
Other
For reasons that have not been determined, in children with
primary varicella infections, the skin lesions may  be preferentially
localized to the injection site for inﬂuenza or other vaccines [37].
5.3. Hypersensitivity reactions
Hypersensitivity reactions to drugs and biologicals are char-
acterized by WHO  as dose-independent, unpredictable, noxious,
and unintended [38]. Hypersensitivity reactions can be immune
mediated or mediated through other mechanisms (non-immune
mediated).
5.3.1. Immune mediated reactions
Most immune-mediated hypersensitivity reactions are aller-
gic reactions mediated by IgE antibodies and result in urticaria
(hives), generalized pruritus, angioedema, conjunctivitis, rhinitis,
bronchospasm, gastrointestinal symptoms, and/or cardiovascular
collapse. A severe, life-threatening generalized or systemic hyper-
sensitivity reaction is considered to be anaphylaxis [39] although
more speciﬁc criteria have been proposed and the presentation in
infants is different than for older children and adults [40]. Prior
exposure to the allergen can generate IgE antibodies that attach
to basophils and mast cells. Re-exposure to the allergen results
in degranulation and release of a variety of inﬂammatory medi-
ators including histamine [41]. IgE-mediated reactions generally
occur within an hour after exposure, but later reactions have been
described [42].
An estimated 1.6% of the adult population in the United States
has had an episode of anaphylaxis following exposure to foods,
drugs, insect stings, latex, and other environmental allergens [43].
Vaccines represent a very small proportion of the allergens respon-
sible for allergic reactions. Inﬂuenza vaccines contain several
potential allergens that could result in allergic reactions, includ-
ing residual proteins from the media used to produce the vaccine
(egg protein or ovalbumin), small amounts of residual antibiotics
(polymyxin B or neomycin), stabilizers (gelatin), or preservatives
(thiomersal) [43–45]. Some inﬂuenza vaccines have latex in the
vial stoppers and/or the plunger of preﬁlled syringes; the latex can
cause allergic reactions in highly sensitized latex allergic patients
[46]. Egg allergy has been assumed to be responsible for many of
the immediate hypersensitivity reactions to inﬂuenza vaccines and
for many years advisory committees considered egg allergy to be
a contraindication or precaution for administering inﬂuenza vac-
cines (earlier recommendations 1980s to 2000). Variable amounts
of residual egg protein were found in different inﬂuenza vaccines in
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he early 2000s [47]. Some manufacturers introduced additional ﬁl-
ering steps in manufacturing of vaccines used in the United States
esulting in reduced amounts of residual egg protein [48]. Most egg-
llergic individuals can safely receive inﬂuenza vaccines produced
n egg because the very small amount of egg protein is insufﬁcient
o trigger an allergic response [49–51]. In recent years, two vaccines
Flucelvax® manufactured by Novartis and FluBlok® by Protein Sci-
nces Corporation) have been approved that are produced using
ecombinant technology without the use of eggs, but these prod-
cts are currently only approved for use in persons 18–49 years
f age. The ACIP has recommended that persons 18–49 years of
ge who have had allergic reactions to eggs should receive these
ecombinant vaccines [50]. Younger individuals who have had only
ives after ingestion of eggs can safely receive any of the other
gg-based vaccines. Children who have had more serious allergic
eactions after ingestion of eggs can receive egg-based vaccines
dministered by a physician experienced in the management of
evere allergic conditions. Speciﬁc information on the amount of
gg protein content is not available for most inﬂuenza vaccines.
Components other than egg protein appear to be responsible
or some of the immediate hypersensitivity reactions following
nﬂuenza vaccines as children with such reactions have been iden-
iﬁed who have no evidence of egg allergy. In Canada, a case–control
tudy revealed several risk factors for anaphylaxis following an
S03-adjuvanted 2009 pandemic H1N1 vaccine: female gender, a
rior acute respiratory infection, drug allergy, or food allergy (but
ot egg), vaccination during the ﬁrst 4 weeks of the campaign, and
se of asthma inhalers [52].
The majority of patients who have had signs or symptoms of
ypersensitivity reactions following vaccines probably do not have
gE mediated disease [53]. In Canada, skin testing was  performed on
5 individuals 10–64 years of age who reported allergic symptoms
fter receipt of the pandemic 2009 H1N1 vaccine that contained the
S03 adjuvant and the results were compared to 37 controls [54].
ll of the cases had onset of symptoms less than 24 h after receipt of
he vaccine, and 52% were within 1 h after vaccination. Positive skin
ests to the vaccine they received indicating probable IgE antibody
ediated reactions were obtained in 4% of the cases and 3% of the
ontrols. Of the 25 cases who agreed to be revaccinated with the
011–12 inﬂuenza vaccine, ﬁve (20%) had delayed onset allergic
ype reactions. The authors concluded that IgE mediated allergy
as responsible for very few of the reported allergic symptoms
ollowing inﬂuenza vaccination.
Urticaria, angioedema and other manifestations of hypersensi-
ivity can also occur at intervals of up to one week after exposure
o allergens. These late reactions are likely mediated by IgG or
gM antibody, and/or complement and are characterized as serum-
ickness reactions [55]. Most such reactions are hives/urticaria but
ngioedema can occur as well. Although there are many reports of
elayed onset rashes following inﬂuenza vaccines with a presump-
ion of a causal relationship, we have not identiﬁed studies that
rovided evidence of such causal relationships. In these instances,
t is very difﬁcult to determine a causal relationship because of the
otential for other exposures, such as food and other allergens as
ell as inter-current viral illnesses in the interval between vaccine
eceipt and onset of disease.
.3.2. Non-immune or non-allergy mediated hypersensitivity
eactions
Hypersensitivity reactions can be mediated through non-
mmune mechanisms. Some products can interact directly with
ast cells and/or basophils to release histamine and causedverse events that can mimic  immune mediated adverse events
53,56]. These adverse reactions have been called “anaphylactoid”
eactions, but many allergists now prefer to refer to these as “non-
llergy mediated hypersensitivity reactions”. 33 (2015) F1–F67
The term ‘oculorespiratory syndrome’ (ORS) was ﬁrst used in
Canada to describe patients who  developed bilateral red eyes
and/or respiratory symptoms (cough, wheeze, chest tightness, difﬁ-
culty breathing, difﬁculty swallowing/throat tightness, hoarseness
or sore throat) and/or facial swelling beginning within 24 h after
inﬂuenza immunization [57–60]. Most affected patients had reso-
lution of symptoms within 48 h, but up to 10% had symptoms that
lasted as long as a week. ORS occurred in all age groups, including
children 1–19 years of age, although the rates were higher in indi-
viduals over 50 years of age. The rate in females was higher than
males with a ratio of approximately 3:1. ORS is not IgE antibody
mediated. Skin testing of ORS patients with inﬂuenza vaccines was
negative for immediate reactions. ORS was  associated with two vac-
cines, but 96% of cases in one year were associated with vaccine that
was produced using deoxycholate for virion disruption, and this
vaccine was  found to contain increased amounts of unsplit virus
and aggregations of virus products [58,61]. In a retrospective sur-
vey of children with diabetes, the rate of ORS in children vaccinated
in 2000 was  as high, and possibly higher, than the rates reported for
adults [60]. The rate among ﬁrst-time vaccine recipients was higher
than for children who had received inﬂuenza vaccine in the previ-
ous season. Approximately 1% of children who  developed ORS were
hospitalized with this condition, primarily children with respira-
tory symptoms. Changes in manufacturing processes decreased
the amount of aggregated virus and decreased rates of ORS over
a 4-year period from 46 per 100,000 to 9 per 100,000 doses dis-
tributed [58]. Some patients with ORS following inﬂuenza vaccine
are reported each year in Canada in recent years, but the rates are
considerably lower than observed in 2000–2004 (Personal commu-
nication Gaston DeSerres, September 24, 2014). Reports of patients
with onset of facial swelling and/or other signs of ORS  with onset
4–24 h after inﬂuenza vaccines have been identiﬁed in the United
States in recent years [62].
Revaccination of patients with ORS resulted in recurrences
in 34% of recipients of one vaccine and 15% who had received
a different vaccine [57]. The recurrences were usually mild and
there was no increased risk of anaphylaxis or other forms of imme-
diate hypersensitivity reactions. The pathogenic mechanisms
responsible for ORS have not been determined, but aggregation
of viral particles appears to have been a key factor with one
vaccine. Revaccination of affected individuals who did not have
severe lower respiratory symptoms is considered safe by advisory
committees [50,63,326].
Evidence for a causal relationship
The incidence of immediate hypersensitivity reactions is usually
too low to be picked up in clinical trials. Negative data from ran-
domized clinical trials involving relatively small numbers of study
participants does not rule out a causal association for uncommon
or rare adverse events [64].
Individuals who  have developed immediate hypersensitivity
reactions within minutes following inﬂuenza vaccine have had
evidence of hypersensitivity on skin testing to the vaccine or a
vaccine component, supporting a causal relationship [43]. Addi-
tional evidence supporting a causal relationship includes skin
testing with diluted vaccines that induced characteristic wheel
and ﬂare reactions within minutes after the test was performed
[43]. Studies of individuals who have had immediate hypersensi-
tivity reactions have revealed elevated levels of serum IgE speciﬁc
antibody, but the predictability of such test results is variable
and repeat challenge, usually by skin testing, is considered a bet-
ter approach to identifying hypersensitivity to speciﬁc allergens
[65].
The rates of immediate hypersensitivity reactions vary based on
differences in vaccine components, methods of manufacturing, the
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opulations who received the vaccines, and methods of reporting
r investigating these events. In clinical trials involving hundreds
r even a few thousand patients, it is uncommon to ﬁnd patients
ho develop true immediate hypersensitivity reactions because
he incidence is quite low. For example, in one recent trial of 915
hildren who received TIV, one child developed hives, but this child
lso received multiple other vaccines at the same time [66]. In
ost clinical trials no instances of immediate hypersensitivity reac-
ions have been reported. Hypersensitivity reactions are reported
hrough passive surveillance systems and can be among the most
ommonly reported adverse events [67]. For most seasonal vac-
ines rate data are not available. The introduction of 2009 H1N1
andemic vaccines resulted in enhanced surveillance for adverse
vents and provided an opportunity to estimate the rates of seri-
us allergic reactions because denominator data were available in
any countries. Anaphylaxis is the most serious form of imme-
iate hypersensitivity reactions and is probably the most reliably
eported form of hypersensitivity. However, only 50% or less of the
eports of anaphylaxis fulﬁlled the Brighton Collaboration criteria
62] Anaphylaxis meeting the Brighton criteria [68] was  reported
t a rate of approximately 1 case per million doses of the H1N1
009 pandemic inﬂuenza vaccine distributed in the United States
ith no differences in rates for four manufacturers [62]. In Mexico,
he rate of reported anaphylaxis was less than 0.5 per million doses
dministered for similar vaccines [69]. In Europe, 43 cases of ana-
hylaxis were reported following administration of approximately
2 million doses of an MF59 adjuvanted H1N1 2009 pandemic
nﬂuenza vaccine for a rate of 3.5 per million doses distributed [70].
lso in Europe, the rate of anaphylaxis following AS03-adjuvanted
accine was similar to the reporting rate for other vaccines [71].
n Quebec Canada, the rate of Brighton Collaboration conﬁrmed
naphylaxis was 13 per million doses administered for an AS03-
djuvanted H1N1 2009 pandemic inﬂuenza vaccine, substantially
igher than the rate reported for seasonal inﬂuenza vaccine [72].
n Korea, there were 5 cases of anaphylaxis and 10 anaphylactoid
eactions reported among an estimated 13.8 million recipients of
n unspeciﬁed adjuvanted vaccine [73].
In summary, anaphylaxis and other immediate hypersensitiv-
ty reactions have been reported for almost all inﬂuenza vaccines.
lthough there are differences in the rates of reported anaphy-
axis in different countries and with different vaccines, the data
re inconclusive with regard to true differences in rates by the type
f vaccine.
The rates of less severe hypersensitivity reactions including
ives/urticaria and/or angioedema have not been determined accu-
ately because of underreporting and uncertain denominator data.
or passive reports of adverse events following H1N1 inﬂuenza
accine in the United States, the rate of other immediate hypersen-
itivity reactions reported to the Vaccine Adverse Events Reporting
ystem (VAERS) system was approximately 10 times higher than
he rate for anaphylaxis, but there was undoubtedly more under-
eporting of milder events. Allergists believe that the rate for
hese less severe hypersensitivity reactions is much higher than
hat for anaphylaxis and reporting rates are lower. The rates of
ll immediate hypersensitivity reaction were higher in females of
eproductive age than in males in the United States [62]. Simi-
arly, in Europe with the MF59-adjuvanted vaccine, the reporting
ate for allergic reactions in females was more than twice as
igh as in males [70]. Anaphylaxis also has been reported fol-
owing LAIV in children. Seven reports were made of anaphylaxis
o VAERS after the ﬁrst 2.5 million doses of LAIV were admin-
stered in the United States [74]. For the LAIV preparation of
009 H1N1 pandemic inﬂuenza vaccine, the rates of all allergic
eactions reported in the United States was higher than for the
nactivated vaccines, but the rates of anaphylaxis were similar
62]. 33 (2015) F1–F67 F9
5.3.3. Other rash illnesses
There are case reports of other types of rash illnesses which
could be due to delayed hypersensitivity reactions that had onset
several days to two  weeks after inﬂuenza vaccines without other
recognized causes. These include unusual rashes such as Gianotti-
Crosti syndrome [75], cutaneous vasculitis [76], toxic epidermal
necrolysis [77] and Henoch-Schonlein purpura [78]. However, no
evidence of a causal relationship, other than a temporal association,
has been identiﬁed in these reports and coincidental infections or
other exposures that could have stimulated these rashes or illnesses
have not been ruled out in the published case reports. Most of the
patients with these reported rashes and illnesses recover without
sequelae.
5.4. Fever and febrile seizures
5.4.1. Fever
Fever in children is a common occurrence associated with
infections, some vaccines, inﬂammatory diseases, heat stress, and
other factors. The Brighton Collaboration Fever Working Group
has deﬁned fever to be “an endogenous elevation of at least one
measured body temperature of ≥38 ◦C” [79]. Fever induced by
inactivated or subunit vaccines is usually caused by direct effects
of vaccine antigens and other components on macrophages and
other cells which release inﬂammatory cytokines. Residual endo-
toxin from the vaccine production process can directly stimulate
the release of inﬂammatory cytokines [80]. Fever from IIV and other
inactivated vaccines has onset within the ﬁrst 24 h but may  occur up
to 48 h after the vaccine has been administered [26,27,81]. With live
attenuated vaccines, the interval from vaccination to onset of fever
varies depending upon the replication time and incubation period
associated with the live agent. For measles containing vaccines, the
increase in fever is 7–10 days following vaccination [26,27,82].
5.4.2. Changes in inﬂuenza vaccine production methods
Inﬂuenza vaccines were rarely used in children prior to 1976
because of high rates of fever and other adverse events. Most vac-
cines were whole-virus vaccines and bacterial endotoxins were
present in microgram quantities as a residual from bacterial con-
tamination of eggs used for vaccine production [80]. However, the
rates of fever in children were not directly correlated with the
amount of endotoxin in the vaccines and investigators suspected
that some viral components contributed to the high rates of fever
[80]. Whole-virus vaccines induce fever in 45–69% of the small
numbers of children studied, some had fever to 40 ◦C, and febrile
seizures occurred in 3 of 42 children in two trials [81,83]. The rates
of adverse events were lower with half the usual dose (0.25 mL)
and with split-virion vaccines, which were ﬁrst developed in 1969
(Fig. 1) [81,84–88]. The immunogenicity of the split-virus vaccine
was less than the whole virion vaccines and so two  doses were nec-
essary in young children to induce an adequate immune response.
In 1977, US advisory committees recommended inﬂuenza vaccine
only for children at high risk for inﬂuenza complications and recom-
mended that young children receive 2 doses of split-virus vaccines
[89].
Additional changes in manufacturing processes for whole and
split-virion inactivated vaccines have been made over the past 30
years which resulted in decreased rates of fever and local reactions,
but most of these changes have not been outlined in the published
literature. For example, allergists studied the amount of egg
protein in inﬂuenza vaccines and noted that some manufacturers’
products had much lower egg protein content than others, and the
allergists sometimes selected the low egg protein content vaccines
for immunizing people with possible egg allergy [48]. Additional
ﬁltration steps were introduced by other manufacturers, as
acknowledged by two  manufacturers at a meeting of the ACIP in
F10 N.A. Halsey et al. / Vaccine
Fig. 1. Frequency of maximal fever at various times after vaccination with whole-
virus (, Merell-National Laboratories, Cincinnati, Ohio; and , Merck Sharp and
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rhome, West Point, Pa.) or split-virus (♦, Parke, Davis and Company, Detroit, Mich.;
nd ©,  Wyeth Laboratories, Philadelphia, Pa.) inﬂuenza A/New Jersey/76 vaccine.
sed by permission [85,86].
011. The splitting agent used to disrupt the virus has changed in
ome instances (e.g. Vaxigrip®, Sanoﬁ Pasteur) [90]. The speciﬁc
etails on manufacturing processes are considered proprietary.
herefore, caution is indicated when interpreting the results of
tudies of fever and local reactions between manufacturers, and
ata from earlier studies are not necessarily reﬂective of what
eactions would occur with currently produced vaccines.
Studies of fever and febrile seizures in young children are avail-
ble for only a small number of the vaccines produced. In many
ountries, IIV produced by only one manufacturer is approved for
outine use in children under 3 years of age, the age group at highest
isk for febrile seizures. Other IIVs are available in most countries
or older children and adults (see Appendix 3).
.4.3. Inconsistencies in study methods for assessing fever after
accines
Inconsistencies in the study methods utilized by different inves-
igators make it somewhat difﬁcult to draw conclusions about
ifferences in vaccines. Inactivated inﬂuenza vaccines have been
ssociated with increased rates of fever in the 24–48 h after vacci-
ation and some studies suggested a small increase in fever 24–72 h
ollowing LAIV [26,27]. Epidemiological studies and clinical trials
ave used longer time windows for reporting adverse reactions
5, 7, 10, 21, or 30 days after vaccination). However, these longer
ntervals often include fever and febrile seizures caused by other
actors not biologically consistent with inﬂuenza vaccine. Studies
ave varied in the methods for measuring body temperature and
ut-points for deﬁnitions of fever have included subjective fever
eported by parents or caregivers. Inﬂuenza vaccines administered
o children are often administered simultaneously with other vac-
ines that cause fever so it is not possible to determine which of
he vaccines was responsible for fever. Also, simultaneous admin-
stration of other vaccines with inﬂuenza vaccine may  increase the
isk of fever and febrile seizures (see Section 5.4.5 below).
Fever occurs commonly in young children and, in the absence
f an unvaccinated control group, it is not possible to determine
 causal relationship with a vaccine. The Brighton Collaboration
ever Working Group developed guidelines for the gathering and
eporting of fever in vaccine trials [79]. Few of the following trials 33 (2015) F1–F67
meet these guidelines, in part because many were performed prior
to their development.
5.4.4. Rates of fever after inﬂuenza vaccination
Rates of fever following inﬂuenza vaccines are highest in the
youngest children and usually decrease with increasing age. In a
summary of 7 clinical trials of different formulations of Vaxigrip®
(Sanoﬁ Pasteur) conducted between 1991 and 2002, the rates of
fever in the ﬁrst 3 days after vaccination among children 6–35
months of age were approximately twice the rate observed in chil-
dren 3–10 years of age [90]. In other studies of split-virion vaccines
in children 6–23 months or 6–35 months of age, fever in the 5 or 7
days after vaccination are usually in the 8–20% range and vary by
the cut point for deﬁning fever [91,92]. Some studies have found
rates of only 4% [93,94], and one study reported rates of 1–3% in chil-
dren 6–36 months of age using the same vaccines that had reported
rates of 8–13% observed in other settings [382]. In general, fevers
found after split-virus vaccines are low-grade, and rarely exceed
39 ◦C.
Fever rates in young children following split-virus vaccines
without adjuvants do not correlate with immunogenicity. In stud-
ies of direct comparison of two  different vaccines, similar rates of
fever have been noted but one vaccine was  more immunogenic
than the other [93–95,382,383]. The fevers could have been caused
by coincidental infections or there are factors in the vaccines that
cause fever unrelated to the development of protective immune
responses.
Quadrivalent inactivated inﬂuenza vaccines (QIV) produced by
GSK (Fluarix®) and Sanoﬁ Pasteur (Fluzone®) have been approved
for use in children. Fluarix® QIV recipients had more injection site
pain than the TIV preparation, but there was  no signiﬁcant differ-
ence in rates of fever [96]. As with TIV, after the receipt of QIV
children 6 months to 3 years of age had higher rates of any fever
than the older children and 2.5% had fever >39 ◦C after ﬁrst and
5.4% after the second dose [97]. Fluzone QIV recipients did not have
higher rates of fever than in the TIV recipients in children 6–23
months or 2 to <9 years of age in the 7 days after vaccination [98].
5.4.5. Fever associated with adjuvanted vaccines
Several manufacturers developed monovalent 2009 H1N1
split-virus pandemic vaccines containing adjuvants including alu-
minum, virosomes, and oil-in-water immersion adjuvants. In
China, a comparison of a 2009 H1N1 split-virus vaccine with an
aluminum adjuvant (Hualan Biological Bacterin Company) in 440
children 3–11 years old found fever in the 21 days after vacci-
nation in 11.8% of placebo recipients and 11.5–18% who received
7.5–30 mcg  HA of the adjuvanted vaccine [99]. Systemic adverse
events were 13.6% in the 15 mcg  HA group and 25.5% in the 30 mcg
HA group. Some studies did not report safety data separately for
aluminum adjuvanted vs. unadjuvanted vaccines or separate adults
from children to allow interpretation of results [19]. In studies of
an aluminum phosphate adjuvanted H5N1 prepandemic split-virus
vaccine in children 6–35 months of age, fever (>37.5 ◦C) was  noted
in 48.3% of recipients of 30 mcg  HA and 70% of those who received
45 mcg  HA [100]. The rates were much lower in children over 3
years of age.
AS03 (squalene, dl--tocopherol, and polysorbate 80) is an
adjuvant used in Pandemrix (GSK) in Europe and Arepanrix (GSK)
in Canada. In persons over 18 years of age, rates of fever were
minimal (1.3–4%) following the ﬁrst or second doses of an H1N1
vaccines containing 3.75–15 mcg of vaccine with AS03 adjuvants
[33]. In children, the rates of fever were higher after the second
dose than the ﬁrst dose. In 157 children 6–35 months of age studied
in Spain, the rate of fever >37.5 ◦C was 20.2% after the ﬁrst dose and
67.3% after the second dose in children who received the 1.9 mcg
(0.25 mL)  dose [101]. Higher fevers (>39.0 ◦C) occurred in 3.8% of
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ubjects receiving a second 0.25 mL  dose, and in >15% of those who
eceived the 0.5 mL  dose [101]. A Canadian study in the same age
roup found rates of fever ≥38.5 ◦C of 3.6% and 8.6% after the ﬁrst
nd second doses [384]. In a study in the UK, fever ≥38 ◦C occurred
n 8.9% of 270 children 6 months to <5 years after the ﬁrst dose and
2.4% after the second dose [16]. Fever rates were lower in older
hildren, 20% in children 3 to <6 years old after the ﬁrst dose of
.9 mcg; 16.9% in children 10–17 years old after a second 3.75 mcg
ose 6 months later [102,103].
MF59 (squalene, polyoxyethylene sorbitan monooleate
TweenTM 80) and sorbitan trioleate) adjuvant has been in
luad® (Novartis) subunit seasonal vaccine since 1997 [104].
ocetria® (Novartis) is the European licensed egg-based pandemic
1N1 vaccine adjuvanted with MF59. Celtura® (Novartis) is the
ell culture equivalent distributed in Japan, Europe and Latin
merica. In an integrated analysis of 5 trials involving 545 children
onducted by Novartis, no differences in rates of fever were found
n recipients of MF59 adjuvanted inﬂuenza vaccines as compared
o unadjuvanted vaccines [105]. The overall rates of adverse events
ere lower in recipients of MF59 adjuvanted vaccines. Fever
ates after the second dose of MF59 adjuvanted vaccines were
ither similar to or lower than the rates after the ﬁrst dose in
everal studies [30,106–109,385]. The rates of fever in children
ho were born preterm were similar to term infants [106]. Fever
usually ≥38.0 ◦C) rates varied by study, but were similar to or
lightly higher than the rates following licensed unadjuvanted
accines in several studies of children 6–35 months of age in
ifferent countries including Finland [30], the United States [107]
uatemala [385] and Argentina, Australia, Chile, the Philippines,
nd South Africa [109].
A pandemic monovalent H1N1 vaccine adjuvanted with AF03,
nother squalene-in-water emulsion (Sanoﬁ-Pasteur) was com-
ared to unadjuvanted vaccine in 303 children ages 3–17 years
nd 401 age 6–35 months in Finland [31]. Fever rates in the 7 days
fter vaccination were higher in the younger children: for infants
–11 months 41.3% of those who received the adjuvanted vaccine
ad temperature ≥38 ◦C compared to 13.7% in the unadjuvanted
roup. Fever rates were 25% in 12–23 month old recipients of the
djuvanted vaccine, and 17% in those 24–35 months of age [31].
.4.6. Increased fever with simultaneous pneumococcal
onjugate vaccines
Studies of children 6–35 months of age who received TIV with
neumococcal conjugate vaccine showed higher rates of fever than
hen TIV was administered alone [92,110,386].
.4.7. Febrile seizures
Fever predisposes to seizures in a small percent of children and
he risk of seizures increases with increasing temperatures. Febrile
eizures are deﬁned as seizures which occur in febrile children
≥38 ◦C from any source) without evidence of intracranial infection,
etabolic disturbances, or history of afebrile seizures [111,112].
ebrile seizures are age-dependent and are most common in chil-
ren 6 months to 2 years of age, but occur up to 5 years of age [111].
he cumulative risk of developing one or more febrile seizures in
he ﬁrst 5 years of life varies from 2 to 5% of children in North Amer-
ca and Europe to 6–9% in some Asian countries [113,114]. The risk
f developing one or more febrile seizures has not been clearly
eﬁned in children in many other areas of the world. Risk fac-
ors associated with developing febrile seizures include high fever,
nfections, some immunizations, low birth weight, and family his-
ory of seizures [114,115]. Children who develop febrile seizures
iffer from children who have not developed febrile seizures in
peciﬁc genetic loci associated with control of pro-inﬂammatory
ytokine interleukin 1 (IL-1) and they develop increased levels
f IL-6 [116]. 33 (2015) F1–F67 F11
Febrile seizures can be categorized as simple or complex. Simple
febrile seizures last less than 10 min  as deﬁned in the United King-
dom, and 15 min  in the United States, occur once in a 24-h period,
and are generalized (non-focal) [111,114]. Although simple febrile
seizures are generally benign, they are a source of signiﬁcant con-
cern and distress to families. Complex febrile seizures last longer
than 15 min, can occur more than once in 24 h, and may have a focal
component [111]. There are no long-term adverse effects of simple
febrile seizures [111]. However, a small proportion of children can
develop recurrent febrile seizures, and a subset may be at higher
risk for developing epilepsy [111,117]. Febrile seizures may also
unmask a predisposition to seizures. Studies in the Netherlands
have shown that 65% of children who  go on to have additional
seizures have an underlying disease that is associated with recur-
rent seizures or other neurologic problems [118]. Complex febrile
seizures have a higher risk of recurrent febrile seizures and future
afebrile seizures, and prolonged febrile seizures can be associated
with neurologic damage.
Most seizures in young children are witnessed only by parents
and criteria for deﬁning seizures and possible seizure-like activity
have not been included in most studies. The Brighton Collaboration
has developed deﬁnitions for seizures, including febrile seizures,
which should help standardize methods for future studies [119].
Although there were numerous reports of febrile seizures after
inﬂuenza vaccine to passive reporting systems such as VAERS in
the US, no conclusions can be drawn with regard to causal relation-
ships; many of these reports included children who  received other
vaccines simultaneously [120–122]. However, passive reports can
provide a signal that warrants further investigation as occurred
with a vaccine in Australia discussed below.
Epidemiologic studies using the Vaccine Safety Datalink (VSD)
in the US and self-controlled analyses in children and risk windows
of 14 or 21 days after vaccination found no evidence of increased
risk of febrile seizures [123,124]. Most seizures occurred 7–14
days after TIV administration and were thought to be due to
concomitant MMR  vaccination. In a case–control study of febrile
seizures using insurance group enrollees 6–34 months of age from
2002 to 2004, the hazard ratio for FS associated with TIV was
1.17 (95% CI 0.36–3.86) [125]. A later study in the VSD using a
self-controlled study design over 4 inﬂuenza seasons (2002–2006),
revealed a small increased risk of medically attended fever in
66,283 children 24–59 months of age (IRR 1.71; 95% CI 1.64–1.80),
but no serious adverse events were observed and there was  no
mention of FS [126].
5.4.8. Febrile seizures after pandemic (H1N1) 2009 vaccine
Several prelicensure studies involving relatively small numbers
of young children did not show an increased risk of FS includ-
ing trials of adjuvanted vaccines Arepanrix® and Pandemrix ®
[93,94,109,127]. However, a signal of increased febrile seizures
was seen in post-marketing surveillance in Australia in 2010. The
Department of Health in the state of Western Australia had offered
TIV to children 6 months to 4 years old since 2008. In 2010, three
TIV vaccines were distributed: Fluvax® and Fluvax Junior® (CSL
Biotherapies), Inﬂuvac® (Solvay Pharmaceuticals) and Vaxigrip®
(Sanoﬁ Pasteur). All contained A/California/7/2009 (H1N1)-like
virus, A/Perth/16/2009 (H3N2)-like virus and B/Brisbane/60/2008-
like virus. The program was  suspended 3 weeks into the campaign
when clinicians noted an increase in children presenting with fever,
vomiting, and febrile convulsions within 12 h of TIV vaccination
[128–130]. A retrospective cohort analysis revealed a signiﬁcant
(p < 0.001) increase in febrile seizures in 2010 (see Fig. 2) [128].Elevated risk of febrile convulsions was associated with two vac-
cines (Fluvax® and Fluvax Junior®) produced by CSL Biotherapies in
children under 5 years of age, but not the other manufacturers. No
febrile seizures were reported in recipients of Inﬂuvac®, compared
F12 N.A. Halsey et al. / Vaccine 33 (2015) F1–F67
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o a rate of 4.4 per 1000 doses administered (95% CI 3.4–5.6) for
he CSL products (p < 0.0001). The rate of other fever related reac-
ions was 14.8 (95% CI 8.3–26.7) times greater for the CSL products
han for Inﬂuvac®. Prior vaccination with TIV or monovalent 2009
1N1 pandemic vaccine was not associated with febrile convul-
ions [128]. CSL’s inﬂuenza vaccines are no longer recommended
or children <5 years in Australia, and recommended only for chil-
ren 9 years of age and older in the United States [50]. Similarly, the
epartment Of Health in the United Kingdom recommended not
sing either of the two CSL produced inﬂuenza vaccines (Enzira®
r CSL Biotherapies generic inﬂuenza vaccine marketed by Pﬁzer)
n children [131].
Previous published trials did not indicate safety concerns with
he CSL products. A randomized trial of monovalent unadjuvanted
009 H1N1 vaccine produced by CSL administered to 370 patients 6
onths to <9 years old in Australia reported one febrile convulsion
n an 18 month old 20 days after vaccination who  had concur-
ent pneumonia [132]. Surveillance data in Australia of monovalent
1N1 non-adjuvanted vaccine (Panvax® and Panvax Junior®, CSL),
ncluded more than 300,000 doses of Panvax Junior® in children <5
ears. Seven febrile seizures were reported in the ﬁrst six months of
he vaccination program, two of which occurred with concomitant
aricella vaccine, below the expected background rate convulsions
n children <5 years of age cited in the package insert [133]. In
ddition, a prospective uncontrolled phase IV clinical trial of CSL
IV vaccine was conducted in Australia in 2009, to evaluate safety
f Fluvax® and Fluvax Junior® in children 6 months to 18 year
f age. Among 1992 participants, fever was more common than a
009–2010 Northern Hemisphere split-virion comparator, but no
ebrile seizures were discussed [134].
There was a suggestion of increased reactogenicity in previ-
us studies. An Australian study of Fluvax® in 2005–2006 reported
ever in 22% of children under 3 years in 2005, and 40% after a
econd dose in 2006, with one febrile convulsion [135]. In New
ealand, retrospective telephone surveys of parents of children 6
onths to 5 years revealed that fever occurred more frequently
ith Fluvax® compared to Vaxigrip® (Relative Risk 4.33 [95% CI
.44–7.70], p ≤ 0.001). The authors concluded that similar to pre-
ious studies, Fluvax® was more pyrogenic in infants and youngission [128].
children [136]. Citing unpublished studies, investigators noted
that there was  evidence for higher rates of fever and possibly
febrile seizures associated with the CSL products prior to 2010
[137]. They also identiﬁed a possible publication bias and called
for standardization in the methods used to identify and report
fever associated with inﬂuenza vaccines in children. In 5 published
trials, the median average weekly risk of fever was  8.2% (range
5.3–28.3%) in children from 6 months to <36 months of age fol-
lowing inﬂuenza vaccines, signiﬁcantly (p = 0.04) lower than the
rate (26.0% (range10.3–70.0%)) in 14 unpublished trials [137].
In an effort to understand increased rates of FS and other
adverse events associated with the CSL products, the manu-
facturer conducted studies in several animal species, including
nonhuman primates, which did not reveal any differences between
the CSL products and other manufacturers with regard to detectable
adverse events [138]. However, studies with peripheral blood from
both children and adults revealed signiﬁcant increases in stimula-
tion of cytokines and chemokines after stimulation with the CSL
products as compared to other manufacturer’s products. Further
studies demonstrated that the increase cytokine and chemokine
reactions were due to heat labile viral derived fragments and
a viral lipid-mediated delivery of fragmented RNA [139,140].
Inadequate splitting of the vaccine virions by the sodium tau-
rodeoxycholate used in manufacturing these products associated
with changes in the virus strains resulted in the differences in
reactivity. By introducing additional steps in the manufacturing
process to further disrupt virions and remove lipid, the manu-
facturer hopes to be able to develop a product that would be
satisfactory for use in children [139–141]. Other manufacturers
use deoxycholate in the manufacture of inﬂuenza vaccines, includ-
ing the manufacturer of inﬂuenza vaccine that was most strongly
associated with ORS (see section on ORS below) [142]). The high
rates of ORS reduced with the introduction of additional steps to
assure adequate viral disruption in the production of split-virus
vaccines.Several countries, including China, Denmark, Slovenia, the
Netherlands, and the UK published results of passive surveillance
systems in the context of the 2009 H1N1 pandemic, most receiv-
ing monovalent vaccine. Although some febrile convulsions were
N.A. Halsey et al. / Vaccine 33 (2015) F1–F67 F13
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eported, no strong signals or increased risk of FS with TIV among
hildren were noted [143–147].
.4.9. Increased febrile seizures with simultaneous pneumococcal
onjugate vaccines
Following the identiﬁcation of FS associated with the CSL vac-
ine, many countries enhanced vaccine safety monitoring. In the
nited States, enhanced surveillance of VAERS from 2010 to 2011
dentiﬁed 51 reports of FS after Fluzone® TIV (Sanoﬁ Pasteur)
n children <2 years of age, which exceeded a predetermined
hreshold [148]. VSD data for 2010–2011 showed the risk for FS
mong children 6 months to 5 years was highest for those receiv-
ng concurrent pneumococcal conjugate vaccine (PCV13) and TIV
149,150]. Using a self-controlled method, the incidence of FS that
et  Brighton Collaboration criteria in the 0–1 days after vacci-
ation was compared to the incidence in the 14–20 days after
accination. The results shown in Fig. 3 revealed a small increased
isk associated with TIV alone or PCV 13 alone, but a much larger
ncrease in risk when both vaccines were administered simulta-
eously. There was an elevated risk in all the ages studied, but the
isk was greatest in children 6–24 months of age. At 16 months of
ge, the risk difference was 12.5 per 100,000 doses for TIV without
CV13, 13.7 per 100,000 doses for PCV13 without TIV, and 44.9 per
00,000 doses for TIV and PCV13.
In a follow-up study using VSD data from 2006 to 2011 in chil-
ren 6–23 months of age, 333 FS were identiﬁed [151]. The analysis
onﬁrmed the increased rate of FS with simultaneous adminis-
ration of PCV 13 and inﬂuenza vaccine, but also showed that
oncomitant administration of TIV, PCV13, and DTaP was  associ-
ted with the highest risk of FS, which was observed for all inﬂuenza
easons. A separate study using different methods to assess the risk
f FS among participants in a health plan during the 2010–2011
eason revealed elevated point estimates of risk of FS, but no sta-
istically signiﬁcant increased risk associated with TIV, PCV13, or
dministration of both vaccines on the same day [152]. Post mar-
eting surveillance of TIV in Canada among 592 children 6–59
onths old in 2010 indicated fever was more likely with concurrentdministration of PCV13, although no seizures were reported [153].
tudies evaluating co-administration of LAIV with other vaccines,
ncluding MMR,  varicella vaccine, and oral polio vaccine, have not
hown increased risk of FS [154,343].ssion [149,150].
Overall, at least 19 different vaccines by 10 different manufac-
turers have been evaluated for fever and/or FS (Appendix 4). Given
lack of direct comparisons between manufacturers, aside from the
risks associated with CSL Fluvax discussed above, it is difﬁcult to
determine if the relative risk of FS differs by manufacturer; the over-
all risk of FS was  low across most manufacturers. The risk of FS
can vary by manufacturing method and perhaps by vaccine strain.
Studies with sufﬁcient power to determine the rates febrile seizures
have only been published recently for a relatively small number of
manufacturers. Trials done to date with newer inﬂuenza vaccines,
such as quadrivalent (QIV) and thiomersal-free formulations, have
not shown increased risk of FS [96–98,373]. A prospective study to
evaluate the safety of a monovalent cell culture-derived inﬂuenza
vaccine reported two convulsions, both outside the 7-day risk win-
dow generally associated with vaccine effects [155].
5.4.10. Febrile seizures following LAIV
No increased risk of FS has been reported for LAIV. In a post
marketing evaluation of VAERS reports for the 2003–2005 seasons,
approximately 2.5 million people received LAIV and only 460 AE
were reported during the study period including one febrile seizure
reported in a 4 year-old boy 26 h after LAIV [74]. An analysis of the
VAERS data from 2005 to 2012 revealed 2619 reports of AE follow-
ing LAIV, 15 of which were seizures, 2 reported as febrile [156].
The authors did not believe that this was an increase above what
was expected by chance. A randomized controlled trial comparing
LAIV [157] to TIV (Fluzone®) in 2004–2005 among 8352 children
6–59 months of age at sites across the US, Europe, Middle East, and
Asia, reported one episode of FS in the TIV group and none in LAIV
group [158]. In addition, an analysis of AE associated with LAIV in
the 2007–2010 seasons using MarketScan insurance data, noted 1
seizure among children younger than 5 years [159,160].
5.4.11. Conclusions
With improvements in manufacturing processes, febrile
seizures in children receiving IIV have become relatively rare. With
improved study methods including narrowing risk windows and
focusing on the age groups at highest risk for FS, large population-
based studies have revealed a small increased risk associated with
IIV, especially with simultaneous administration of PCV13 and
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ith DTaP. The experience with the use of LAIV in children is
ore limited. LAIV is not recommended for children younger than
wo years of age so there are only limited data from pre-licensure
tudies on the risk of fever and FS in the population at highest risk
f FS. Additional data from large studies using LAIV and LAIV-L are
eeded to determine if there is any increased risk of FS associated
ith these vaccines.
Experience with the increased rate of FS with vaccines produced
y CSL indicates the need for careful monitoring of vaccine safety
n an ongoing basis in all countries and studies to help understand
he biologic basis for fever and FS, as well as the possibility of devel-
ping vaccines by new methods that might be associated with even
ower risks [141].
.5. Malaise, myalgia, and related symptoms
Reports of myalgia, malaise, chills and a sensation of fever after
IV have been reported in adults and are often the most common
ymptoms reported [17,161,162]. Some people have reported these
ymptoms as a “ﬂu-like” illness [26,27,163,164] and these symp-
oms have resulted in refusal of subsequent inﬂuenza vaccinations.
The onset of these symptoms is higher in the ﬁrst day after vacci-
ation and may  persist into the second day, but many studies have
ombined data for the 7 or 10 days after vaccination. These symp-
oms are nonspeciﬁc and there is a relatively high background rate
n actively solicited symptoms among adults. Higher rates of appar-
nt inﬂuenza-like illness symptoms have been reported among
accine recipients vs. controls especially in the ﬁrst 2 days after
accination in some studies [163,164], but not in others [163–165].
igher rates of myalgia were reported in recipients of high dose as
ompared to standard dose vaccines [166].
The rates of myalgia were similar for adult recipients of split-
irion unadjuvanted TIV vs. QIV (14.3% vs. 16.2% respectively) in the
 days after vaccination [167]. The rates were signiﬁcantly higher in
he same study for recipients of AS03-adjuvanted vaccines: 31.4%
or TIV and 38.5% for QIV. Similar results were found in a compari-
on of whole virion pandemic H1N1 vaccine where the rate was
4% for unadjuvanted recipients and 49% for recipients of AS03
djuvanted vaccine [17].
In children, these symptoms following inﬂuenza or other vac-
ines are usually mild and, since they do not often result in medical
isits, they are not generally reported in population-based stud-
es of medically attended events [126,168]. Myalgia comprised 6%
f non-serious adverse events after TIV in children in an analy-
is of VAERS reports in children 5–17 years of age from 1990 to
006 [122]. Active follow-up in pediatric clinical trials shows a
reater incidence of malaise and myalgia after vaccination. Myalgia
nd malaise were the most commonly reported systemic symp-
oms and occurred in more than 30% of children 2–8 of age who
eceived QIV or TIV (Fluzone, Sanoﬁ Pasteur) [98]. Myalgia occurred
n approximately 30% of children 5–17 years of age in the 3 days
fter vaccination following two different TIV formulations (Flu-
one, Sanoﬁ and Fluarix GlaxoSmithKline) [95]. Other studies have
eported rates of 4% to >30% in children old enough to verbalize
omplaints [96,97,135,169,170]. These symptoms usually started
ithin the ﬁrst 24 h after receipt of the vaccine.
.5.1. Pathogenesis
Myalgia and malaise are associated with inﬂuenza infection and
he pathogenesis involves viral replication and the systemic inﬂam-
atory response [171,172]. Myalgia and malaise after inﬂuenza
accination arise in the absence of viral infection and are most likely
elated to the increase in inﬂammatory cytokines and a decrease in
L-8 that occurs shortly after vaccination [173–177] (Talaat unpub-
ished). A better understanding of the role of cytokines play in the
dverse events following immunization is needed. 33 (2015) F1–F67
5.6. Inﬂammatory arthritis
Juvenile idiopathic arthritis (JIA), formerly called juvenile
rheumatoid arthritis, is a chronic and often relapsing autoimmune
inﬂammatory arthritis in children with onset before the age of 16
years [178]. JIA includes seropositive rheumatoid arthritis as well
as chronic arthritis in children with other predisposing risk factors
but, in the majority of cases, there is lack of serum IgM-rheumatoid
factor, lack of family history, and no known underlying etiology
[179]. Environmental factors, especially infections, are suspected
to be either trigger factors or contributing factors in the pathogen-
esis of JIA [180–182]. The association of transient arthralgia and
inﬂammatory arthritis with several different acute infections and
live attenuated rubella vaccines has led to the hypothesis that other
live and inactivated vaccines could cause or trigger the onset of JIA
in genetically predisposed individuals or stimulate exacerbations
of quiescent disease. No known association exists between natural
inﬂuenza infection and the onset or exacerbation of JIA or other
inﬂammatory arthritides to support a causal relationship between
inﬂuenza vaccine and inﬂammatory arthritis.
Case reports
There are rare case reports of children with onset or relapses of
JIA following IIV [183], and other reports of onset of inﬂammatory
arthritis in adults following inﬂuenza vaccines with assumptions of
causal relationships based upon temporal associations [184–186].
Epidemiologic evidence of associations between inﬂuenza vaccines
and exacerbation or new onset of JIA in children or rheumatoid
arthritis in adults
In 2012, the IOM concluded that the few studies [187,188] of
associations between inﬂuenza vaccines and onset or exacerbation
of arthropathy were limited and did not have sufﬁciently stan-
dardized measures of disease severity or deﬁnitions to allow for
an assessment of causal relationships; the IOM concluded that the
evidence was “inadequate to accept or reject a causal relationship”
([7], p. 385). More recent studies have included objective meas-
ures of disease assessment. Clinical trials in patients with JIA and
other forms of autoimmune inﬂammatory arthritis have consis-
tently revealed no evidence of increases in relapse rates or changes
in disease severity for patients with JIA and other forms of inﬂam-
matory arthritis following IIV with or without adjuvants [189–195].
In an exploratory cohort analysis using the VSD population in
the United States, a possible increased risk of rheumatoid arthritis
was found in persons 15–59 years of age using time windows of 180
and 365 days following immunization (RR = 1.36, p = 0.03; RR = 1.34,
p = 0.01), but not in the more biologically plausible 90 days follow-
ing immunization [196]. In the same study using a case–control
methodology, there was no evidence of an increased likelihood of
having received inﬂuenza vaccine or other vaccines in any of the
time windows prior to onset of disease in 378 cases of new onset
rheumatoid arthritis.
A retrospective cohort study involving all persons residing
in Stockholm County, Sweden, using data from January 1, 1998
through August 31, 2010, revealed no evidence of any increased
risk of inﬂammatory arthritis associated with the AS03 adjuvanted
Pandemic (H1N1) 2009 vaccine immunization campaign [197].
In a matched retrospective cohort study involving children 5–17
years of age and using data from inﬂuenza seasons 2003–4 through
2007–8 seasons in the US-based VSD, no evidence of increased
rates of inﬂammatory arthritis was found in 43,702 who received
LAIV or their matched IIV recipients as compared to controls [198].
In a population-based case–control study in Sweden involving
1998 incident cases of rheumatoid arthritis from 1996 to 2006 in
persons 18–70 years of age, no evidence of any association with
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eceipt of inﬂuenza vaccine or other vaccines was  noted (OR 1.0,
5% CI: 0.9–1.1) [199].
ummary and conclusions
Although there are some case reports of onset or relapses of JIA
ollowing administration of inﬂuenza vaccine, the evidence from
ultiple epidemiologic studies indicates that inﬂuenza vaccines
re not risk factors for new onset of JIA in children or inﬂammatory
rthritis in adults, and there is no association with exacerbation of
ymptoms in patients with JIA.
.6.1. Subacromial or deltoid bursitis and shoulder injury
Injection of inﬂuenza and other vaccines too high in the del-
oid muscle can result in inﬂammation of the subacromial bursa
ssociated with persistent pain and restriction of range of motion
200–203]. The onset of signiﬁcant shoulder pain is usually within
ours after injection, increases for several days and persists for
everal weeks to months. Clinically, differentiation from brachial
euritis and adhesive capsulitis (frozen shoulder) can be difﬁcult
201,204]. Magnetic resonance imaging (MRI) reveals inﬂamma-
ion and extra ﬂuid collection in the subacromial bursa which
xtends to above the humorous [201,202]. There are also rare
eports of inﬂammatory changes in the head of the humorous with
steonecrosis or osteolysis associated with subacromial bursitis
ollowing injection of standard inﬂuenza vaccine and one report fol-
owing an AS03 adjuvanted H1N1 inﬂuenza vaccine [202,205,387].
he cases of subacromial bursitis reported to date appear primarily
n adults. Contributing factors include injection too high in the del-
oid, injection at an upward angle, and small or thin deltoid muscles.
These injuries can be prevented by injection of inﬂuenza vaccine
nto the middle third of the deltoid [28,201,206,207].
.7. Guillain-Barré syndrome
Guillain-Barré syndrome (GBS) is an immune-mediated dis-
rder in which an antigenic stimulus results in an aberrant
mmunologic response that attacks self-proteins on peripheral
erve and nerve roots. GBS is divided into subgroups based on
eurologic ﬁndings and neurophysiological characteristics, and
ncludes acute inﬂammatory demyelinating polyradiculoneuropa-
hy (AIDP), acute motor axonal neuropathy (AMAN), acute motor
nd sensory neuropathy (AMSAN), acute sensory neuropathy, acute
an-dysautonomia and the Fisher syndrome [208]. Pathologic ﬁnd-
ngs vary for the subgroups, but inﬂammatory macrophages and/or
ntibodies against self-proteins attacking neuronal tissue at differ-
nt points is a common feature [208]. Circulating antibodies play
 role in the pathogenesis of most cases of GBS as evidenced by
he rapid clinical response to the administration of large doses of
ntravenous immune globulin, which has become the standard of
are. The passively administered antibodies presumably compete
ith and displace host anti-neuronal antibodies. The most likely
andidate is anti-GM1 ganglioside antibody [209]. These studies
ave led to the hypothesis that, among the antecedent antigenic
timuli that can result in GBS, selective inﬂuenza vaccines and/or
nﬂuenza viruses may  contain cross-reactive antigens that stimu-
ate the autoimmune response.
The majority of patients with GBS have had a recent infection
ue to respiratory viruses and/or gastrointestinal infections, espe-
ially Campylobacter jejuni. Cytomegalovirus infections have been
mplicated as another infection associated with an increased risk
f GBS [210–212]. Inﬂuenza has been associated with GBS [210].
he preceding infections suggest a role for possible molecular
imicry in the pathogenesis of most GBS cases. The strongest
vidence for molecular mimicry comes from GBS associated with
. jejuni infections where there is evidence that 33 (2015) F1–F67 F15
lipo-oligosaccharide moieties on the cell wall of the Campylobacter
bacterium share antigenic and epitopic features to gangliosides
expressed on human peripheral nerve, and induced antibodies
against GM1  gangliosides result in neuronal damage [213,214].
5.7.1. Epidemiological evidence
The incidence of Guillain-Barré syndrome (GBS) is far too low
to be picked up in clinical trials. Negative data from randomized
clinical trials involving relatively small numbers of study partici-
pants does not rule out a causal association for uncommon or rare
adverse events [215] and, with a background rate of about 1 case
per 100,000 person-years, GBS cannot be evaluated in most clinical
trials given their size.
A systematic review of the literature (see methods and
appendix) identiﬁed 24 studies with unduplicated data that
included a control group (including self-controlled studies) as
described in Appendices 1 and 2. Of these 24 studies, 10 included
the 2009–2010 inﬂuenza season. Study designs included cohort (9),
case control (3), and self-controlled (12). Studies were conducted
using US data (13), European (6), Canadian (2), Taiwanese (2) and
an international collaboration including 10 other countries. Inactiv-
ated vaccines were the focus of 15 of these studies; however many
of the publications did not specify which inﬂuenza vaccine(s) were
studied. Only 4 of these studies included any meaningful data for
children. Additional publications included subsets of the data pub-
lished from the US studies in 1976–77 [216] and 2009–10 [217] and
to reduce redundancy, these studies are not listed in Appendix 5.
The epidemiological evidence assessing the relationship between
GBS and inﬂuenza vaccines is based on these observational studies
with a control group.
There are numerous case reports of GBS following inﬂuenza (and
other) vaccines, two of which were reported prior to 1976. How-
ever, the 1976–77 swine ﬂu vaccination program was the ﬁrst time
a vaccine was  causally associated with GBS [216,218]. The emer-
gence of a new strain of inﬂuenza in 1976 with similarities to the
strain causing the 1918 ﬂu pandemic led to the largest inﬂuenza
vaccination program in the United States. While the feared pan-
demic never materialized, safety surveillance established for the
vaccine program indicated two  clusters of GBS in recent vaccinees
reported in Minnesota and Alabama [216]. Surveillance for GBS was
expanded to include the entire US, the vaccination program was
halted, and careful epidemiological studies were conducted amid
considerable public and political scrutiny.
With about 35 million vaccine doses administered, local and
state health authorities contacted neurologists to ascertain cases
of GBS. A standardized case reporting form was  developed by the
Centers for Disease Control and Prevention (CDC) to collect clini-
cal and laboratory ﬁndings, antecedent events, medical histories,
patient characteristics, and history of swine ﬂu vaccination. Some
states also surveyed non-neurologist practitioners and hospitals to
identify additional cases. The incidence of GBS in vaccinated per-
sons was  compared to the incidence in unvaccinated persons.
Between October 1, 1976 and January 21, 1977, 1098 cases of
GBS were identiﬁed [216]. Vaccinated persons were found to be
9.5 (95% CI: 8.2–10.3) times as likely to be identiﬁed as a GBS case
compared to unvaccinated persons, translating into an estimated
attributable risk of about 1 case per 100,000 vaccinees. The attack
rate was lower in persons 18–24 years of age compared to older
persons. The vaccine program was terminated before widespread
vaccination of children was  implemented and consequently there
were not enough cases among children for meaningful study. The
risk of GBS did not differ by type of vaccine, vaccine manufacturer,
or vaccine lot suggesting the problem was not related to the manu-
facturing process. However, there were limitations to fully explore
these issues. There was  a clear temporal clustering of cases in the
number of days after vaccination. The increase in risk was seen for
F16 N.A. Halsey et al. / Vaccine 33 (2015) F1–F67
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s long as 10 weeks after vaccination with the highest risk in the 2–3
eeks after vaccination and most of the risk occurred in the ﬁrst
 weeks post vaccination (see Fig. 4 from [216]). Rates of acute ill-
esses, a risk factor for GBS, were lower in vaccinated compared to
nvaccinated cases, suggesting that the vaccine might have been
erving as a trigger for some of these vaccinated cases who  did
ot have another identiﬁed trigger. This risk was not seen among
ilitary personnel vaccinated in 1976–77 [220]. The US Institute
f Medicine carefully reviewed these data and determined “the
vidence favored acceptance of a causal relationship between the
976–77 Swine Inﬂuenza vaccine and GBS in adults” [221]. While
ome controversy may  always remain, the scientiﬁc community
idely accepts that the 1976–77 inﬂuenza vaccine was  an infre-
uent cause of GBS.
Enhanced surveillance has been undertaken since the swine ﬂu
accination program in 1976–77 to ensure that GBS was not a con-
inuing problem with inﬂuenza vaccines. Eleven published studies
ave been conducted between the 1977–2008 inﬂuenza seasons.
s can be seen in Appendix 5, most of these studies have been in
he US (9 of 11) and did not ﬁnd a statistically signiﬁcant association
etween inﬂuenza vaccines and GBS. Two of these studies report
 small, statistically signiﬁcant increased risk for GBS associated
ith the vaccine ([222], relative risk 1.7; 95% CI: 1.0–2.8; [223],
ncidence rate ratio 1.45; 95% CI: 1.05–1.99). Together, these stud-
es very convincingly demonstrate that the risk in 1976–77 has not
ccurred at nearly the rate in subsequent seasonal inﬂuenza vac-
ine formulations and, if inﬂuenza vaccines have been associated
ith GBS since 1976–77, the risk is extremely low. The US Insti-
ute of Medicine reviewed these studies from 1977 to 2008 and
oncluded that, aside from the 1976–77 vaccination program, the
vidence was “inadequate to accept or reject a causal relationship
etween inﬂuenza vaccines and GBS.”
One hypothesis to explain the much higher rate of GBS follow-
ng the 1976 swine inﬂuenza vaccines was that the eggs used for
roduction of the vaccines could have been contaminated with C.
ejuni antigens [224]. However, careful PCR studies of residual vials
f these vaccines found no evidence of C. jejuni. Immunization of
ice with these vaccines did induce low levels of anti-ganglioside
ntibodies but inﬂuenza vaccines from other years also induced
ariable levels of anti-ganglioside antibodies in mice [224]. In other
tudies, rabbit polyclonal anti-ganglioside antibodies cross-reacted
ith several different H1N1 and H3N2 inﬂuenza viruses [225].
hese investigators also studied mice injected with 1988–1989
nd 2007–2008 or 2009 pandemic inﬂuenza vaccines and found
inimal evidence for development of anti-ganglioside antibodies,ission [216].
which varied by mouse strain. The same investigators found no
association between the antibody response in humans to inﬂuenza
vaccines and the development of anti-ganglioside antibodies, but
individuals over 60 were more likely than younger individuals
to develop some anti-ganglioside antibodies. In another study,
persons infected with the 2009 pandemic H1N1 inﬂuenza virus
and individuals who  were vaccinated with the 2009 pandemic
vaccines did not develop anti-ganglioside antibodies [226]. The
available evidence does not support the hypothesis that inﬂuenza
vaccines induce anti-ganglioside antibodies that could be respon-
sible for development of GBS, but additional studies are needed
to investigate this and other possible mechanisms in genetically
predisposed individuals [227,228]. Injection of myelin protein
with adjuvants can induce neurologic syndromes in some animal
species [229,230]. Therefore, studies were conducted to determine
if there might have been inadvertent contamination of the 1976
vaccines with myelin protein. Studies of nine 1976 vaccines
revealed no evidence of myelin P2 protein in the vaccines [229].
The 2009–10 inﬂuenza season afforded an opportunity to fur-
ther examine the epidemiology of GBS. Concerns about a pending
H1N1 pandemic led to mass immunization in many countries some
of which had the capacity to conduct rigorous safety surveillance
including, but not limited to, GBS. In the US, approximately 23
million vaccinated persons were under active surveillance for GBS
through 6 large-linked databases capturing the general population
as well as special populations. Extensive active surveillance for
GBS post H1N1 vaccine was  also conducted in many countries
across Europe and Asia. Data were combined across Europe, in
the US and in an international study including 10 countries (3
separate protocols). The US and international study beneﬁted
from a self-controlled case series (SCCS) methodology, comparing
the risk of GBS in one time window to a second time window
among vaccinated persons who  contracted GBS. This approach
has many advantages over comparisons between vaccinated and
unvaccinated persons as these population groups may  differ in
important ways that would impact the incidence of GBS. While
SCCS studies control for individual level variables (demographics,
comorbidities, genetic variability) they are prone to bias if the dis-
ease of interest has seasonal or time dependent variability. H1N1
vaccines became available late in the 2009–10 inﬂuenza season
when inﬂuenza circulation in many countries had already begun.
Consequently, there was  the potential for individuals to contract
GBS after both receiving a vaccine and contracting inﬂuenza; stud-
ies may  then be prone to inadvertently ascribe the vaccine, rather
than natural disease, as the cause of GBS. Nonetheless, 2009–10
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fforded an unprecedented opportunity to apply modern epi-
emiological tools to efﬁciently study extremely large and diverse
opulations.
A European case–control study recruited subjects from the
K, Denmark, the Netherlands, France and Sweden; 104 GBS
atients were matched to one or more controls based on age,
ex, index date and country [374]. The unadjusted pooled risk
or all countries was 2.8 (95% CI: 1.3–60). However, the associa-
ion between H1N1 vaccine and GBS no longer remained (adjusted
dds ratio 1.0 (95% CI 0.3–2.7)) after adjusting for inﬂuenza-like
llness/upper respiratory tract infection and seasonal inﬂuenza
accine. The risk of GBS was higher but not signiﬁcant (and unsta-
le) among persons who received H1N1 vaccine and did not have
nﬂuenza-like illness/upper respiratory tract infections. The study
as prone to several biases, including the potential that people at
ncreased risk of GBS might have been less likely to receive the vac-
ine and over-reporting or selective inclusion of exposed people
ith GBS.
Six active surveillance systems in the US conducted rapid
ssessment of the actual vs. expected number of cases (based
n GBS incidence in previous years) and then conducted end-
f-season analysis using self-controlled methods. Each of these
ystems showed a small increased risk (some reaching statistical
igniﬁcance) for GBS in the 42 days after vaccination compared
o a comparison time window (days 50–91 post vaccination)
227,228,231–238]. A meta-analysis of these data found 54 cases
n the vaccine exposure period compared to 23 cases in the con-
rol period ([217], incident rate ratio 2.35 (95% CI 1.53–3.68)). Fig. 5
217] shows the preliminary results from the 6 active surveillance
ystems and the meta-analysis. Sensitivity analyses used different
ase deﬁnitions and stratiﬁed by receipt of seasonal inﬂuenza vac-
ine, more and less stringently deﬁned inﬂuenza-like illness, time
indows for vaccine exposure, and age. The results were remark-
bly consistent in these sensitivity analyses. Among people without
nﬂuenza-like illness, the incident risk ratio for GBS in the 42 days
ost-H1N1 vaccination was 2.80 (95% CI 1.66–4.89). For people
ithout inﬂuenza-like illness or fever or cough, the IRR was  3.00
95% CI 1.72–5.47). These analyses suggest that wild inﬂuenza dis-
ase did not have an important impact on study ﬁndings. There
id not seem to be a seasonality problem with the data as the inci-
ent rate ratios were similar between time periods. The risk did
ot vary by age; however the risk was not statistically signiﬁcant
mong children (incident rate ratio 2.33 (95% CI: 0.65–10.46)) likely
ecause of insufﬁcient power in this subpopulation. With a con-
istent risk ratio across ages, the attributable risk ranged from 1
ase per 1,000,000 vaccinations for persons <18 years of age to 3
Fig. 5. Used by perm 33 (2015) F1–F67 F17
cases per 1,000,000 vaccinations for persons 65 and older due to
the increasing background rate of GBS by age.
An international collaboration including Australia, Canada,
China, Denmark, Finland, the Netherlands, Singapore, Spain, the
UK, the US (including some of the same US and UK cases) used
two SCCS methods: (1) data were pooled across all sites; and (2)
a meta-analytic approach which estimates rate ratios from each
database were weighted based on within and between study errors
and subsequently merged [239]. Sensitivity analyses were used
to assess the effect of seasonal vaccine, different post-vaccination
time windows, different case deﬁnitions, exclusion of missing data,
and stratiﬁcation by gender, age categories, history of GBS, presence
of recent infections, and adjuvanted vs. non-adjuvanted vaccines.
Seasonality was adjusted for in the meta-analytic approach. H1N1
vaccines were associated with GBS in the pooled analysis (rel-
ative incidence (RI) 2.86; 95% CI: 1.88–4.34)) and meta-analytic
analysis (RI 2.42 (95% CI 1.58–3.72)). Sensitivity analyses found
these results to be very robust. Excluding patients with reported
inﬂuenza-like illness or upper respiratory illness in the 30 days
before GBS onset slightly increased the risk estimate (RI 2.73; 95%
CI 1.75–4.26) suggesting that the increased risk was not a result of
circulating wild inﬂuenza virus. These ﬁnding are highly consistent
with the US data. This study suggested a higher risk in adjuvanted
vaccines (RI 2.97; 95% CI 1.13–7.84) than non-adjuvanted vac-
cines (RI 1.88; 95% CI 1.03–3.41); however the difference was not
statistically signiﬁcant. Age-stratiﬁed analysis suggested a trend
rather than statistically signiﬁcant differences in relative incidence
by age. Among children (<19 years), the RI was 0.73 (95% CI
0.16–3.46).
Many of the country and surveillance speciﬁc data that make up
the European, US and international study are also published inde-
pendently. The combined data are described as they offer the most
power and beneﬁt from a standardized protocol. Two additional
studies of GBS in 2009–10 that were not a part of these coordinated
efforts are published separately and shown in the table in Table 5,
lines 17 and 18. A SCCS of 2009–10 H1N1 vaccine in Germany found
an increased relative incidence of GBS (4.65 (95% CI 2.17–9.98))
[240]. A SCCS of 2009–10 H1N1 vaccine in Taiwan found an IRR of
3.81 (95% CI 0.43–33.85) [241].
Several epidemiological studies including inﬂuenza seasons
after 2009–10 [242–244] revealed non-signiﬁcant point estimates
of an increased risk of GBS following inﬂuenza vaccine and the con-
ﬁdence intervals are consistent with the ﬁndings from 2009 to 10;
however these studies are under-powered to deﬁnitively identify
such a small increase in risk. One study after 2009–10 [152] found
a decreased risk of GBS (relative risk 0.5; 95% CI 0.3–0.9), perhaps
ission [217].
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xplained by problems with the comparator group some of whom
ay have been vaccinated with the 2009–10 H1N1 vaccine which
as been shown to be associated with GBS.
While there are 22 epidemiological studies since 1976–77
xamining the relationship between inﬂuenza vaccines and GBS
Appendix 5, lines 3–24), there is not a clear consensus in the
cientiﬁc community regarding the interpretation of these data.
he 2009–10 U.S meta-analysis and the international collaborative
tudy from the same year are likely the strongest methodologi-
ally. These ﬁndings of a roughly doubling of risk of GBS in the
2 days after inﬂuenza vaccine are consistent with nearly all the
tudies done since 1976–77; the majority (18 of 22) of these stud-
es’ conﬁdence intervals overlap with 2.0. Doubling the risk of
BS during a 42-day risk window translates into 1–3 excess GBS
ases per million persons vaccinated. The beneﬁts of inﬂuenza
accine, including prevention of GBS caused by inﬂuenza, greatly
utweigh this very small risk. When studied with adequate power,
ifferences in risk have not been observed between types of
nﬂuenza vaccines; however some vaccines such as live attenu-
ted and adjuvanted vaccines have not been studied as extensively
s the non-adjuvanted inactivated vaccines (Appendix 5). Only
wo of these studies have been conducted outside the US, Canada
nd Europe. Consequently, it is problematic to generalize these
ata to countries where there may  be differences in genetics
nd in the health status of the population (nutrition, concurrent
nd past infections). The vast majority of these data are among
dults, primarily because inﬂuenza vaccine recommendations for
hildren are relatively new in many countries. Only 3 of 24 stud-
es provide data on children and these ﬁndings are inconclusive
Appendix 5).
.7.2. Conclusions
Epidemiological studies provide convincing evidence that the
976–77 vaccine caused GBS among adults. Since 1976–77, the
pidemiological evidence indicates a small increased risk of GBS
mong adults of approximately 1–3 per million doses of IIV. Incon-
istent ﬁndings in several studies can largely be explained by lack
f statistical power among negative ﬁndings. The biological mecha-
ism(s) for the small increased risk following inactivated inﬂuenza
accines is not understood. The small increased risk associated with
IV appears to be much lower than the risk associated with inﬂuenza
nfections [210]. Epidemiological evidence is insufﬁcient in chil-
ren and for live attenuated vaccines to draw any conclusions.
.8. ADEM
Acute disseminated encephalomyelitis (ADEM), Multiple scle-
osis (MS), and transverse myelitis (TM) are demyelinating
isorders affecting different areas of the central nervous system.
hese diseases have several characteristics in common, includ-
ng inﬂammatory pathological focal lesions in the central nervous
ystem that are often preceded by infections, especially inﬂuenza
223,224,241,242]. The pathogenesis is not fully understood for
ny of the diseases but appears to involve genetic predisposi-
ion and autoimmune responses triggered by acute infections
227,228,245,247]. The animal models for experimental autoim-
une encephalomyelitis (EAE) are a possible model for what occurs
ith MS  and/or ADEM [388]. However, these animal models involve
njection of myelin and/or other CNS tissues with complete Fre-
nd’s adjuvant. There is no myelin or other CNS tissue present in
nﬂuenza vaccines and there is no animal model that reproduces the
bservations of CNS demyelinating diseases in humans following
atural infections or vaccines.
The focal inﬂammatory lesions in ADEM affect primarily white
atter in the brain and spinal cord [247]. There are no speciﬁc
aboratory tests for making the diagnosis of ADEM; the diagnosis 33 (2015) F1–F67
is based on clinical criteria and the results of CNS imaging
[227,228,247,248]. Inconsistencies in criteria for deﬁning ADEM
have resulted in variability in the clinical illnesses reported in
association with infections and/or vaccines. Illnesses that might
have been ADEM have been called by other names such as
“brain stem encephalitis” or “post-vaccination encephalitis” prior
to the availability of MRI  and CT scans and standard deﬁnitions.
Some published case-reports of ADEM following inﬂuenza vac-
cines would not meet criteria most neurologists accept today. In
some reports, neurologists have not attempted to differentiate
ADEM from other disorders including encephalitis. ADEM has been
reported in all age groups with a predominance of cases in males
and children [248,249].
5.8.1. Case deﬁnition
ADEM is a usually deﬁned as a monophasic illness associated
with brain inﬂammation and demyelination involving primarily
white matter [227,228,250]. ADEM deﬁnitions have varied. Some
authors have noted that ADEM can be diagnosed without a pre-
ceding infection or vaccine. Authors often include evidence of a
recent infection or receipt of a vaccine as a criteria for the diag-
nosis [250,389]. In 2007, the Brighton Collaboration established a
standardized deﬁnition for ADEM [247]. The Brighton Collaboration
recognized that an infection or vaccine may  or may  not have been
a causal or contributing factor in the development of the disease.
Also, the deﬁnition should not include a prespeciﬁed time interval
for a possible causal factor to have occurred prior to the onset of
disease as doing so again suggests a causal or contributing factor in
the development of the disease.
The Brighton collaboration criteria require that ADEM is a
monophasic illness. Patients that relapse after a 3-month inter-
val have other diseases, most commonly MS [251,247]. Although
these criteria have resolved inconsistencies in previous deﬁnitions
of ADEM, not all groups have followed the lead of the Brighton
Collaboration and continue to use other less rigorous case deﬁni-
tions. The Pediatric Multiple Sclerosis Study Group has continued to
use criteria for ADEM that include a preceding infection or vaccine
[389]. In 2012, this group proposed a revision to their case deﬁni-
tion for ADEM in order to assist with the differentiation between
ADEM and MS  because they note that ADEM recurrences are noted
in 2–18% of cases and some patients with recurrences do not meet
the criteria for MS  [389].
5.8.2. Causality assessment
Biologic plausibility for inﬂuenza vaccines to be a possible trig-
ger for ADEM comes from the observation that up to 90% of
patients with ADEM have a preceding infection or have received
a vaccine [247]. Respiratory infections, including inﬂuenza-like ill-
nesses, have been frequently documented prior to the onset of
ADEM and inﬂuenza virus has been identiﬁed in nasal secretions
at the time of onset of neurological symptoms in several patients
with ADEM [227,228,247,252,390]. ADEM has been reported after
several different vaccines, including inactivated and live attenu-
ated inﬂuenza vaccines in the United States [247]. A recent review
identiﬁed 71 published reports of ADEM following vaccines includ-
ing 21 reports following inﬂuenza vaccines published from 1979
to 2013 [391]. Most reviews of ADEM published in respected peer-
reviewed journals and chapters in textbooks of neurology conclude
that immunizations, including inﬂuenza vaccines, are a contribut-
ing or causal factor [249,248,251]. The bases for this conclusion
are temporal associations, biologic plausibility, and possibly exten-
sions of logic from experience with the Semple rabies vaccine
which contained myelin basic protein and caused neurologic ill-
nesses [227,228,253]. The Semple vaccine is the only vaccine with
evidence of a causal relationship with ADEM or an ADEM-like ill-
ness; the peak onset was  one to two weeks after vaccination [247].
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mallpox vaccines were associated with neurologic disorders
abeled encephalitis, but the illnesses were consistent with ADEM,
lthough imaging studies were not available for most affected indi-
iduals diagnosed at that time [227,228,254]. In some reports, the
ssumption of a causal association was, “Based on the temporal
ssociation and exclusion of alternative etiologies” [255]. However,
t is impossible to rule out all alternative causes because ADEM has
een reported following a many viral and bacterial illnesses and no
ne knows the entire list of infectious diseases that might trigger
he development of ADEM [256,257].
.8.3. Mechanistic evidence
No biologic evidence directly implicating inﬂuenza or other vac-
ines in the pathogenesis of ADEM has been identiﬁed. In the future,
nvestigators might be able to identify speciﬁc immunologic mark-
rs responsible for the demyelinating inﬂammatory processes that
ill help conﬁrm or rule out a vaccine in the pathogenesis of ADEM.
.8.4. Epidemiologic evidence
There are limited epidemiologic studies evaluating a possible
ausal relationship between inﬂuenza vaccines and ADEM. Using
opulation-based data in Sweden, investigators conducted a ret-
ospective cohort study for selected outcomes in a population of
,845,039 individuals (61% of the Swedish population) where 57%
f the population received the AS03 adjuvanted 2009 H1N1 vac-
ine [258]. Investigators identiﬁed an increased risk of narcolepsy
ssociated with the vaccine (see narcolepsy section below) but
here was no signiﬁcant increased risk of ADEM or other neuro-
ogic events associated with the vaccine. The hazard ratio was  1.41
95% CI 0.35–5.73) based on three cases of ADEM in the 6 weeks
ollowing the vaccine [258].
The rates of reported neurologic events, including ADEM, fol-
owing pandemic H1N1 inﬂuenza vaccines did not differ for
djuvanted vs. unadjuvanted vaccines in the EudraVigilance
urveillance system, but these data cannot be used to determine
ausal associations as no control populations were studied [259].
ne child with ADEM after an AS03 adjuvanted pandemic H1N1
nﬂuenza vaccine was reported in Canada [260].
.8.5. Other reviews
The Clinical Immunization Safety Assessment (CISA) network
stimated the biologically plausible time window for ADEM follow-
ng immunizations should be from 48 h to six weeks [26,27]. Case
eports of ADEM with onset less than 48 h following inﬂuenza vac-
ines have concluded the vaccine as a causal factor, even though it
ppears to be too short an interval for an immune response with an
nactivated vaccine to cause this type of illness [26,27,261]. CISA
eviewed individual cases of ADEM following vaccines and con-
luded that the causal evidence was indeterminate based on the
ausality algorithm [62,262,263]. In 2011, the IOM concluded that
he evidence was “inadequate to accept or reject a causal relation-
hip between inﬂuenza vaccine and ADEM” ([7] p. 309). Similar
onclusions were reached by other experts following a detailed
eview of the evidence regarding vaccines causing neurological
vents. CDC investigators commented that “although speciﬁc inci-
ents cannot be excluded, and the current available evidence
annot determine that particular host factors in predisposed indi-
iduals may  in some cases result in neurologic disease following a
articular vaccine, the overwhelming evidence suggests that cur-
ently utilized vaccines are safe and not associated with increased
isk of neurologic illness” [227,228].
In summary, the available evidence does not establish a causal
elationship between inﬂuenza vaccines and ADEM, but the evi-
ence cannot rule out the possibility of a small increased risk. There
s no evidence to suggest that any one type of inﬂuenza vaccine may
e more or less likely to be associated with ADEM. 33 (2015) F1–F67 F19
5.9. Multiple sclerosis
Multiple Sclerosis (MS) is an autoimmune chronic inﬂammatory
disease affecting various areas of the central nervous system asso-
ciated with demyelination and axonal loss [264]. Case deﬁnitions
for MS  have evolved over the past 15 years and different criteria
are used for establishing the diagnosis in pediatric patients [264].
As with other autoimmune diseases, there is evidence for a
genetic predisposition. Multiple genes have been associated with
MS and there is evidence for different rates of disease in different
ethnic groups [264]. The pathogenesis appears to involve T cells,
B cells, antibodies, and most likely the innate immune system.
Environmental factors believed to contribute to the pathogene-
sis include decreased exposure to sunlight, vitamin D deﬁciency,
infections, and passive exposure to cigarette smoke [264]. Multiple
infectious agents have been investigated as possible contributing
factors without clear and convincing evidence for any single infec-
tious agent. The focus of attention in recent years has been on
Epstein–Barr virus (EBV), herpes simplex virus type I (HSV-1), and
cytomegalovirus (CMV) infections early in life. The evidence for
an association with EBV infection has biologic plausibility because
the primary genetic marker associated with MS  (human leukocyte
antigen (HLA)-DRB1) codes for a co-receptor for EBV entry into cells
[264,265]. Some studies found an increased prevalence of antibody
to EBV in children with MS  [265]. However, a recent study of 189
children with MS  found no differences in antibody to EBV, HSV-1,
or CMV  [393]. Associations between HSV-1 had either a protec-
tive effect or increased risk depending on other genetic markers in
patients with MS;  some data suggested that CMV  infections could
be a possible protective factor [392].
MS must be differentiated from several other neurologic dis-
orders. Many patients have an initial episode of neurologic illness
diagnosed as ADEM that later is found to be MS based on relapses
and additional clinical criteria. Most affected individuals have onset
as adults, but 1.7–5.6% in different populations have onset prior to
18 years of age [264]. The majority of pediatric cases have onset at
13–16 years of age, but cases have occurred in individuals less than
10 years of age. The incidence is higher in temperate climates than
tropical climates and risk may  be related to decreased exposure to
ultraviolet light.
Authors of case reports have made the assumption that since
infections play a role in the pathogenesis of MS,  vaccines, including
inﬂuenza vaccines, could cause or exacerbate MS.
5.9.1. Epidemiological evidence
The incidence of MS  is too low to be detected in clinical trials.
Finding no increased risk in randomized clinical trials involving
relatively small numbers of study participants with limited follow-
up does not rule out a causal association for uncommon or rare
adverse events [215]. With an annual incidence of about 0.5 cases
per 100,000 person years among children [264], MS  risk cannot be
evaluated in moderate sized clinical trials.
A systematic review of the literature (see Methods and
Appendices 1 and 2) identiﬁed 7 studies (with some duplication
of data among two of these studies) that included a control group
(Appendix 6). Four of the 7 studies were case–control studies and
3 were cohort studies. Inactivated vaccines were the focus of 6 of
these studies. Only 2 of these studies included meaningful num-
bers of children and results were not stratiﬁed by age. Four of these
studies were conducted in Europe and one each in Canada, the US,
and Taiwan. All 7 studies found no relationship between MS  onset
with inﬂuenza vaccination.The IOM reviewed data through the 2008–09 inﬂuenza season
and concluded that there was  limited epidemiological evidence
regarding inﬂuenza vaccines and MS  onset among adults [7]. The
IOM based their conclusions on two of the studies in Appendix 6
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[266,267], lines 2–3) and did not consider one of the studies in
ppendix 6 ([268], line 4) because of serious methodological lim-
tations. One additional study ([269], Appendix 6 line 2) was  not
dentiﬁed by the IOM and is described below. Subsequent to the
OM review three additional studies have been published examin-
ng MS  onset and inﬂuenza vaccines, described below.
A case–control study was conducted in Italy among 140 consec-
tive patients at an MS  center who were matched by age and gender
ith 131 blood donor controls ([269], Appendix 6 line 2). Results
f this study indicated that inﬂuenza vaccines were not associated
ith MS  (OR 1.6, 95% CI 0.7–3.3).
A retrospective cohort study was conducted of all residents of
tockholm, Sweden in the 2009–10 inﬂuenza vaccination season
[197], Appendix 6, line 4). The study included nearly 2 million peo-
le, 52% of which were vaccinated with 2009–10 pandemic A/H1N1
some with AS03 adjuvant). MS  and other outcomes were identiﬁed
y International Classiﬁcation of Diseases, 10th revision (ICD-10)
odes for hospital admissions and visits to specialty care. The study
ound 3795 MS  cases among vaccinated and unvaccinated persons,
ith an adjusted odds ratio of 0.93 (95% CI 0.68–1.26). Children
ere included in the study but results were not stratiﬁed by age.
he study did not consider prior inﬂuenza vaccination nor were
CD-10 diagnostic codes validated with chart review.
A prospective cohort study ([258], Appendix 6, line 6; note some
verlap with [197], Appendix 6, line 4) monitored disease in all
 Swedish regions associated with the immunization campaign
gainst the 2009 inﬂuenza pandemic. With nearly 6 million resi-
ents, about 57% received 2009–10 pandemic A/H1N1 (some with
S03 adjuvant), with higher vaccination rates among children. ICD-
0 codes were identiﬁed from hospitalizations and non-primary
are outpatient visits, identifying 1003 incident MS  cases, for an
djusted odds ratio of 1.04 (95% CI 0.95–1.15) for vaccinated com-
ared to unvaccinated individuals. Children were included in the
tudy but results are not presented stratiﬁed by age. The study did
ot consider prior inﬂuenza vaccination nor were ICD-10 diagnostic
odes validated with chart review.
The third study published since the IOM review ([270], Appendix
, line 5) was a small retrospective study conducted in Taiwan with
 cases aged 65 years and older, ﬁnding an adjusted odds ratio of
.35 (95% CI 0.07–1.77) for vaccinated compared to unvaccinated
ersons.
A meta-analysis [271] combined data across the four studies
n Appendix 6 published before 2011 ([266], line 1; [269], line 2;
267], line 3; and [268], line 4) and found no relationship between
nﬂuenza vaccines and MS  (odds ratio 0.97, 95% CI 0.77–1.23).
Six studies that included a control group examined associations
etween inﬂuenza vaccines and MS  relapse; 4 were clinical trials,
 was a case-crossover, and 1 was a cohort study. Inactivated vac-
ines were the focus of 3 of these studies. Four of these studies
ere conducted in the US, 1 in Israel and one in Europe. All six
tudies found no relationship between MS  relapse associated with
nﬂuenza vaccination.
The IOM concluded that there was limited conﬁdence in the
pidemiological evidence regarding inﬂuenza vaccines and MS
elapse, considering data through the 2008–09 inﬂuenza season.
he IOM based their conclusions on the two studies in Appendix 6
[272], line 9 and [273], line 11). The IOM determined one of the
tudies included in Appendix 6 ([274], line 10) was too small to
e informative and the publication did not state if the treatment
ssignment was random. The IOM review did not identify two  of
he studies included in Appendix 6 ([275], line 7; [276]) and did
ot include one study in Appendix 6 ([277], line 12) as it was pub-
ished beyond the time frame of the IOM review. These two studies
n Appendix 6 not considered by the IOM ([275] line 7; [276], line
; [277], line 12) were all relatively small (122 cases among the 3
tudies). 33 (2015) F1–F67
A meta-analysis [271] combined data across four studies in
Appendix 6 published before 2011 ([275], line 8; [276], line 9; [272],
line 10; and [274], line 11 ([273], line 12 was  not included in this
meta-analysis)) ﬁnding no relationship between inﬂuenza vaccines
and MS  relapse (odds ratio 1.24, 95% CI 0.89–1.72).
Two letters to the editor were published with data on MS  relapse
that are not included in our table as they are not research articles
identiﬁed by the systematic search (see appendix for methods). In
a self-controlled case series, 137 MS  patients with deﬁnitive clini-
cal diagnosis of relapsing-remitting MS  in Argentina were offered
monovalent H1N1 and trivalent seasonal vaccine containing the
H1N1 strain [394]. Risk windows of 30, 60 and 90 day risk windows
following vaccination were evaluated and compared to control
windows of up to 11 months following vaccination. The relapse
ratio for risk vs. control window was  0.86 (95% CI 0.2–3.6) for the
30-day risk window and similar results were found in the sec-
ondary analysis for 60- and 90-day risk windows. A case-crossover
study conducted among MS  patients who  attended an acute relapse
clinic in the UK in 2009–10 suggested the possibility of an increased
relapse rate associated with H1N1 inﬂuenza vaccine [278]. Among
30 consecutive patients with relapses, 10 patients (33.3%) had
received H1N1 vaccination within 3 weeks prior to relapse com-
pared to lower rates in the control periods prior to relapse (relative
risk 6.0, 95% CI 1.4–26.2). The authors acknowledge several limita-
tions, including small numbers of patients studied, but this report
has other limitations, including selection of patients during the
time when H1N1 vaccine was  administered and picking a shorter
risk window than other investigators have used. Also, information
was not provided to document lack of referral bias to a clinic with
an interest in inﬂuenza vaccine as a possible trigger for MS  relapses.
5.9.2. Summary and conclusions
The hypothesis that inﬂuenza vaccines could cause MS  onset or
relapse was  based on the belief that infectious agents may trigger
MS in genetically susceptible populations and case reports show-
ing a temporal relationship between receipt of inﬂuenza vaccines
and onset or relapse of MS.  Epidemiological evidence indicates that
exposure to environmental factors in the ﬁrst 15 years of life is asso-
ciated with the risk of development of MS.  In recent years, inves-
tigators have focused on EBV, HSV-1, and CMV  as possible factors
associated with MS  as there is some biologic plausibility for these
viruses to have an interaction with the underlying genetic factors
that have been identiﬁed. There is much less interest in inﬂuenza
infection or vaccines as causative factors because of consistent neg-
ative ﬁndings with regard to association with risk of MS  in multiple
studies and no biologically plausible mechanism has been identi-
ﬁed to explain how these exposures early in life contribute to the
risk of MS  later in life. Although each of the epidemiological stud-
ies reported to date has had relatively low power to rule out an
increased risk, these studies as a group provide consistent evidence
against a causal association between inﬂuenza vaccines and MS
onset or relapse among adults. Studies are more limited in children
due, in part, to the lower risk of disease but there is no signal to indi-
cate evidence of concern. Taking all of the evidence into considera-
tion, it is highly unlikely that the inﬂuenza vaccines studied to date
are associated with MS  onset or relapse among children or adults.
5.10. Narcolepsy
5.10.1. Background
Narcolepsy is a chronic disorder of excessive daytime sleepiness
associated with loss of hypocretin secreting cells in the hypotha-
lamus and absence of hypocretin in the cerebrospinal ﬂuid [279].
Many affected individuals also have cataplexy, sudden episodes
of voluntary muscle weakness, including collapse. The diagnosis
of narcolepsy based on the International Classiﬁcation of Sleep
accine
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isorders requires the presence of excessive daytime sleepiness
nd cataplexy or abnormally low CSF hypocretin-1 concentration,
ith some modiﬁcations for young children [279]. The Brighton
ollaboration level I criteria include excessive daytime sleepiness
r cataplexy, and CSF hypocretin-1 deﬁciency [280]. Criteria for
evel 2 or level 3 do not require measurement of CSF hypocretin-1,
ut do have requirements for abnormal test results based on the
ultiple Sleep Latency Test (MSLT). All levels require the absence
f other mimicking disorders.
The onset of narcolepsy is usually after four years of age, with a
eak onset between 10 and 30 years of age [279]. Prior to the pub-
icity about narcolepsy in 2010, the diagnosis was  often delayed
or several years after onset of symptoms due to the nonspe-
iﬁc nature of presenting signs and symptoms, and the need for
eﬁnitive tests at referral centers. There is evidence for a genetic
redisposition to narcolepsy. Almost all affected pediatric patients
ave the HLA-subtype DQB1*602, but only a small proportion of
ndividuals with this marker developed narcolepsy. Environmen-
al factors, including infections, appear to play a role in triggering
he onset of disease. These observations have led to the hypoth-
sis that narcolepsy is an autoimmune disease [279,281]. Several
andidate mechanisms for autoimmunity have been proposed with
nconsistent ﬁndings [279,281,282]. One study found evidence for
ross reactivity between an inﬂuenza virus nucleoprotein and a
ypocretin receptor and that patients with vaccine-associated nar-
olepsy had antibodies to this receptor [409]. Several studies have
evealed that patients with narcolepsy are more likely to have
ntibodies to Streptococcus pyogenes, commonly known as group
 beta-hemolytic streptococcus, a common cause of pharyngitis
nd skin infections, or higher titers of antibodies to streptococcal
ntigens as summarized in a recent review [279].
The prevalence of narcolepsy varies by ethnic group and geo-
raphic region from 0.23 per 100,000 people in Israel to 160 per
00,000 people in Japan, with an overall geometric mean of approx-
mately 30 per 100,000 people [279]. This variability in background
ates of narcolepsy generally corresponds to different prevalence
ates of the HLA-subtype DQB1*602 markers in Europe and North
merica (see Fig. 6) [279]. However, there are no data on the
revalence of narcolepsy in areas of Africa where there is a high
revalence of the HLA-subtype DQB1*602.
Eight different pandemic H1N1 inﬂuenza vaccines were licensed
nd used in Europe in 2009–2010. Approximately 39 million
Fig. 6. Used by perm 33 (2015) F1–F67 F21
doses of a pandemic H1N1 vaccine produced by GlaxoSmithKline
(Pandemrix) containing AS03 adjuvant were administered in
Europe [283]. Smaller numbers of the other vaccines were adminis-
tered to selective populations in some countries. Active monitoring
of reports of adverse events in most countries during the large-
scale campaigns to administer pandemic 2009 H1N1 vaccines did
not detect unusual numbers of reports of narcolepsy following the
vaccines in most countries [284]. In Finland and Sweden, dramatic
increases in the rate of diagnoses of narcolepsy were noted in
children following the immunization campaigns. The majority of
children who  developed narcolepsy had received pandemic H1N1
vaccine [285,375]. These concerns were initially met  with skep-
ticism, but population-based epidemiologic studies conﬁrmed an
increased risk associated with the vaccine [258,283,286,395].
In Finland, a retrospective cohort study was conducted among
4–19 year-old children [286]. Cases meeting levels 1–3 of the
Brighton collaboration criteria were included and, in the primary
analysis, only cases diagnosed prior to publicity about a possible
causal relationship with the vaccine were included. There are often
long delays from the onset of symptoms to establishment of a diag-
nosis at a referral center. The primary analysis used time to ﬁrst
contact with a healthcare provider for the onset of disease. The inci-
dence of narcolepsy among vaccinated children was  9.0 per 100,000
person years compared to 0.7 per 100,000 person years for unvac-
cinated children for a rate ratio of 12.7 (95% CI 6.1–30.8). Sensitivity
analyses revealed statistically signiﬁcant elevated rate ratios using
(a) different time periods for inclusion of cases to evaluate the
impact of publicity on case recognition, (b) time from vaccination to
parental recall of symptom onset, (c) time to referral to a specialist,
and (d) time to diagnosis (see Fig. 7).
Retrospective cohort, case–control, self-controlled case series,
case coverage, and self-controlled risk interval studies were con-
ducted in other countries. These studies used different time
windows for comparison of incidence rates before and after
vaccination, comparisons between vaccinated and unvaccinated
populations, the dates used for capture of cases, and the statis-
tical tests applied. Studies in Sweden, Norway, Ireland, England,
and France revealed signiﬁcant increases in risk associated with
the vaccine (Appendix 7). The estimated relative risks (RR), odds
ratios (OR), or incidence rate ratios (IRR) ranged from 2 to 16.
The increased risk was  primarily in children, but studies have
revealed smaller elevated risks in adults in France, Sweden, and
ission [378].
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inland. In France, a case–control study of patients with narcolepsy
ith cataplexy from 13 centers matched with multiple controls,
ound an odds ratio of 6.5 (95% CI 2.1–19.9) in subjects <18 years
f age, and 4.7 (95% CI 1.6–13.9) for those 18 and over [396]. In
weden, a 2-fold increase in risk was noted in individuals 21–30
ears of age [279]. In Finland, a 3–5 fold increased risk was noted in
dults 20–64 years of age with an attributable risk of 1/100,000 per-
on years as compared to 6/100,000 person years for children [287].
Upon a request from the European Medicines Agency (EMA),
he ECDC (E219) and the Vaccine Adverse Events Surveillance and
ommunication consortium (VAESCO) coordinated a case–control
tudy in both children and adults in Denmark, Finland, Italy,
he Netherlands, Norway, Sweden, and the UK (E219). Cases met
righton Collaboration criteria. The same cases included in the
tudy were also included in the individual country studies. Con-
rols were selected from the same population and matched on age,
ex, and index date. In the primary analysis the timing for cases
as based on the referral to the MSLT; in the sensitivity analy-
is to use time to onset of excessive daytime sleepiness and time
o diagnosis. In the signaling countries of Sweden and Finland, a
ighly signiﬁcant association was found with exposure to the AS03
djuvanted vaccine (OR 14.2 (95% CI 2.5–inﬁnity) for children and
dolescents. No signiﬁcant association was found in adults (OR 1.2
95% CI 0.2–9.1). In the non-signaling countries, no signiﬁcant asso-
iations with the vaccine were found for children and adolescents
.6 (95% CI 0.5–6.1), or for adults (OR = 3.7 95% CI 0.7–20.7) (E219).
VAESCO also compared the rates of narcolepsy diagnoses in the
ine years prior to the immunization campaign and the year fol-
owing the campaign in large linked databases for health outcomes
n Sweden, Finland, the UK, the Netherlands, Denmark, and Italy
289]. This study conﬁrmed increases in rates of diagnosis of nar-
olepsy in Sweden, Finland, and Denmark following immunization
ampaign, but did not identify increases in the other countries.
n Denmark, which used a different vaccine, the cases included
ere not conﬁrmed and some had onset prior to vaccination. A
ollow-up report from the Netherlands Pharmacovigilance Centerission [286].
indicates that there may  have been a number of cases that had
not been diagnosed at the time of the VAESCO report, and that
many of these were in children under ﬁve years of age. Many of
the cases included in the above two studies have been included in
reports from the individual countries; these are not independent
studies.
An AS03 adjuvanted pandemic 2009 H1N1 vaccine (Arepanrix®,
GlaxoSmithKline Inc.) used in Canada was  manufactured at a dif-
ferent location than the vaccine used in Europe with some
differences in production methods [281,283]. No signal of an
association between this vaccine and narcolepsy was  noted during
the active monitoring period. In Ontario, Canada, 4.8 million doses
of Arepanrix® were administered in a population of 13.2 million.
Among the 1603 reports of adverse events following immunization
in 2009 and 2010, no cases of narcolepsy were identiﬁed among
persons 4–29 years of age [2]. In Québec, analyses were conducted
using cases meeting Brighton Collaboration criteria and analyzed
by three different methods [377]. A retrospective cohort study
revealed a RR of 4.58 (95% CI: 1.59–11.77) based on a small number
of cases (see Appendix 7). The absolute attributable risk estimate
was about 1 case per million vaccine doses. A self-controlled
case series analysis revealed a RR of 4.82 (95% CI: 1.75–13.31).
For persons <20 years of age the RR was 6.39 (95% CI 1.6–23.38)
and was not signiﬁcantly increased for those ≥21 years of age.
A case–control study using the same patients revealed a non-
signiﬁcant OR of 1.48 (95% CI: 0.37–7.03). The OR was  3.21 (95% CI:
0.37–90.37) among persons less than 20 years of age (6 exposed
vs. 2 not exposed) and was  0.73 (95% CI: 0.06–6.70) among adults
(2 exposed vs. 3 not exposed).
Differences in the risk estimates for associations between the
Pandemrix vaccine in different countries may  be due, in part, to dif-
ferences in the prevalence of the HLA-subtype DQB1*602 [279]. The
strongest associations were in northern Europe with intermediate
rates in the rest of Europe and a lower risk in Canada, consistent
with the relative frequencies of the prevalence of HLA-subtype
DQB1*602 markers.
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No cases of narcolepsy have been reported as adverse events fol-
owing the distribution of 23.26 million doses of a pandemic 2009
1N1 inﬂuenza vaccine containing the MF59 adjuvant in Europe
281,290]. No studies have been published with the other 6 vaccines
sed in Europe indicating any evidence of an increase in risk of nar-
olepsy following these vaccines. In a claims-based system in the
nited States involving 12 million persons (approximately 4% of the
S population), no increased risk of narcolepsy was detected in the
0 days following vaccination using electronic medical records and
he self-controlled risk interval method for the monovalent vaccine
sed in 2009, or trivalent seasonal vaccines used in 2009–10 or in
010–11 [291]. Also, no cases were noted in the 180 days follow-
ng administration of 650,995 doses of the 2009 pandemic 2009
1N1 inﬂuenza vaccine without an adjuvant in the VSD popula-
ion. In the following year, only 2 cases were noted in the 180 days
ollowing administration of the seasonal vaccine when 8.83 cases
ould be expected based upon the baseline incidence rate in the
S population [292].
Historically, clinical descriptions of a disorder called “encephali-
is lethargica”, which could have been narcolepsy, were reported
ollowing the 1918 H1N1 inﬂuenza pandemic [397]. There is evi-
ence for seasonality in the reported diagnoses of narcolepsy
onsistent with inﬂuenza infections as a trigger factor, and an
ncrease in diagnoses of narcolepsy was temporally associated with
1N1 disease at one sleep disorder center in China where no H1N1
accines were administered, with a subsequent decline in reported
ases the following year [293]. However, no increase in narcolepsy
iagnoses associated with the pandemic virus has been reported
rom other countries affected by this pandemic virus where the
S03 adjuvanted vaccine was not used, including the United States
nd South Korea [279]. There was also speculation that infection
ith the H1N1 virus along with exposure to the AS03-adjuvanted
accines could have resulted in an increased risk of narcolepsy.
owever, in Finland less than 10% of the children who  developed
arcolepsy had a history of a respiratory infection prior to the onset
f illness [279]. Also, only 2 of 45 children in Finland who  developed
arcolepsy had evidence of antibody to a nonstructural protein in
he H1N1 virus that was not present in the vaccine [294].
Speculation that a unique viral protein in combination with the
S03 adjuvant could have explained the higher risk associated with
he Pandemrix vaccine than the vaccine used in Canada [281]. The
nal data from Québec revealed some increased risk associated
ith the Arepanrix vaccine [377]. The estimated attributable risk
n Canada was one per million children immunized, as compared
ith one per 16,000 in Finland. This difference in risk could be due
o differences in manufacturing processes and/or the prevalence of
enetic predisposition to narcolepsy [283]. Pandemrix vaccine con-
ained higher amounts of a structurally altered viral nucleoprotein
han Arepanrix, and children with narcolepsy had higher antibody
esponses to this protein than did control children. These differ-
nces in vaccine composition might explain the differences in the
isk of narcolepsy [295,409].
One report of CD4+ cells in persons with narcolepsy cross-
eacting with hypocretin was subsequently withdrawn because of
n inability to reproduce the results [296].
.10.2. Summary and conclusion
The evidence from multiple studies by different investigators
n different populations using different methods has revealed
 consistent strong association between the Pandemrix vaccine
eceipt and narcolepsy. The geographic differences in estimated
isks are consistent with the geographic distribution of genetic
arkers associated with narcolepsy. This evidence indicates a
ausal relationship with narcolepsy. The evidence available to date
oes not indicate any increased risk of narcolepsy associated with
ther inﬂuenza vaccines, including vaccines without an adjuvant 33 (2015) F1–F67 F23
and the MF59-adjuvanted vaccine. Further studies are needed to
identify the biological mechanisms responsible for increased risk
of narcolepsy.
5.11. Bell’s palsy
5.11.1. Deﬁnition
Bell’s palsy (seventh cranial nerve paralysis) is an acute uni-
lateral lower motor neuron facial paralysis. The deﬁnition of
Bell’s palsy has evolved and varied over time [297]. The Brighton
Collaboration has a working group developing a standard deﬁni-
tion of Bell’s palsy. Key features generally include: acute onset,
peripheral nerve involvement, unilateral, non-recurrent, complete,
monosymptomatic, and idiopathic. This monosymptomatic illness
can manifest with varying severity: ranging from mild paresis to
complete paralysis. Reactivation of HSV-1 or varicella zoster virus
and Lyme disease are recognized predisposing infections to paraly-
sis of the seventh cranial nerve [297]. Some authors consider these
infections to be diagnoses of exclusion for Bell’s palsy and others
list them as known causes of the conditions. The incidence of Bell’s
palsy in adults is 25 per 100,000/year [298]. The annual incidence of
Bell’s palsy is 2.7 per 100,000 children under 10; the rate incidence
increases to 10.1/100,000 for persons 10–20 years of age [297].
The pathophysiology of Bell’s palsy is not completely under-
stood. In children, the onset usually occurs hours to days after an
upper respiratory tract infection and resolves spontaneously with-
out treatment. In some cases, it is inﬂammation of the facial nerve
with mononuclear cells [298] and this can be due to infection or
an inﬂammatory process. The inﬂammation of the facial nerve and
entrapment in the meatal foramen and the labyrinthine segment
[297] lead to the disorder. The pathogenesis in some instances may
be due to a post-infectious demyelinating process [297]. Bell’s palsy
may  be preceded by sensory disturbances, pain behind the ear, loss
of taste unilaterally on the tongue [297,298]. Infections most com-
monly associated with Bell’s palsy include Lyme disease, HSV-1;
varicella zoster virus reactivation in the geniculate ganglion with or
without vesicular rash (Ramsay Hunt syndrome), with other viruses
causing it less commonly.
5.11.2. Causal association
There is no known association between inﬂuenza virus infection
and Bell’s palsy [246,299]. Bell’s palsy associated with inﬂuenza
vaccine was ﬁrst reported after the introduction of an inactivated
virosomal-subunit intranasal inﬂuenza vaccine that was  adju-
vanted with E. coli heat-labile (LT) toxin. This vaccine (Nasalﬂu®)
was developed by Berna Biotech and licensed in Switzerland for
the 2000–2001 inﬂuenza season. The vaccine was ﬁrst available
in October 2000 and by April 2001, 46 cases of Bell’s palsy after
vaccination had been reported [300,399]. A total of 412 patients
with Bell’s palsy were identiﬁed during the study period. Two hun-
dred ﬁfty cases were matched to 722 controls. Of  the cases, 68
(27.2%) had received the intranasal vaccine compared with 8 (1.1%)
of the controls, leading to an adjusted odds ratio of 84.0 (95% CI
20.1–351.9). In this study, there was  no increased risk of Bell’s palsy
after receipt of the parenteral vaccine: OR 1.1 (9%CI 0.6–2.0). The
peak onset interval of Bell’s palsy after the intranasal vaccination
was 31–60 days. These ﬁndings led Berna Biotech to withdraw that
product permanently [300]. Since this ﬁnding, there has been inter-
est in determining whether or not other inﬂuenza vaccines cause
Bell’s palsy.
Two  phase I vaccine trials, one of intranasal Mycobacterium
tuberculosis antigen and the second, an HIV antigen both adju-
vanted with modiﬁed E. coli heat labile toxin were halted when 1 of
9 recipients of the adjuvanted M.  tuberculosis vaccine recipients and
1 of 20 of the subjects in the adjuvanted arms of the HIV vaccine trial
developed Bell’s Palsy [301]. E. coli LT and cholera toxins are actively
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aken up by peripheral nerves and undergoes retrograde axonal
ransport by binding neuronal gangliosides [299,302]. Subsequent
tudies in mice, although not in other species, found endotoxin in
he olfactory bulb after intranasal installation [303]. The most likely
ypothesis for the association with all three vaccines and Bell’s
alsy is that the E. coli enterotoxin resulted in inﬂammation and
ntrapment of the facial nerve in the facial canal [301].
.11.3. Case reports
Individual reports of Bell’s palsy after currently licensed IIV have
een made [304], including a recent report of a 9 year old boy with
solated left facial nerve palsy 9 days after receipt of the H1N1 pan-
emic inﬂuenza vaccine [305]. MRI  of the brain in this case revealed
nhancement of both internal auditory canals and facial nerves,
ight greater than left. Other than a temporal association with vac-
ination, these cases do not provide additional evidence for a causal
elationship.
.11.4. Population-based studies
Reports of Bell’s palsy to VAERS in the US after IIV from
991 to 2001 revealed a signal of possible increased number of
ell’s palsy reports the ﬁrst month after IIV vaccination in all
ge groups, greatest for those >65 years and 40% of the 154
ases reported occurred within 1–3 days after vaccination [400].
owever, population-based studies of Bell’s palsy after inﬂuenza
accination found no association [70,291,306]. A VSD analysis over
 seasons (2005–2008) in which 1.2 million doses of IIV were given
o children and 4.7 million were given to adults found no increased
ignal of Bell’s palsy after vaccination [306]. Claims-based data
fter H1N1 (both inactivated and live) vaccination of over 500,000
eople in a large insurer revealed that, in the ﬁrst 42 days after
accination compared with days 43–84 after vaccination, there
as an incident rate ratio (IRR) for Bell’s palsy in all ages 1.16
95% CI 0.75–1.84) [291]. Analysis of nearly 1 million seasonal IIV
ecipients also showed no increased risk of Bell’s palsy in that popu-
ation [IRR 0.83 (95% CI 0.60–1.15)] [291]. PRISM (FDA Postlicensure
apid Immunization Safety Monitoring) data also looking at H1N1
nactivated vaccination with or without seasonal vaccine (over 3
illion doses) showed an IRR of 1.21 (99% CI: 0.54–2.69) in per-
ons 6 months to 24 years of age, and 1.23 (99% CI: 0.88–1.73) in
hose ≥25 years [307]. When those who had received only pan-
emic H1N1 vaccine were analyzed, the rate was not signiﬁcant
or persons ≤24 year olds, however those ≥25 years of age had an
RR of 1.65 (99%CI 1.03–2.64; p = 0.006). The authors cautioned that
ndings might have been confounded by seasonal differences in
ates. No clusters of timing after immunization were found using
he temporal scan statistic. In addition, corrections for multiple
omparisons were not made in these analyses. A self-controlled
ase series of a large database in the United Kingdom (the Gen-
ral Practice Research Database) identiﬁed 2263 episodes of Bell’s
alsy between 1992 and 2005. The relative incidence of Bell’s palsy
as 0.97 (95% CI: 0. 84–1.13) for onset 1–91 days after vaccination
ompared to control periods [401].
The VSD was also used to monitor the safety of seasonal and pan-
emic (H1N1) 2009 vaccines during the 2009–10 inﬂuenza season
sing a self-controlled study design with variable risk windows for
ignal detection of 11 different disease outcomes [402]. Since multi-
le outcomes were tested at weekly intervals for four different vac-
ines, sequential statistical testing was used to adjust for multiple
esting. All age groups were monitored, and more than 4.5 million
oses of vaccine were administered (1,345,663 H1N1 inactivated
accine, 267,715 H1N1 live attenuated vaccine, 2,741,150 seasonal
IV, and 157,838 LAIV). The coverage rates for seasonal vaccines was
1% for children 6–23 months of age, 56% for those 24–59 months
f age, 36% for children 5–17 years of age. Coverage rates for the
andemic (H1N1) 2009 vaccines were somewhat lower [402]. No 33 (2015) F1–F67
signals were detected in children for any of the outcomes. For adults
25 years of age and older, a signal was detected for Bell’s palsy fol-
lowing the inactivated pandemic (H1N1) 2009 vaccines, but not for
the other vaccines. There was no evidence of temporal clustering;
adjusting for seasonality using a case-centered logistic regression
analysis revealed an odds ratio of 1.26 (95% CI: 0.97–1.63) for adults.
Seasonality has been observed for Bell’s palsy in other popula-
tions. Chart reviews to conﬁrm cases were not performed. The
authors noted that in a previous study using the VSD, only 72%
of reported cases of Bell’s palsy were conﬁrmed after chart review
[402].
For the MF59-adjuvanted pandemic (H1N1) 2009 vaccines
(Focetria, Novartis), in passive reporting from the EU, no signiﬁ-
cant difference in facial palsy reports were submitted as compared
to reports following a non-adjuvanted seasonal vaccine [70].
5.11.5. Summary
Although some signals suggested the possibility of an increased
risk of Bell’s palsy, the available evidence does not indicate an
increase in adults and the overall evidence does not support an
increased risk in any age group.
5.12. Immune thrombocytopenia (ITP) or immune
thrombocytopenic purpura
Immune thrombocytopenia (ITP) is currently the preferred term
for diseases that were previously called idiopathic thrombocy-
topenic purpura or immune thrombocytopenic purpura [308]. For
the purposes of this review, we  will use the acronym ITP to refer
to all three names that have appeared in the literature. ITP is
usually deﬁned as the development of a platelet count less than
100 × 109 L−1 in the absence of other causes or diseases that may
cause thrombocytopenia [308]. Most pediatric patients present
with petechiae and no or mild bleeding; rarely severe bleeding
occurs, but children with ITP are at increased risk of signiﬁcant
bleeding from mild trauma [309]. The majority of patients with
ITP have autoantibodies directed against receptors on the platelet
surface [310].
5.12.1. Causal factors
Most pediatric patients have a preceding respiratory illness
and the pathogenesis is assumed to involve development of cross-
reacting antibodies stimulated by the infection. Measles-containing
vaccines are a recognized cause of ITP [311]. Transient decreases in
platelet counts are observed in most children within a few days
after receiving measles vaccine, presumably because of a direct
interaction between the measles vaccine virus and circulating
platelets [312]. Several population-based studies have documented
an increased risk of ITP and a meta-analysis of 12 studies indicates
a rate of 2.6/100,000 children receiving a ﬁrst dose of measles-
containing vaccines [311,313,403–405]. The pathogenesis appears
to involve the measles vaccine virus attachment to platelets and
stimulation of antibodies that cross react with platelet surface anti-
gens.
5.12.2. Case reports
Case reports of new onset ITP following inﬂuenza immun-
izations stimulated speculation that these vaccines might also
stimulate cross-reacting autoimmune response and cause ITP
[311,314–316]. There are also reports of relapses of ITP associated
with TIV [316].5.12.3. Epidemiologic studies
None of the controlled epidemiologic studies reviewed identi-
ﬁed a signiﬁcant association between inﬂuenza vaccines and ITP. In
a case–control study in France involving 224 incident cases of ITP
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n persons ≥15 years of age, 20% of cases and 26% of controls had
eceived inﬂuenza vaccines in the preceding 12 months (OR 0.66,
5% CI: 0.45–0.98) [317].
Self-controlled case series methods have been used to assess
he risk of ITP following inﬂuenza vaccines in several popula-
ions using the 42 days following vaccines as a risk window. In
 health plan in the United States where 3.1 million persons of
ll ages received seasonal inﬂuenza vaccines between 2006 and
009, there was no evidence of an increased risk of ITP follow-
ng vaccine as compared to the pre-vaccination control window
IRR = 0.74, 95% CI: 0.42–1.31) or the post-vaccination control win-
ow (IRR = 0.78, 95% CI: 0.43–1.40) [406]. In Taiwan, 3.5 million
oses of pandemic H1N1 inﬂuenza vaccines were administered; the
ncidence of ITP was not signiﬁcantly different in the risk vs. control
indows for inﬂuenza vaccines without an adjuvant (IRR = 1.09,
5% CI: 0.65–1.85) or for vaccines containing the MF59 adjuvant
IRR = 0.56, 95% CI: 0.13–2.36) [241]. In a population of 1.8 million
hildren <18 years of age who participated in a managed care orga-
ization in the United States, 197 chart conﬁrmed cases of ITP were
dentiﬁed in 2000–2009 [313]. No signiﬁcantly elevated risks were
dentiﬁed following TIV, but this study did conﬁrm the elevated risk
ssociated with MMR  (IRR = 5.48, 95% CI: 1.61–18.64). A 2009–2010
etrospective cohort study in northern Italy matched 103,642 per-
ons (12,447 0–17 years of age) who received an MF59-adjuvanted
andemic H1N1 vaccine with an equal number of controls [318].
here was no evidence for an increased risk of ITP (OR of 1.0) in
he 6 weeks following vaccination. Also, there was no elevated risk
f ITP during the six weeks following inﬂuenza vaccines with the
F59 adjuvant or without an adjuvant among persons 65 years of
ge or older.
There was no increased risk of ITP among 2.1 million veterans
n the United States in the 42 days following inﬂuenza vaccines in
010–2011 as compared to later times using a self-controlled case
eries method (IRR = 0.71, 95% CI: 0.32–1.59) [319].
.12.4. Summary
Epidemiological evidence from different studies by different
nvestigators in different populations, consistently reveals no
ncreased risk of ITP associated with inﬂuenza vaccines.
.13. Other disorders
There are case reports of other disorders following inﬂuenza
accines involving different organ systems including pericarditis,
enous thrombosis, myocardial infarctions, stokes, etc. However,
his review did not identify sufﬁcient epidemiologic or other data
o justify in depth reviews of these topics.
. LAIV and LAIV-L
.1. Brief history of live attenuated inﬂuenza vaccines and safety
ssues
Safety concerns that have been raised about live attenuated
nﬂuenza vaccines include fever, respiratory infections or symp-
oms, wheezing, increased hospitalizations, and use in individuals
ith underlying conditions, including immunosuppression and
sthma. Pre-licensure studies in the development of live vac-
ines utilized different cold-adapted strains for the backbone virus
320]. These backbones were not consistently attenuated or were
enetically unstable [320]. When tested in humans, some were
nacceptably reactogenic. The A/Mallard/6750/78 avian-human
old-adapted backbone was found to have unacceptable reactogen-
city in children. An H1N1 monovalent vaccine with A/Kawasaki/86
n the Mallard backbone was tested in children 6–48 months of age
n a dose-escalating trial. The avian-human strain caused greater 33 (2015) F1–F67 F25
febrile reactions than did the A/Ann Arbor strain or placebo. The
children who  received the Mallard vaccine were also more likely
to have upper respiratory tract or inﬂuenza-like symptoms and
otitis media than were the children in the other groups [407].
Eventually, cold-adapted, temperature-sensitive backbones were
developed which were genetically stable and sufﬁciently atten-
uated yet effective in protecting against inﬂuenza infection and
disease. In the United States, Canada, Israel and Europe, the back-
bone for the inﬂuenza A virus in LAIV (FluMist® and Fluenz®)
is the A/Ann Arbor/6/60 (H2N2) strain and for the B viruses it
is the B/Ann Arbor/1/66. In Russia, the cold-adapted strains are
A/Leningrad/134/47/57 (H2N2) and B/USSR/60/69 [321]. Much of
the English language literature about LAIV safety is based on the
Ann Arbor backbones. The term LAIV is used in this document to
represent the vaccine made on the Ann Arbor backbones. The live
vaccine using the Leningrad and USSR backbones is referred to as
LAIV-L.
6.2. Preferential use and restrictions for use of LAIV
Live attenuated inﬂuenza vaccine (LAIV) has been shown to
be very effective at preventing inﬂuenza illness in children, and
may  be more effective than inactivated vaccine in young children
[158,322,323]. Health agencies from several countries and jurisdic-
tions recommend LAIV as the preferred vaccine for eligible children
2–8 years of age [324,325,326]. This recommendation is tempered
by the restrictions for the use of LAIV in children with some under-
lying conditions which vary by country. In February 2015, the ACIP
removed the preference for LAIV because of inconsistency in vac-
cine effectiveness in the previous two years. In the United states,
LAIV “should not be used” in children 2–4 years with a history of
wheezing or asthma in the 12 months prior to vaccination, and
there is a precaution for use in persons of any age with asthma
who might be at increased risk for wheezing after LAIV because
of the concern for worsening symptoms after vaccination ([50],
FluMist® package insert). Also, LAIV should not be used in per-
sons with underlying medical conditions that might put them at
increased risk (chronic pulmonary, cardiovascular, renal, hepatic,
neurologic, or metabolic disorders, or anyone with an egg allergy)
primarily due to a lack of data in these populations, rather than
known increased risk for adverse events.
In the UK, LAIV is preferred and indicated for children 2 to
<18 years of age except those with active wheezing (within 7
days), on oral steroids, or high dose inhaled steroids. LAIV is also
contraindicated in persons with severe immunodeﬁciency from
HIV, malignancy, primary immunodeﬁciency or immunosuppress-
ive therapy [325]. In Canada, the National Advisory Committee on
Immunization (NACI) recommends LAIV preferentially over TIV in
children and adolescents 2–17 years old. Children with stable, non-
severe asthma are also included in the recommended category.
In children with chronic illness, with the exception of immune
compromise or severe asthma, there is no preference for LAIV or
TIV because of lack of evidence (http://www.phac-aspc.gc.ca/naci-
ccni/ﬂu-grippe-eng.php#v).
6.3. Adverse events following LAIV
Vaccine virus shedding following LAIV is inversely correlated
with age; young children are the most likely to shed virus and for
the longest time [327,328,329]. The majority of young children who
receive LAIV shed the vaccine virus for several days; in 9–36 month
olds, viral shedding continues for a mean of 7.6 days [328].In general, the rate of attributed adverse events after LAIV
decreased with increasing age [158,327,330]. The most frequently
reported adverse event after LAIV administration in any age group
was coryza. In early trials of LAIV, more respiratory symptoms
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ere noted after LAIV than after inactivated vaccine or controls
331]. Rates of rhinorrhea varied from 26% in vaccinees of all ages
o 80% in young children compared with rates in placebo recipi-
nts of 19–75% in the same studies 154,158,211,322,328,331–333].
ncreased rates of rhinorrhea are most signiﬁcant in days 2 and
 after vaccination, but are still higher than in controls at 8
r 9 days after vaccination [330]. Although rhinorrhea has been
elated to shedding, there is not a strong correlation between vac-
ine virus shedding and respiratory symptoms after vaccination
327]. An integrated analysis was performed of data from 20 con-
rolled studies with LAIV in children 2–17 years of age (including
any of the studies discussed individually in this review) [334].
n the studies that compared TIV, 4108 children who received
AIV were compared with 4118 TIV recipients. In the placebo-
ontrolled studies, the numbers were 3245 LAIV recipients and
994 placebo recipients. In the TIV controlled study, the most
ommon reactogenicity event among LAIV recipients compared
o TIV recipients was runny/stuffy nose (rate difference 11.8%
fter dose 1 and 4.2% after dose 2 (p < 0.01) [334]. No other
eactogenicity event assessed was greater in the LAIV recipients
han the TIV recipients. In the placebo controlled studies, after
ose 1 LAIV recipients had more runny/stuffy nose (rate dif-
erence 6.8%, p < 0.01), headache (rate difference 6.9%, p = 0.02),
nd tiredness/decreased activity (rate difference 2.1% p = 0.03).
hese adverse events decreased with subsequent vaccinations
334].
.3.1. Fever
It is not clear whether there is an increased risk of fever in
AIV recipients. An early trial of bivalent LAIV vs. IIV and control
n 5210 persons ages 1–65 years over 5 seasons (1985–1990; in
hich 12,500 doses were given) showed that LAIV did not cause
ore fever than IIV or placebo [331]. The authors did not break
he data down by age or year of vaccination but did note that reac-
ion rates were comparable for different age groups and did differ
y year. Later trials in children [158,330,332] showed an increase
n fever rates on day 2 after vaccination compared with placebo
6.5% vs. 1.6% (p < 0.001) [332]; OR 5.23 (95% CI: 2.48–11.0) [330]]. A
lacebo-controlled multicenter study of LAIV vs. placebo in 8 Asian
egions between 2000 and 2003 randomized over 3000 children
ges 12–35 months to LAIV or placebo [211]. One thousand nine
undred children received at least 1 dose (and up to 3 doses over 2
ears) of LAIV. Fever (deﬁned as ≥37.5 ◦C) occurred in 22.0% of vac-
inees and 17.6% of placebo recipients in the 11 days after the ﬁrst
ose (p = 0.004). There was no difference in rates of fever ≥38.6 ◦C
4.9% LAIV, 4.1% placebo (p = 0.323) after dose 1) [211]. This increase
n fever rates was seen after the ﬁrst dose of vaccine and the risk
as lessened or absent in subsequent doses [158,211] and in subse-
uent years with different vaccine components [330]. Other studies
n children as young as 6 months did not ﬁnd increased risk of fever
ue to LAIV [328,322,323,335]. In the integrated analysis, which
ooked at reactogenicity in children 2–17 years of age, no statisti-
ally signiﬁcant increase in fever was found in LAIV vs. TIV or LAIV
s. placebo. Importantly, this analysis did not subdivide the children
y age, and there may  have been differences in rates for different
ge groups [334].
.3.2. Wheezing following LAIV
Interest in whether LAIV vaccines can cause wheezing stems
rom the fact that inﬂuenza virus infections have been associ-
ted with wheezing in young children [336,337]. Although the
echanisms involved in inﬂuenza infection causing wheezingre not completely understood, the pathophysiology is thought
o involve inﬂammatory cytokines [338–340] and perhaps virus-
nduced inﬂammasome activation [341]. Theoretically, the same
echanisms that could lead wild-type inﬂuenza viruses to cause 33 (2015) F1–F67
wheezing could be involved in the pathophysiology of LAIV-
induced wheezing. However, the attenuated vaccine virus is
temperature sensitive and therefore should not be replicating in
the lower respiratory tract.
Several studies have looked at the potential risk of wheezing
after LAIV in children <2 years of age [154,158,211,335,342,343],
with most ﬁnding no increased risk of wheezing after vaccina-
tion. Two  large studies in young children have shown that LAIV
was associated with small, but not signiﬁcantly, higher rates of
wheezing. A large multi-country (US, 12 countries in Europe and
the Middle East, 3 countries in Asia) double-blind, randomized trial
was conducted in 8475 children 6–59 months of age. The rate of
medically-attended wheezing in the 6 weeks after vaccination in
children under 12 months of age who received LAIV compared
to children who  received IIV was  3.8% vs. 2.1% (p = 0.076) [158].
No difference was seen in any other age group. For all children
under 24 months, 3.2% of LAIV recipients and 2.0% of TIV recipi-
ents had medically-attended wheezing (adjusted difference of 1.18
(95% CI: 0.13–2.29) [158]. In another study of 9689 children 1–18
years of age randomized 2:1 to receive LAIV vs. placebo, a higher
level of “asthma events” was  found in 18–35 month-old children
who received LAIV compared with placebo recipients (RR 4.06 90%
CI: 1.29–17.86) [342]. This increased risk occurred throughout the
42-day observation period was not related to the timing of immu-
nization, and was  not seen in other age groups. That study used
conﬁdence intervals of 90%; if the data were reanalyzed using a tra-
ditional 95% CI, the relative risk would not be statistically signiﬁcant
(95% CI: 0.36–23.72) [221]. Of interest, 44% of the children 18–35
months old who  had “asthma” after vaccination had a previous his-
tory of reactive airway disease [342]. For children of all ages (1–18
years) in this study who  had a previous history of asthma/reactive
airway disease, there was  no increased risk, suggesting that the risk,
if any, was  limited to the youngest recipients. In a subset analysis
of the children with wheezing from one of the sites in the Belshe
study, the primary risk factor for wheezing after vaccination was
a family history of asthma, suggesting a genetic predisposition for
wheezing [344].
Several studies of LAIV in children over 2 years of age have not
found a signal for increased wheezing after LAIV [156,158,342].
A prospective observational study of over 82,000 children 24–59
months of age over 3 years showed no increase in asthma or wheez-
ing in children who  received LAIV (n = 28,226 receiving 33,433
doses) compared with 3 different controls (within-cohort controls
(self-controlled risk interval analysis), matched concurrent unvac-
cinated controls and matched concurrent TIV-vaccinated controls)
[345]. Hospitalization for wheezing and asthma was lower in
the LAIV vs. TIV recipients [345]. A non-randomized open label
community-based trial of LAIV conducted over 4 years in 11,000
children 18 months to 18 years [346] found no overall increase in
wheezing or asthma. In a subanalysis, children 18 months to 4 years
had a marginally signiﬁcant increase wheezing during the ﬁrst year
on days 15–42 after vaccination (RR 2.85; 95% CI: 1.01–8.03). How-
ever, this ﬁnding was not seen in the subsequent 3 years [year 2,
identical vaccine, RR 1.42 (95% CI: 0.59–3.42); year 3 RR 0.47 (95%
CI: 0.122–1.83), year 4 RR 0.20 (95% CI: 0.03–1.54)], and the authors
noted it was  likely due to chance as they had not corrected for mul-
tiple comparisons [346]. Children were grouped 18 months to 4
years, so it is not possible to determine if wheezing after LAIV was
greater in those younger than 2 years of age. The integrated anal-
ysis of LAIV trials in children (which included data from several of
the studies mentioned above) found no increase in wheezing or
lower respiratory symptoms in either children 2–17 years of age or
in the subset of children 24–35 months of age [334]. Post-licensure
surveillance of VAERs and other systems have not identiﬁed any
greater than expected reports of asthma or wheezing after LAIV
[74,156,159,160].
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.3.3. LAIV in children with wheezing or asthma
Early studies of LAIV safety demonstrated that rates of wheez-
ng after LAIV were higher in children with a history of asthma or
ecurrent wheezing than in those without that history [158,342].
hese results led to advisory committee recommendations cau-
ioning against using LAIV in children <5 years who had at least
ne episode of wheezing within the last 12 months [50]. Subse-
uently, several studies sought to determine the safety of LAIV in
hildren with a history of asthma or wheezing. When compared to
ither IIV recipients or placebos, there was no difference between
he rates of medically attended wheezing after either LAIV or IIV in
hildren older than 2 years with a history of asthma or recurrent
heezing [158,322,323,347,348]. No difference was  noted in FEV1,
VC, or FEF between vaccinees and placebo recipients after vaccina-
ion or as compared with baseline [347]. In addition, there were no
igniﬁcant differences in asthma symptom scores, nighttime awak-
ning or mean PEFR in 6–17 year olds with asthma who received
AIV [322]. Retrospective analysis of health claim data in children
5 who received LAIV despite having contraindications showed
o increase in hospitalizations in the children who received LAIV
ompared with those receiving TIV over several seasons [159,160].
 multicountry European study found no difference in rates of
heezing between LAIV and TIV recipients (9.3% and 9.9% in the
2 days after the ﬁrst dose, respectively) in children 6–71 months
f age with a history of recurrent respiratory tract infections
323].
.3.4. LAIV in children with underlying conditions
LAIV has generally been found to be well tolerated in the rela-
ively small numbers of children with underlying medical problems
or whom the vaccine is not recommended. LAIV was  given to
4 mildly immunocompromised HIV infected children 1–7 years
f age [349] with no difference in safety signals when compared
o placebo in a crossover design. A larger study of LAIV vs. IIV
n 243 HIV infected children 5–18 years of age on highly active
ntiretroviral therapy also found no increase in adverse events in
he LAIV recipients compared with the IIV recipients [350]. Two
mall studies have examined LAIV in children with cancer who
ad mild-moderate immunosuppression [237,351]. In one study,
8 LAIV recipients were compared to 27 TIV recipients [237] and
n the other, 20 subjects were randomized to LAIV or to placebo
uring the inﬂuenza off-season [351]. Other than more rhinorrhea
nd congestion, the children who received LAIV did not have sig-
iﬁcantly more adverse events than the comparator groups. Also,
hey did not shed LAIV virus (as determined by viral culture and
CR) longer than would be expected (maximum of 7 and 10 days
fter vaccination) [237,351]), which is comparable to shedding in
ealthy children [327].
A recent study in 168 children 2–18 years of age with cys-
ic ﬁbrosis followed children for 56 days after LAIV. Comparing
he “at-risk” period (days 0–28 after vaccination) with the non-
t-risk time window (days 29–56 following LAIV). The LAIV
ecipients did have a greater incidence of mild wheezing after
AIV, especially on the day of vaccination, than in the control
eriod, but no signiﬁcant difference in respiratory deteriora-
ions or hospitalization was found between the time periods
352].
.3.5. LAIV and hospitalizations
A post hoc analysis of the data in the large multi-country
tudy [158] revealed an increased risk for hospitalization from all
auses in LAIV recipients over the 6 months following vaccination
or children 6–11 months of age regardless of prior history of
heezing (6.1% vs. 2.6% in the IIV group p = 0.002). There was also
n increased risk for hospitalization from all causes in children 1–4
ears of age who had a previous history of wheezing at the time of 33 (2015) F1–F67 F27
immunization. The differences for each individual year were not
statistically signiﬁcant. For children without a history of wheezing,
the rates of hospitalization were lower for LAIV recipients over 1
year of age; and for all children over 4 years of age the rates of hos-
pitalization were lower for LAIV recipients, presumably because
of better prevention of inﬂuenza in LAIV recipients [158]. Other
studies have not found an increase in hospitalizations after LAIV
but most have not studied as many children under 2 years of age.
6.3.6. Other adverse events
For other adverse events after LAIV in children, there is less con-
sistency among studies. While some studies described decreased
activity levels or irritability in children after LAIV [211,330–332],
others found no difference in the rates [154,328,323,335]. Other
studies have been inconsistent regarding gastrointestinal symp-
toms such as decreased appetite or nausea. It is unclear if these
symptoms are attributable to the vaccine or whether the meth-
ods of adverse event monitoring or patient populations studied
can explain the differences in ﬁndings. One multi-country random-
ized placebo controlled study (South Africa, Brazil and Argentina)
of LAIV in 3200 vaccine naïve children age 6–36 months found no
increase in any adverse events between LAIV and placebo group,
including fever, activity level and rhinorrhea. They did note that
the recipients of LAIV had less cough than the placebo recip-
ients (50.3% vs. 8.2% p < 0.004) [335]. The study done in Asian
countries also found that LAIV recipients had less cough after
the ﬁrst (but not subsequent) dose (34.1% vs. 38.6% p = 0.010)
[211].
6.4. Concomitant administration of LAIV with other vaccines
Few studies have examined adverse events after LAIV
co-administered with another childhood immunizations. A multi-
national study from 7 countries in Asia and South America enrolled
2166 children age 6 to <36 months who received either LAIV with
OPV, placebo plus OPV or LAIV alone [343]. No differences in fever
or cough rates were found between the three groups except for
an increase in fever ≥40 ◦C axillary in the placebo plus OPV  group
compared with the LAIV groups (0.5% vs. 0%, p = 0.037). There
was an increase in runny nose and nasal congestion in the LAIV
groups: 70% in LAIV + OPV; 67.2% in LAIV group alone vs. 62.7%
in the OPV group after the ﬁrst dose (p = 0.006) [343]. A second
multicenter phase III study in 13 countries in Asia, Europe and Cen-
tral America administered LAIV or placebo with measles, mumps
and rubella vaccine (MMR)  to 1233 children 11 to <24 months
of age [154]. After the ﬁrst dose, the children who  received both
vaccines were more likely to have fever >37.5 ◦C axillary than
the children who  received placebo and MMR  (49.9% vs. 41.7%,
p = 0.009), but there were no differences in the rates of fever
>38.6 ◦C or ≥40 ◦C. Children who  received LAIV and MMR  vaccines
together were also more likely to have runny nose or nasal dis-
charge (70% vs. 51.6%, p < 0.001) and to use antipyretics (37.7% vs.
29.2% p = 0.004) than were children receiving placebo and MMR
[154].
A US and Australian trial in 1251 children 12–15 months of
age compared children randomized to receive MMR, varicella and
LAIV vaccines with children who received MMR  and varicella vac-
cines plus placebo, or LAIV alone [100]. Children who received LAIV
with MMR  and varicella vaccines were more likely to have fever
in the subsequent 10 days than those who  received LAIV alone
(>100 ◦F oral 51.7% vs. 29.1%; >101 ◦F 29.4% vs. 13.9% and >102 ◦F
16.3% vs. 7.7%). Recipients of all 3 vaccines had no increased rates
of wheezing as compared to LAIV only recipients (0.2% vs. 1.3%).
Children who  received all 3 vaccines were also more likely to be
irritable than LAIV only recipients (60.4% vs. 51.5%). In the 42 days
after vaccination children who received all 3 vaccines were more
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ikely to have runny nose and congestion than those who  received
MR and varicella vaccines plus placebo (84% vs. 77.6%), and there
as no signiﬁcant difference in rates of wheezing (1.2% vs. 2.5%)
100].
.5. Quadrivalent LAIV
The US Food and Drug Administration licensed a quadrivalent
AIV in 2012 and the ﬁrst doses were available in the 2013–14
nﬂuenza season. In healthy children 2–17 years of age, most
dverse events following quadrivalent LAIV were similar to those
xperienced following trivalent LAIV [107]. A small increase in fever
as noted in children 2–8 years of age after the ﬁrst dose; 5.1%
f quadrivalent LAIV recipients had fever ≥38 ◦C, compared with
.1% of trivalent LAIV recipients (p = 0.04). There was  also a slight
ncrease in fever >39 ◦C (1.2% vs. 0.3%, p = 0.04) in the quadriva-
ent group. An analysis of the VAERS and VSD data comparing the
013–2014 inﬂuenza season (quadrivalent LAIV) and 2012–2013
eason (trivalent LAIV) found no new safety concerns in children
408].
.6. LAIV-L
Far less English language literature exists on the safety of LAIV-
. Early studies of 337 children comparing the LAIV-L to inactivated
hole virion vaccine or placebo showed that adverse events in the
 groups were similar [353]. A larger study in 34 schools (>12,000
hildren 7–14/years of age) over 2 years compared the efﬁcacy
f LAIV-L to whole virion inactivated virus vaccine and placebo.
 subset of >100 children/group was identiﬁed for reactogeni-
ity assessment for 7 days after vaccination. In the ﬁrst year for
he 7–10 year olds, 1/162 LAIV-L recipients had a low-grade fever
37.5–38.5 ◦C), the following year, 2/323 LAIV recipients, 2/278
lacebo recipients and 5/271 inactivated vaccine recipients had
ow grade fever [321]. A large study comparing mono-, bi- or
rivalent-LAIV-L to placebo in 130,000 children ages 3–14 years
as performed in Russia and Cuba between 1986 and 1991. In the
ubset of 1366 children assessed for safety there was  no signiﬁcant
ncrease in adverse events in the LAIV-L recipients over placebo
ecipients in either the 3–6 or 7–14 years of age groups [354]. This
AIV-L was also shown to be effective in preventing inﬂuenza like
llness in children, and perhaps, more effective than the IIV [321].
An H1N1 based LAIV-L (Nasovac®) made in India was evaluated
n retrospective post-marketing survey of 7565 people 3–85 years
f age approximately 1 year after the vaccine was administered
355]; 81 adverse events were reported in 49 individuals. Runny
ose was reported in 0.32% and was the most commonly reported
ymptom [355].
Recent phase 2 and phase 3 studies of LAIV-L made by the
erum Institute of India, Ltd involving more than 2000 children
4–59 months old in Bangladesh, found no increased risk of
heezing, despite the fact that more than ¼ of the children had
een previously treated for asthma or wheezing (Ortiz, Brooks
manuscripts in revision, Vaccine)). In the phase 3 study, LAIV-
 recipients were less likely to have wheezing from Day 43–6
onths after vaccination as compared to placebo recipients (3.3%
s. 5.5%, risk difference −1.87 (95% CI −4.23, −0.3; p = 0.039). Sys-
emic adverse events, primarily tachypnea and subjective fever,
ere observed in 37.7% of LAIV-L recipients and 30.3% of placebo
ecipients (p = 0.002). Tachypnea was greater in 2 and 4 year-olds
ho received LAIV-L, but not in 3 year olds. Also, in the 2 year olds,
ocal reactions following LAIV-L were reported in 30.9% vs. Placebo
1.5% (p = 0.021), primarily an increase in runny nose/nasal conges-
ion. There was no difference in hospitalizations in the 6 months
fter receipt of LAIV or placebo (Brooks manuscript in revision,
accine). 33 (2015) F1–F67
6.6.1. Conclusions
In conclusion, LAIV and LAIV-L are well tolerated in children.
The most common adverse events are transient symptoms of stuffy
nose or rhinorrhea. Fever may  also be increased as compared to
placebo in younger children. In children 2 years of age and older, the
majority of studies reveal no increased rates of wheezing. The data
on LAIV use in children less than 2 or those with underlying health
conditions is limited, and these vaccines are not recommended for
those populations. Studies of wheezing in children <2 year of age
are inconsistent. Most studies of LAIV and LAIV-L in children have
not shown increased risks of hospitalization. Most children with
underlying asthma/wheezing or other chronic medical problems
reveal no clinically signiﬁcant increased rates of adverse events.
More studies are needed in children less than two  years of age and in
children living in low and middle-income countries. These studies
should include follow-up periods long enough to ascertain whether
there is an increased risk of hospitalization in young children and
children with prior wheezing or asthma. No long-term studies of
the impact of wheezing episodes in LAIV or LAIV-L recipients have
been conducted.
7. Summary and conclusions
In summary, most inﬂuenza vaccines are generally safe, but
inﬂuenza vaccines can cause rare serious adverse events. Some
adverse events, such as fever and febrile seizures, are more com-
mon  in children than adults. There can be differences in the safety
of vaccines in different populations due to underlying differences
in genetic predisposition to the adverse event. Live attenuated vac-
cines have not been studied adequately in children under 2 years
of age to determine the risks of adverse events; more studies are
needed to address this and several other priority safety issues with
all inﬂuenza vaccines in children. All vaccines intended for use in
children require safety testing in the target age group, especially in
young children. Safety of one inﬂuenza vaccine in children should
not be extrapolated to assumed safety of all inﬂuenza vaccines
in children. The low rates of adverse events from inﬂuenza vac-
cines should not be a deterrent to the use of inﬂuenza vaccines
because of the overwhelming evidence of the burden of disease
due to inﬂuenza in children.
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Inﬂuenza Vaccines (included with all searches using “AND” term)
PubMed:  Version 1 (V1) EMBASE: V1
((“inﬂuenza vaccines”[Mesh]) OR
((“Vaccination”[Mesh] OR vaccinations OR
vaccination OR “Vaccines”[Mesh] OR “Viral
Vaccines”[Mesh] OR vaccine OR vaccines OR
“Immunization”[Mesh] OR Immunization OR
Immunizations OR Immunisation OR
Immunisations OR immunized OR
immunised OR immunize OR immunise)
AND (“inﬂuenza, human”[Mesh] OR
inﬂuenza OR ﬂu OR inﬂuenzavirus)))
((‘inﬂuenza vaccination’/ex
vaccine’/exp) OR ((‘inﬂuen
OR inﬂuenzavirus OR ﬂu) A
vaccines OR vaccination OR
immunization OR immuniz
immunisation OR immunis
immunized OR immunised
immunise)))
PubMed:  Version 2 – Reﬁned (V2) EMBASE:V2
((“inﬂuenza vaccines”[Mesh]) OR
((“Vaccination”[Mesh] OR “Vaccines”[Mesh]
OR “Viral Vaccines”[Mesh] OR
“Immunization”[Mesh]) AND “inﬂuenza,
human”[Mesh]) OR (“inﬂuenza vaccine” OR
“inﬂuenza vaccines” OR “inﬂuenza
vaccination” OR “inﬂuenza vaccinations” OR
“inﬂuenza vaccine” OR “inﬂuenza
immunization” OR “inﬂuenza
immunizations” OR “inﬂuenza
immunisation” OR “inﬂuenza
immunisations” OR “ﬂu vaccine” OR “ﬂu
vaccines” OR “inﬂuenzavirus vaccine” OR
“inﬂuenzavirus vaccines” OR “ﬂu
vaccination” OR “ﬂu vaccinations” OR
“inﬂuenzavirus vaccination” OR
“inﬂuenzavirus vaccinations” OR “ﬂu
immunization” OR “ﬂu immunizations” OR
“ﬂu immunisation” OR “ﬂu immunisations”
OR “inﬂuenzavirus immunization” OR
“inﬂuenzavirus immunizations” OR
“inﬂuenzavirus immunisation” OR
“inﬂuenzavirus immunisations”)
((‘inﬂuenza vaccination’/ex
vaccine’/exp) OR (‘inﬂuenz
‘inﬂuenza vaccines’ OR ‘inﬂ
OR ‘inﬂuenza vaccinations
immunization’ OR ‘inﬂuen
OR ‘inﬂuenza immunisatio
immunisations’ OR ‘ﬂu vac
vaccines’ OR ‘ﬂu vaccinatio
vaccinations’ OR ‘ﬂu immu
immunizations’ OR ‘ﬂu imm
immunisations’ OR ‘inﬂuen
‘inﬂuenzavirus vaccines’ O
vaccination’ OR ‘inﬂuenzav
OR ‘inﬂuenzavirus immuni
‘inﬂuenzavirus immunizat
‘inﬂuenzavirus immunisati
‘inﬂuenzavirus immunisati
GBS
PubMed (247 results): EMBASE (858 results): 
(“Guillain-Barre Syndrome”[Mesh] OR “Guillain
Barre” OR “Guillain-Barre” OR “Guillain-Barré
Syndrome” OR “Guillaine-Barre Syndrome” OR
“Guillaine Barre Syndrome” OR
“Landry-Guillain-Barre Syndrome” OR “Landry
Guillain Barre Syndrome” OR “Miller Fisher
Syndrome”[Mesh] OR “Miller Fisher Variant” OR
“Miller-Fisher Syndrome” OR “Miller Fisher
Syndrome” OR “Fisher Syndrome” OR “Acute
Inﬂammatory Polyneuropathy” OR “Acute
Inﬂammatory Polyneuropathies” OR “Acute
Inﬂammatory Demyelinating Polyneuropathy”
OR “Acute Inﬂammatory Demyelinating
Polyradiculoneuropathy” OR “Acute
Inﬂammatory Polyradiculoneuropathy” OR
“Acute Inﬂammatory Polyradiculoneuropathies”
OR “Acute Inﬂammatory Demyelinating
Polyradiculoneuropathy” OR “Acute
Inﬂammatory Demyelinating
Polyradiculoneuropathies” OR “Acute
Autoimmune Neuropathy” OR “Acute
Autoimmune Neuropathies”)
(‘guillain-barre syndrome’/ex
OR ‘guillain-barre’ OR ‘guilla
‘guillaine-barre syndrome’ O
syndrome’ OR ‘landry-guillai
‘landry guillain barre syndro
variant’ OR ‘miller-ﬁsher syn
ﬁsher syndrome’ OR ‘ﬁsher s
inﬂammatory polyneuropath
inﬂammatory polyneuropath
inﬂammatory demyelinating
‘acute inﬂammatory polyrad
‘acute inﬂammatory polyrad
‘acute inﬂammatory demyeli
polyradiculoneuropathy’ OR 
demyelinating polyradiculon
‘acute autoimmune neuropa
autoimmune neuropathies’) 33 (2015) F1–F67 F29
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Appendix 1. Systematic literature search terms
p OR ‘inﬂuenza
za’/exp OR inﬂuenza
ND (vaccine OR
 vaccinations OR
ations OR
ations OR
 OR immunize OR
((TITLE-ABS-KEY(inﬂuenza OR inﬂuenzavirus
OR ﬂu) AND TITLE-ABS-KEY(vaccine OR
vaccines OR vaccination OR vaccinations OR
immunization OR immunizations OR
immunisation OR immunisations OR
immunized OR immunised OR immunize OR
immunise)))
p OR ‘inﬂuenza
a vaccine’ OR
uenza vaccination’
’ OR ‘inﬂuenza
za immunizations’
n’ OR ‘inﬂuenza
cine’ OR ‘ﬂu
n’ OR ‘ﬂu
nization’ OR ‘ﬂu
unisation’ OR ‘ﬂu
zavirus vaccine’ OR
R ‘inﬂuenzavirus
irus vaccinations’
zation’ OR
ions’ OR
on’ OR
ons’))
Scopus (807 results):
p OR ‘guillain barre’
in-barré syndrome’ OR
R ‘guillaine barre
n-barre syndrome’ OR
me’ OR ‘miller ﬁsher
drome’ OR ‘miller
yndrome’ OR ‘acute
y’ OR ‘acute
ies’ OR ‘acute
 polyneuropathy’ OR
iculoneuropathy’ OR
iculoneuropathies’ OR
nating
‘acute inﬂammatory
europathies’ OR
thy’ OR ‘acute
((TITLE-ABS-KEY(“Guillain Barre” OR
“Guillain-Barre” OR “Guillain-Barré Syndrome” OR
“Guillaine-Barre Syndrome” OR “Guillaine Barre
Syndrome” OR “Landry-Guillain-Barre Syndrome”
OR “Landry Guillain Barre Syndrome”) OR
TITLE-ABS-KEY(“Miller Fisher Variant” OR
“Miller-Fisher Syndrome” OR “Miller Fisher
Syndrome” OR “Fisher Syndrome”) OR
TITLE-ABS-KEY(“Acute Inﬂammatory
Polyneuropathy” OR “Acute Inﬂammatory
Polyneuropathies” OR “Acute Inﬂammatory
Demyelinating Polyneuropathy” OR “Acute
Inﬂammatory Demyelinating
Polyradiculoneuropathy”) OR
TITLE-ABS-KEY(“Acute Inﬂammatory
Polyradiculoneuropathy” OR “Acute Inﬂammatory
Polyradiculoneuropathies” OR “Acute
Inﬂammatory Demyelinating
Polyradiculoneuropathy” OR “Acute Inﬂammatory
Demyelinating Polyradiculoneuropathies”) OR
TITLE-ABS-KEY(“Acute Autoimmune Neuropathy”
OR  “Acute Autoimmune Neuropathies”)))
F accine 33 (2015) F1–F67
Scopus (473 results):
R ‘febrile convulsion’/exp)
er’ OR ‘fevers’ OR ‘febrile’
al’ OR ‘pyrexias’ OR
hyperthermia’ OR
‘seizure’ OR ‘seizures’ OR
lsions’)))
(TITLE-ABS-KEY (“febrile” OR  “fever” OR “fevers”
OR “pyrexia” OR “pyrexial” OR “pyrexias” OR
“hyperthermia” OR “hyperthermias”) AND
TITLE-ABS-KEY (“seizure” OR “seizures” OR
“convulsion” OR “convulsions”))
ASE (4418 results):
er’/exp OR ‘fever’ OR ‘fevers’ OR ‘febrile’ OR ‘pyrexia’ OR ‘pyrexial’ OR  ‘pyrexias’ OR
erthermia’/de OR ‘hyperthermia’ OR ‘hyperthermias’) NOT (‘seizure’ OR ‘seizures’ OR
vulsion’ OR ‘convulsions’ OR ‘febrile seizure’/exp OR ‘febrile convulsion’/exp)
ASE (258 results):
zure’ OR ‘seizures’ OR ‘convulsion’ OR ‘convulsions’) NOT (‘fever’/exp OR ‘fever’ OR
rs’ OR ‘febrile’ OR ‘pyrexia’ OR ‘pyrexial’ OR ‘pyrexias’ OR ‘hyperthermia’/de OR
erthermia’ OR ‘hyperthermias’ OR ‘febrile seizure’/exp OR ‘febrile convulsion’/exp)
ASE (V2 1249 results):
phylaxis’/de OR anaphylaxis:ti OR ‘anaphylactic shock’/de OR ‘anaphylactic shock’:ti
angioedema’/de OR angioedema:ti OR angioedemas:ti OR ‘quincke edema’/de OR
ncke edema’:ti OR ‘quinckes edema’:ti OR ‘quincke oedema’:ti OR ‘quincke edema’:ti
giant urticaria’/de OR ‘giant urticaria’:ti OR ‘angioneurotic edema’/de OR
ioneurotic edema’:ti OR ‘facial edema’/de OR ‘facial edema’:ti OR ‘facial oedema’:ti OR
ersensitivity’/de OR hypersensitivity:ti OR hypersensitivities:ti OR ‘allergy’/de OR
gy:ti OR allergies:ti OR ‘allergic reaction’:ti OR ‘allergic reactions’:ti OR ‘allergic
unctivitis’/de OR ‘allergic conjunctivitis’:ti OR ‘respiratory hypersensitivity’:ti OR
iratory hypersensitivities’:ti OR ‘immediate hypersensitivity’/de OR ‘immediate
ersensitivity’:ti OR ‘immediate hypersensitivities’:ti OR ‘pruritus’/de OR pruritus:ti OR
ing:ti OR ‘stevens johnson syndrome’/de OR ‘stevens johnson syndrome’:ti OR
ens-johnson syndrome’:ti OR ‘toxic epidermal necrolysis’/de OR ‘toxic epidermal
olysis’:ti OR ‘toxic epidermal necrolyses’:ti OR ‘nonstaphylococcal scalded skin
rome’:ti OR ‘lyell syndrome’:ti OR ‘lyell syndromes’:ti OR ‘lyells syndrome’:ti OR
ls syndromes’:ti OR urticaria:ti OR urticarias:ti OR hives:ti OR vasculitis:ti OR
litides:ti OR angiitis:ti OR angiitides:ti OR anaphylaxis:ab OR ‘anaphylactic shock’:ab
ngioedema:ab OR angioedemas:ab OR ‘quincke edema’:ab OR ‘quinckes edema’:ab OR
ncke oedema’:ab OR ‘quincke edema’:ab OR ‘giant urticaria’:ab OR ‘angioneurotic
a’:ab OR ‘facial edema’:ab OR ‘facial oedema’:ab OR hypersensitivity:ab OR
ersensitivities:ab OR allergy:ab OR allergies:ab OR ‘allergic reaction’:ab OR  ‘allergic
tions’:ab OR ‘allergic conjunctivitis’:ab OR ‘respiratory hypersensitivity’:ab OR
iratory hypersensitivities’:ab OR ‘immediate hypersensitivity’:ab OR ‘immediate
ersensitivities’:ab OR pruritus:ab OR itching:ab OR ‘stevens johnson syndrome’:ab OR
ens-johnson syndrome’:ab OR ‘toxic epidermal necrolysis’:ab OR ‘toxic epidermal
olyses’:ab OR ‘nonstaphylococcal scalded skin syndrome’:ab OR ‘lyell syndrome’:ab
lyell syndromes’:ab OR ‘lyells syndrome’:ab OR ‘lyells syndromes’:ab OR urticaria:ab
rticarias:ab OR hives:ab OR vasculitis:ab OR vaculitides:ab OR angiitis:ab OR
itides:ab
ASE (191 results):
 palsy’/exp OR (‘Bell Palsy’ OR ‘Bells Palsy’ OR ‘Bell Palsies’ OR ‘Bells Palsies’) OR (‘facial
ropathy’ OR ‘facial paralysis’ OR ‘facial paralyses’ OR ‘facial palsy’ OR ‘facial palsies’)
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Febrile seizures
PubMed (94 results): EMBASE (491 results): 
(“seizures, febrile”[MeSH Terms] OR
((“fever”[MeSH Terms] OR “fever”[All Fields] OR
“fevers”[All Fields] OR “febrile”[All Fields] OR
“pyrexia”[All Fields] OR “pyrexial”[All Fields] OR
“pyrexias”[All Fields] OR “hyperthermia”[All
Fields] OR “hyperthermias”[All Fields]) AND
(“seizure”[All Fields] OR “seizures”[All Fields] OR
“convulsion”[All Fields] OR convulsions)))
((‘febrile seizure’/exp O
OR ((‘fever’/exp OR ‘fev
OR ‘pyrexia’ OR ‘pyrexi
‘hyperthermia’/de OR ‘
‘hyperthermias’) AND (
‘convulsion’ OR ‘convu
Fever  (no seizures)
PubMed (1098 results): EMB
(“fever”[MeSH Terms] OR “fever”[All Fields] OR “fevers”[All Fields]
OR “febrile”[All Fields] OR “pyrexia”[All Fields] OR “pyrexial”[All
Fields] OR “pyrexias”[All Fields] OR “hyperthermia”[All Fields]
OR “hyperthermias”[All Fields]) NOT (“seizure”[All Fields] OR
“seizures”[All Fields] OR “convulsion”[All Fields] OR convulsions
OR “seizures, febrile”[MeSH Terms])
(‘fev
‘hyp
‘con
Seizures (no fever)
PubMed (54 results): EMB
(“seizure”[All Fields] OR “seizures”[All Fields] OR “convulsion”[All
Fields] OR convulsions) NOT (“fever”[MeSH Terms] OR
“fever”[All Fields] OR “fevers”[All Fields] OR “febrile”[All Fields]
OR “pyrexia”[All Fields] OR “pyrexial”[All Fields] OR
“pyrexias”[All Fields] OR “hyperthermia”[All Fields] OR
“hyperthermias”[All Fields] OR “seizures, febrile”[MeSH Terms])
(‘sei
‘feve
‘hyp
Hypersensitivity
PubMed (V2 1115 results): EMB
“anaphylaxis”[MeSH Terms] OR “anaphylaxis”[All Fields] OR
“anaphylactic”[All Fields] OR “angioedema”[MeSH Terms] OR
“angioedema”[All Fields] OR ((“quincke”[All Fields] OR
“quinckes”[All Fields] OR “quincke’s”[All Fields] OR
“angioneurotic”[All Fields] OR “facial”[All Fields]) AND
(“edema”[MeSH Terms] OR “edema”[All Fields] OR “oedema”[All
Fields])) OR “hypersensitivity”[MeSH Terms] OR
“hypersensitivity”[All Fields] OR “hypersensitivities”[All Fields]
OR  “allergy”[All Fields] OR “allergy and immunology”[MeSH
Terms] OR “allergies”[All Fields] OR “allergic”[All Fields] OR
“pruritus”[MeSH Terms] OR “pruritus”[All Fields] OR
“itching”[All Fields] OR “Stevens-Johnson Syndrome”[All Fields]
OR  “Stevens Johnson Syndrome”[All Fields] OR “toxic epidermal
necrolysis”[All Fields] OR “toxic epidermal necrolyses”[All Fields]
OR “nonstaphylococcal scalded skin syndrome”[All Fields] OR
“Lyell syndrome”[All Fields] OR “Lyell’s syndrome”[All Fields] OR
“Lyells syndrome”[All Fields] OR “Lyell syndromes”[All Fields]
OR “Lyell’s syndromes”[All Fields] OR “Lyells syndromes”[All
Fields] OR “urticaria”[MeSH Terms] OR urticaria[All Fields] OR
urticarias[All Fields] OR hives[All Fields] OR “vasculitis”[MeSH
Terms] OR vasculitis[All Fields] OR vasculitides[All Fields] OR
angiitis[All Fields] OR angiitides[All Fields]
‘ana
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conj
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‘stev
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Bells  Palsy
PubMed (36 results): EMB
“Bell Palsy”[MeSH] OR (“Bell Palsy”[All Fields] OR “Bells Palsy”[All
Fields] OR “Bell’s Palsy”[All Fields] OR “Bell Palsies”[All Fields]
OR “Bells Palsies”[All Fields] OR “Bell’s Palsies”[All Fields]) OR
(“facial neuropathy”[All Fields] OR “facial paralysis”[All Fields]
OR “facial paralyses”[All Fields] OR “facial palsy”[All Fields] OR
“facial palsies”[All Fields])
‘bell
neu
MS
PubMed (83 results): EMB
(“multiple sclerosis”[MeSH Terms] OR “multiple sclerosis”[All
Fields] OR “disseminated sclerosis”[All Fields] OR “insular
sclerosis”[All Fields])
(‘multiple sclerosis’/exp OR ‘disseminated sclerosis’ OR ‘insular sclerosis’)
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ASE (154 results):
te disseminated encephalomyelitis’/exp OR (‘acute disseminated’ OR ‘postinfectious’
post-infectious’ OR ‘postinfection’ OR ‘post-infection’ OR ‘postvaccinalis’ OR
tvaccinal’ OR ‘post-vaccinal’ OR ‘postvaccinial’ OR ‘post-vaccinial’ OR ‘postvaccination’
postvaccine’ AND (encephalitis OR encephalitides OR encephalomyelitis OR
phalomyelitides)) OR ‘vaccination encephalitis’
ASE (245 results):
V’ OR ‘live attenuated’ OR ‘FluMist’ OR ‘Fluenz’ OR ‘CAIV-T’ OR ‘cold-adapted’ OR  ‘nasal
y’ OR ‘pLAIV’
ma’/exp or ‘asthma’ or ‘asthmatic’ or ‘lung allergy’ or ‘wheezing’/exp or ‘wheezing’ or
eze’ or ‘wheezes’ or ‘wheezed’ or ‘rhonchi’ or ‘rhonchus’ or ‘rale’ or ‘rales’ or
nchiolitis’/exp or ‘Bronchiolitis’ or ‘cough’/de or ‘cough’ or ‘coughs’ or ‘coughed’ or
ghing’ or ‘abnormal respiratory sound’/exp or ‘abnormal respiratory sound’
ASE (200 results):
colepsy’/exp OR ‘cataplexy’/exp OR ‘Paroxysmal Sleep’ OR ‘Narcoleptic’ OR ‘Gelineau’
Gelineaus’ OR ‘Narcolepsy’ OR ‘Cataplexy’ OR ‘Narcolepsy-Cataplexy’ OR ‘sleep
epsy’ OR ‘narcolepsis’ OR ‘neurolepsy’
ASE (113 results):
icarditis’/de OR ‘constrictive pericarditis’/de OR ‘Pericarditis’ OR ‘Pericarditides’ OR
icardial’ OR ‘Pericardium’ OR ‘Pick Disease of Heart’ OR ‘Picks Disease of Heart’ OR
rt Pick Disease’ OR ‘Heart Picks Disease’
ASE (V2 234 results):
chial plexus neuropathy’/de OR ‘brachialgia’/de OR ‘neuralgia’/de OR ‘paresthesia’/de
injection site paresthesia’/de OR ‘neuritis’:ti OR ‘neuritides’:ti OR ‘neuralgia’:ti OR
ralgias’:ti OR ‘neuralgic’:ti OR ‘neuropathy’:ti OR ‘neuropathic’:ti OR ‘nerve pain’:ti OR
ve pains’:ti OR ‘paresthesia’:ti OR ‘paresthesias’:ti OR ‘dysesthesia’:ti OR
esthesias’:ti OR ‘formication’:ti OR ‘formications’:ti OR ‘Parsonage Aldren Turner
rome’:ti OR ‘Parsonage Turner Syndrome’:ti OR ‘neuritis’:ab OR ‘neuritides’:ab OR
ralgia’:ab OR ‘neuralgias’:ab OR ‘neuralgic’:ab OR ‘neuropathy’:ab OR ‘neuropathic’:abN.A. Halsey et al. / V
Encephalomyelitis, Acute Disseminated
PubMed (56 results): EMB
“encephalomyelitis, acute disseminated”[MeSH Terms] OR
((“acute disseminated”[All Fields] OR “postinfectious” OR
“post-infectious” OR “post infectious” OR “postinfection” OR
“post-infection” OR “post infection” OR “postvaccinalis” OR
“postvaccination” OR “postvaccine” OR “post-vaccinal”[All
Fields] OR “post vaccinal”[All Fields] OR “postvaccinal”[All
Fields] OR “post-vaccinial”[All Fields] OR “post vaccinial”[All
Fields] OR “postvaccinial”[All Fields]) AND
(“encephalitis”[All Fields] OR “encephalitides”[All Fields] OR
“encephalomyelitis”[All Fields] OR
“encephalomyelitides”[All Fields])) OR “vaccination
encephalitis”[All Fields]
‘acu
OR  ‘
‘pos
OR  ‘
ence
LAIV  and Asthma/Wheezing
PubMed (70 results): EMB
“LAIV”[All Fields] OR “live attenuated”[All Fields] OR
“FluMist”[All Fields] OR “Fluenz”[All Fields] OR “CAIV-T”[All
Fields] OR “cold adapted”[All Fields] OR “cold-adapted”[All
Fields] OR “nasal spray”[All Fields] OR “pLAIV”[All Fields]
AND
“asthma”[Mesh] or “asthma”[All Fields] or “asthmatic”[All
Fields] or “lung allergy”[All Fields] or “wheezing”[All Fields]
or  “wheeze”[All Fields] or “wheezes”[All Fields] or
“wheezed”[All Fields] or “rhonchi”[All Fields] or
“rhonchus”[All Fields] or “rale”[All Fields] or “rales”[All
Fields] or “Bronchiolitis”[Mesh] or “Bronchiolitis”[All Fields]
or “cough”[Mesh] or “cough”[All Fields] or “coughs”[All
Fields] or “coughing”[All Fields] or “coughed”[All Fields] or
“respiratory sounds”[Mesh] or “abnormal respiratory
sounds”[All Fields]
‘LAI
spra
AND
‘asth
‘whe
‘Bro
‘cou
Narcolepsy
PubMed  (84 results): EMB
“Narcolepsy”[Mesh] OR “Cataplexy”[Mesh] OR “Paroxysmal
Sleep”[All Fields] OR “Narcoleptic”[All Fields] OR
“Gelineau”[All Fields] OR “Gelineau’s”[All Fields] OR
“Gelineaus”[All Fields] OR “Narcolepsy”[All Fields] OR
“Cataplexy”[All Fields] OR “Narcolepsy-Cataplexy”[All
Fields] OR “sleep epilepsy”[All Fields] OR “narcolepsis”[All
Fields] OR “neurolepsy”[All Fields]
‘nar
OR ‘
epil
Pericarditis
PubMed (12 results): EMB
“Pericarditis”[Mesh] OR “Pericarditis, Constrictive”[Mesh] OR
“Pericarditis”[All Fields] OR “Pericarditides”[All Fields] OR
“Pericardial”[All Fields] OR “Pericardium”[All Fields] OR
“Pick Disease of Heart”[All Fields] OR “Pick’s Disease of
Heart”[All Fields] OR “Picks Disease of Heart”[All Fields] OR
“Heart Pick Disease”[All Fields] OR “Heart Pick’s Disease”[All
Fields] OR “Heart Picks Disease”[All Fields]
‘per
‘Per
‘Hea
Brachial Neuritis, neuralgia, paresthesia
PubMed (V2 103 results): EMB
“Brachial Plexus Neuritis”[Mesh] OR “Neuralgia”[Mesh] OR
“Paresthesia”[Mesh] OR “neuritis” OR “neuritides” OR
“neuralgia” OR “neuralgias” OR “neuralgic” OR “neuropathy”
OR “neuropathic” OR “nerve pain” OR “nerve pains” OR
“paresthesia” OR “paresthesias” OR “dysesthesia” OR
“dysesthesias” OR “formication” OR “formications” OR
“Parsonage Aldren Turner Syndrome” OR
‘bra
OR  ‘
‘neu
‘ner
‘dys
Synd
‘neu“Parsonage-Aldren-Turner Syndrome” OR “Parsonage Turner
Syndrome” OR “Parsonage-Turner Syndrome”
OR  ‘nerve
‘dysesthes
‘Parsonage pain’:ab OR ‘nerve pains’:ab OR ‘paresthesia’:ab OR ‘paresthesias’:ab OR
ia’:ab OR ‘dysesthesias’:ab OR ‘formication’:ab OR ‘formications’:ab OR
 Aldren Turner Syndrome’:ab OR ‘Parsonage Turner Syndrome’:ab
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ASE (56 results):
sitis’/exp or ‘bursitides’ or ‘adhesive capsulitis’ or ‘adhesive capsulitides’ or ‘shoulder
ingement syndrome’/exp or ‘humeroscapular periarthritis’/exp or ‘UAIRVA’ or ‘deltoid
cle’/exp or ‘frozen shoulder’/exp or ‘shoulder pain’/exp or ‘shoulder injury’/exp or
ulder dysfunction’ or ‘shoulder stiffness’ or ‘stiff shoulder’ or ‘rigid shoulder’ or
ulder rigidity’ or ‘arm pain’/exp or ‘arm dysfunction’
ASE (V2 305 results):
ephalopathy’:ti OR ‘encephalon’:ti OR ‘intracranial central nervous system disorder’:ti
intracranial central nervous system disorders’:ti OR ‘intracranial cns disorder’:ti OR
acranial cns disorders’:ti OR ‘encephalopathia’:ti OR ‘panencephalopathy’:ti OR ‘leigh
ase’/de OR ‘leigh disease’:ti OR ‘leighs disease’:ti OR ‘leigh syndrome’:ti OR
ephalomyopathy’/de OR ‘encephalomyopathy’:ti OR ‘encephalomyopathies’:ti OR
ephalitis’/de OR ‘encephalitis’:ti OR ‘encephalitides’:ti OR ‘brain inﬂammation’:ti OR
britis’:ti OR ‘enkephalitis’:ti OR ‘encephalopathy’:ab OR ‘encephalon’:ab OR
acranial central nervous system disorder’:ab OR ‘intracranial central nervous system
rders’:ab OR ‘intracranial cns disorder’:ab OR ‘intracranial cns disorders’:ab OR
ephalopathia’:ab OR ‘panencephalopathy’:ab OR ‘leigh disease’:ab OR ‘leighs
ase’:ab OR ‘leigh syndrome’:ab OR ‘encephalomyopathy’:ab OR
ephalomyopathies’:ab OR ‘encephalitis’:ab OR ‘encephalitides’:ab OR ‘brain
mmation’:ab OR ‘cerebritis’:ab OR ‘enkephalitis’:ab
ASE (136 results):
elitis’/de or ‘myelitis’ or ‘myelitides’ or ‘myelopathy’ or ‘myelopathies’ or ‘spinal cord
mmation’ or ‘spinal cord inﬂammations’ or ‘spinal inﬂammation’ or ‘spinal
mmations’
ASE (V2 339 results):
pathic thrombocytopenic purpura’/de or ‘thrombocytopenia’/de or ‘purpura’/de or
 or ‘Werlhofs Disease’ or ‘Werlhof Disease’ or ‘morbus werlhof’ or ‘thrombocytopenic’
hrombocytopenia’ or ‘thrombocytopenias’ or ‘thrombopenia’ or ‘thrombopenias’ or
crothrombocytopenia’ or ‘macrothrombocytopenias’ or ‘platelet deﬁciency’ or ‘platelet
ciencies’ or ‘thrombocyte deﬁciency’ or ‘thrombocyte deﬁciencies’ or ‘thrombopenia’
hrombopenias’ or ‘purpura’ or ‘purpuras’ or ‘petechiae’
ASE (V2 356 results):
ritis’/de OR ‘arthritis’:ti OR ‘arthritides’:ti OR ‘polyarthritis’:ti OR ‘polyarthritides’:ti
arthrochondritis’:ti OR ‘arthrosynovitis’:ti OR ‘joint inﬂammation’:ti OR ‘joint
mmations’:ti OR ‘oligoarthritis’:ti OR ‘arthritis’:ab OR ‘arthritides’:ab OR
yarthritis’:ab OR ‘polyarthritides’:ab OR ‘arthrochondritis’:ab OR ‘arthrosynovitis’:ab
joint inﬂammation’:ab OR ‘joint inﬂammations’:ab OR ‘oligoarthritis’:ab
ASE (163 results):
ous thromboembolism’/exp or ‘deep vein thrombosis’/exp or ‘Venous
mboembolism’ or ‘Vein Thromboembolism’ or ‘Venous Thrombosis’ or ‘Venous
mboses’ or ‘Deep Vein Thrombosis’ or ‘Deep Vein Thromboses’ or ‘Deep-Vein
mbosis’ or ‘Deep-Vein Thromboses or ‘deep thrombophlebitis’ or ‘deep venous32 N.A. Halsey et al. / V
Bursitis
PubMed (31 results): EMB
“Bursitis”[Mesh] OR “Bursitis”[All Fields] OR “Bursitides”[All Fields] OR
“Adhesive Capsulitis”[All Fields] OR “Adhesive Capsulitides”[All
Fields] OR “Shoulder Impingement Syndrome”[Mesh] OR “Shoulder
Impingement Syndrome”[All Fields] OR ((“periarthritis”[Mesh] OR
“periarthritis”[All Fields] OR “tenosynovitus”[All Fields]) AND
(“shoulder”[All Fields] OR “humeroscapular”[All Fields] OR
“humeroscapularis”[All Fields] OR “scapulohumeral”[All Fields] OR
“scapulohumeralis”[All Fields] OR “scapulo”[All Fields] OR
“scapularis”[All Fields])) OR “UAIRVA”[All Fields] OR “deltoid”[All
Fields] OR “frozen shoulder”[All Fields] OR “shoulder pain”[All
Fields] OR “shoulder injury”[All Fields] OR “shoulder
dysfunction”[All Fields] OR “shoulder stiffness”[All Fields] OR “stiff
shoulder”[All Fields] OR “rigid shoulder”[All Fields] OR “shoulder
rigidity”[All Fields] OR “arm pain”[All Fields] OR “arm
dysfunction”[All Fields] OR “Arm Injuries”[Mesh] OR “arm
injury”[All Fields] OR “arm injuries”[All Fields]
‘bur
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Encephalopathy, Encephalomyopathy, Encephalitis
PubMed (V2 236 results): EMB
“encephalopathy”[All Fields] OR “encephalon”[All Fields] OR
(“Intracranial”[All Fields] AND (“central nervous system”[All
Fields] OR “CNS”[All Fields]) AND (“disease”[MeSH Terms] OR
“disease”[All Fields] OR “disorder”[All Fields] OR “diseases”[All
Fields] OR “disorders”[All Fields])) OR “encephalopathia”[All Fields]
OR  “panencephalopathy”[All Fields] OR “leigh disease”[Mesh] OR
“leigh disease”[All Fields] OR “leigh’s disease”[All Fields] OR “leighs
disease”[All Fields] OR “leigh syndrome”[All Fields] OR
“encephalomyopathy”[All Fields] OR “encephalomyopathies”[All
Fields] OR “encephalitis”[MeSH Terms] OR “encephalitis”[All
Fields] OR “encephalitides”[All Fields] OR “brain inﬂammation”[All
Fields] OR “cerebritis”[All Fields] OR “encephalitis”[All Fields]
‘enc
OR ‘
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Myelitis
PubMed (32 results): EMB
“Myelitis, Transverse”[Mesh] OR “Myelitis”[All Fields] OR
“Myelitides”[All Fields] OR “Myelopathy”[All Fields] OR
“Myelopathies”[All Fields] OR “Spinal Cord Inﬂammation”[All
Fields] OR “Spinal Cord Inﬂammations”[All Fields] OR “Spinal
Inﬂammation”[All Fields] OR “Spinal Inﬂammations”[All Fields]
‘my
inﬂa
inﬂa
ITP,  Transient thrombocytopenia, purpura
PubMed (V2 65 results): EMB
“Purpura, Thrombocytopenic, Idiopathic”[Mesh] OR
“Thrombocytopenia”[Mesh] OR “Purpura”[Mesh] OR “ITP”[All
Fields] OR “Werlhof’s Disease”[All Fields] OR “Werlhofs
Disease”[All Fields] OR “Werlhof Disease”[All Fields] OR “morbus
werlhof”[All Fields] OR “thrombocytopenic”[All Fields] OR
“thrombocytopenia”[All Fields] OR “thrombocytopenias”[All
Fields] OR “thrombopenia”[All Fields] OR “thrombopenias”[All
Fields] OR “macrothrombocytopenia”[All Fields] OR
“macrothrombocytopenias”[All Fields] OR “platelet deﬁciency”[All
Fields] OR “platelet deﬁciencies”[All Fields] OR “thrombocyte
deﬁciency”[All Fields] OR “thrombocyte deﬁciencies”[All Fields] OR
“thrombopenia”[All Fields] OR “thrombopenias”[All Fields] OR
“purpura”[All Fields] OR “purpuras”[All Fields] OR “petechiae”[All
Fields]
‘idio
‘ITP’
or  ‘t
‘ma
deﬁ
or  ‘t
Arthritis
PubMed (V2 158 results): EMB
“Arthritis”[Mesh] OR “Arthritis”[All Fields] OR “Arthritides”[All
Fields] OR “Polyarthritis”[All Fields] OR “Polyarthritides”[All Fields]
OR “arthrochondritis”[All Fields] OR “arthrosynovitis”[All Fields]
OR “joint inﬂammation”[All Fields] OR “joint inﬂammations”[All
Fields] OR “oligoarthritis”[All Fields]
‘arth
OR  ‘
inﬂa
‘pol
OR  ‘
DVT/VTE
PubMed (11 results): EMB
“Venous Thromboembolism”[Mesh] OR “Venous Thrombosis”[Mesh]
OR  “Venous Thromboembolism”[All Fields] OR “Vein
Thromboembolism”[All Fields] OR “Venous Thrombosis”[All Fields]
OR “Venous Thromboses”[All Fields] OR “Deep Vein
‘ven
Thro
Thro
ThroThrombosis”[All Fields] OR “Deep Vein Thromboses”[All Fields] OR
“Deep-Vein Thrombosis”[All Fields] OR “Deep-Vein
Thromboses”[All Fields] OR “deep thrombophlebitis”[All Fields] OR
“deep venous thrombus”[All Fields] OR “Phlebothrombosis”[All
Fields] OR “Phlebothromboses”[All Fields]
thrombus’ or ‘Phlebothrombosis’ or ‘Phlebothromboses’
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ASE (1703 results):
algia’/de or ‘malaise’/exp or ‘myalgia’ or ‘muscle pain’ or ‘muscle pains’ or ‘muscle
ness’ or ‘muscle sorenesses’ or ‘muscle tenderness’ or ‘myodynia’ or ‘malaise’
ASE (700 results):
ulitis’/exp or ‘injection site swelling’/exp or ‘injection site induration’/exp or ‘injection
inﬂammation’/exp or ‘injection site cellulitis’/exp or ‘Cellulitis’ or ‘Phlegmon’ or ‘Large
ction’ or ‘site swelling’ or ‘Large injection site induration’ or ‘Large injection site
tion’ or ‘Large injection site reactions’ or ‘Large injection site inﬂammation’ or ‘Large
ction site inﬂammations’ or ‘Large injection-site swelling’ or ‘Large injection-site
ration’ or ‘Large injection-site reaction’ or ‘Large injection-site reactions’ or ‘Large
ction-site inﬂammation’ or ‘Large injection-site inﬂammations’ or ‘Large vaccination
swelling’ or ‘Large vaccination site induration’ or ‘Large vaccination site reaction’ or
e vaccination site reactions’ or ‘Large vaccination site inﬂammation’ or ‘Large
ination site inﬂammations’ or ‘Large vaccination-site swelling’ or ‘Large
ination-site induration’ or ‘Large vaccination-site reaction’ or ‘Large vaccination-site
tions’ or ‘Large vaccination-site inﬂammation’ or ‘Large vaccination-site
mmations’ or ‘extensive swelling’ or ‘extensive induration’ or ‘extensive reaction’ or
nsive reactions’ or ‘extensive inﬂammation’ or ‘extensive inﬂammations’
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Myalgia/Malaise
PubMed (130 results): EMB
“Myalgia”[Mesh] OR “myalgia”[All Fields] OR “muscle pain”[All
Fields] OR “muscle pains”[All Fields] OR “muscle soreness”[All
Fields] OR “muscle sorenesses”[All Fields] OR “muscle
tenderness”[All Fields] OR “myodynia”[All Fields] OR
“malaise”[All Fields]
‘my
sore
Cellulitis, Large Injection Site Swelling/Induration
PubMed (24 results): EMB
“Cellulitis”[Mesh] OR “Cellulitis”[All Fields] OR “Phlegmon”[All
Fields] OR “Large injection site swelling”[All Fields] OR “Large
injection site induration”[All Fields] OR “Large injection site
reaction”[All Fields] OR “Large injection site reactions”[All
Fields] OR “Large injection site inﬂammation”[All Fields] OR
“Large injection site inﬂammations”[All Fields] OR “Large
injection-site swelling”[All Fields] OR “Large injection-site
induration”[All Fields] OR “Large injection-site reaction”[All
Fields] OR “Large injection-site reactions”[All Fields] OR “Large
injection-site inﬂammation”[All Fields] OR “Large injection-site
inﬂammations”[All Fields] OR “Large vaccination site
swelling”[All Fields] OR ““Large vaccination site induration”[All
Fields] OR “Large vaccination site reaction”[All Fields] OR “Large
vaccination site reactions”[All Fields] OR “Large vaccination site
inﬂammation”[All Fields] OR ““Large vaccination site
inﬂammations”[All Fields] OR “Large vaccination-site
swelling”[All Fields] OR ““Large vaccination-site induration”[All
Fields] OR “Large vaccination-site reaction”[All Fields] OR ““Large
vaccination-site reactions”[All Fields] OR “Large vaccination-site
inﬂammation”[All Fields] OR “Large vaccination-site
‘cell
site  
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‘Larg
vacc
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‘exteinﬂammations”[All Fields] OR “extensive swelling”[All Fields] OR
“extensive induration”[All Fields] OR “extensive reaction”[All
Fields] OR “extensive reactions”[All Fields] OR “extensive
inﬂammation”[All Fields] OR ““extensive inﬂammations”
illidentiﬁedafety data.
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Appendix 2. Results of literature Searches by article type
Articles screened
Database searchc Excluded Article types reviewedb Final
Adverse event Initial search
result total
Not in
English
Comments/Letters/
Notes/Editorials/
News
Not in
humansa
Not in
childrena
Reviews Case reports
and series
Conference
materials
Clinical
trialsa
Other Data used
in table
Otherwise
helpful
Total
included
GBS 1940 173 289 N/A N/A 272 56 70 N/A 286 24 32 56
Febrile  seizures 1058 50 95 N/A N/A 193 18 35 N/A 208 40 50 90
Fever  (no seizures) 5497 547 281 499 3101 116 47 42 254 409
Seizures (no fever) 312 20 17 17 N/A 86 20 18 N/A 107
Hypersensitivity 2364 264 172 298 1097 86 19 29 91 238
MS  480 30 44 N/A N/A 179 8 51 N/A 109 15 19 34
Bells  Palsy 227 18 16 N/A N/A 76 12 20 N/A 63 16
ADEM  210 33 11 N/A N/A 46 24 15 N/A 49 56
LAIV  and
Asthma/Wheezing
315 9 16 23 N/A 79 1 13 70 47
Narcolepsy 284 40 62 N/A N/A 38 12 37 N/A 49 15 39 54
Pericarditis 125 17 7 N/A N/A 53 7 4 N/A 29 7
Brachial  Neuritis/
Neuralgia/Paresthesia
337 29 27 33 N/A 50 49 23 15 60
Bursitis 87 3 6 5 N/A 16 15 2 13 15
Encephalopathy/
Encephalomyopathy/
Encephalitis
541  109 14 66 N/A 113 30 20 11 132
Myelitis 168 16 12 8 N/A 45 17 11 6 37
ITP/Transient Throm-
bocytopenia/Purpura
404 45 30 16 N/A 135 38 19 17 74 8 12 20
Arthritis  514 22 47 32 N/A 104 20 65 34 111 45
DVT/VTE  174 15 12 N/A N/A 75 7 14 15 28
Cellulitis/Large
Injection Site
Swelling
724 13 18 16 N/A 185 13 12 268 188 20
Syncope  117 3 4 2 N/A 38 3 8 13 46
General Safety Data –
Inactivated Inﬂuenza
Vaccines
15,878 1985 416 508 807 2285 87
General  Safety Data –
LAIV
6001 99
a Only some Adverse Events were screened for this category.
b Articles remaining after primary exclusion steps were extracted to EndNote by publication or study type and duplicates were deleted; numbers here represent ﬁnal numbers after deletion of duplicates.
c PubMed and EMBASE for all Adverse Events, Scopus as well for GBS and Febrile Seizures.
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ppendix 3. Recently Produced Inﬂuenza Vaccines
Manufacturer Manf Country Vaccine Date Seasonal/
Pandemic
Strains Type Production
Meth
Approved Ages
Abbott UK Imuvac 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain
(A/California/7/2009,
X-181)
A/Texas/50/2012
(H3N2)-like strain
(A/Texas/50/2012,
X-223A)
B/Massachusetts/2/2012-
like strain
(B/Massachusetts/2/2012,
BX-51B)
Inactivated Eggs 6 mos+
Abbott  Netherlands Inﬂuvac Desu 2013–14 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain
(A/California/7/2009,
X-181)
A/Texas/50/2012
(H3N2)-like strain
(A/Texas/50/2012,
X-223A)
B/Massachusetts/2/2012-
derived strain used
(NYMC BX-51B)
Inactivated Eggs 6 mos+
Abbott  UK Inﬂuvac
sub-unit
2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain
(A/California/7/2009,
X-181)
A/Texas/50/2012
(H3N2)-like strain
(A/Texas/50/2012,
X-223A)
B/Massachusetts/2/2012-
derived strain used
(NYMC BX-51B)
Inactivated Eggs 6 mos+
Adimmune  Taiwan 2009–10 Pandemic A/California/07/2009 Inactivated Eggs
Adimmune  Taiwan AdimFlu-S
(Pediatric
Use) Alt link
2013–14
northern
hemisphere
Seasonal A/California/7/2009
(H1N1) like virus
A/California/7/2009
(Reassortant NYMC
X-179A) (H1N1)
A(H3N2) virus
antigenically like the
cell-propogated
prototype virus
A/Victoria/361/2011
A/Texas/50/2012
(Reassortant NYMC
X-223) (H3N2)
B/Massachusetts/2/2012
like virus
B/Massachusetts/2/2012
(Reassortant NYMC
BX-51B)
Inactivated Eggs 6 mos – <3 yrs
Baxter  Austria Celvapan Pandemic A/California/07/2009
(H1N1)v
Inactivated Vero cells 6 mos+
Baxter  Austria Pandemic
Inﬂuenza
Vaccine H5N1
Baxter
Pandemic A/Vietnam/1203/2004
(H5N1)
Inactivated Vero cells 6 mos+
Baxter  Czech
Republic/
Austria
Vepacel Pandemic A/Vietnam/1203/2004
(H5N1)
Inactivated Vero cells 6 mos+
Berna  Biotech Switzerland Inﬂexal®V 2007–8 Seasonal A/Solomon
Islands/3/2006
(H1N1)
A/Wisconsin/67/2005
(H3N2)
Inactivated EggsBerna  Biotech –
Crucell – Solvay
Switzerland/
Netherlands
2000 Pandemic B/Malaysia/2506/2004
(B)
A/Hong
Kong/1073/99
(H9N2)
Inactivated Eggs
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Manufacturer Manf Country Vaccine Date Seasonal/
Pandemic
Strains Type Production
Meth
Approved Ages
Bharat Biotech India HNVAC Pandemic A/CALIFORNIA/7/2009
NYMC X-179-A
obtained from
WHO-accredited
Centers for Disease
Control and
Prevention, USA
Inactivated MDCK cells 18–65 yrs
Biken,  Japan 2006 Pandemic A/Vietnam/1194/2004 Inactivated Egg
Biken,  Japan Inﬂuenza HA
Vaccine?
2010 Seasonal A/California/7/2009
(H1N1)
A/Victoria/210/2009
(H3N2)
B/Brisbane/60/2008
(B)
Inactivated Egg
BioFarma,  Indonesia Flubio Vaksin
Inﬂuenza HA?
2010 Seasonal A/Brisbane/59/2007
(H1N1)
A(Uruguay/716/2007
(H3N2)
B/Brisbane/60/2008
(b)
Inactivated Egg Older than 12
yrs?
Biondvax  Israel M-001 2012 Seasonal Epitopes of HA, NP
and M1 from
different strains of A
and B subtypes
(M-001)
Recombinant E. coli
Candia  Healthcare India 2010 Pandemic A/California/07/2009 Inactivated Eggs
Cantacuzino
Institute
Romania  CantgripTM 2009–10 Pandemic A/California/07/2009 Inactivated Eggs
Cantacuzino
Institute
Romania  VACCIN
GRIPAL
TRIVALENT,
PURIFICAT S¸ I
INACTIVAT
2011–12 Seasonal A/California/7/2009
(H1N1) strain used:
A/California/7/2009
(NYMC X-179A)
A/Perth/16/2009
(H3N2) strain used:
A/Victoria/210/2009
(NYMC X-187)
B/Brisbane/60/2008
strain used:
B/Brisbane/60/2008
(NYMC BX-35)
Inactivated Eggs 36 mos+
Changchun
Changsheng  Life
Sciences Ltd
China Inﬂuenza
Vaccine (split)
?? Seasonal “A and B strain of
inﬂuenza virus
corresponding to
prevailing
epidemiological
evidence of the year”
Inactivated Chick embryo 6 mos+
Changzhou
Yanshen
Biotechnology
Co.,  Ltd
China Inﬂuenza
Crucell Netherlands 2009–10 Pandemic A/Vietnam/1194/2004 Inactivated Eggs
Crucell  Netherlands Inﬂexal V Seasonal Yearly WHO
recommendations
Adjuvanted
subunit
Eggs 6 mos+
CSL  US Aﬂuria 2014–15 Seasonal A/California/7/2009
(H1N1), NYMC
X-181,
A/Texas/50/2012
(H3N2), NYMC X-223
B/Massachusetts/2/2012,
NYMC BX-51B
Inactivated Eggs 5–64 yrs
CSL  Australia Fluvax 2014 Seasonal A/California/7/2009
(NYMC X-181)
(A/California/7/2009
(H1N1) – like)
A/Texas/50/2012
(NYMC X-223)
(A/Texas/50/2012
(H3N2) – like)
B/Massachusetts/2/2012
(NYMC BX-51B)
(B/Massachusetts/2/2012
– like)
Inactivated Eggs 5
years + (caution
for 5–9 yrs)
CSL  Australia Panvax 2010 Pandemic A/California/7/2009
(H1N1)
(A/California/7/2009
(H1N1)v-like)
Inactivated Eggs 18–65 yrs
Cytos  Switzerland 2013 Pandemic Globulat head Virus-like E. coli
domain (gH1) of HA
from
A/California/07/2009
particle based
on RNA
bacteriophage
Qbeta
(Leviviridae)
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Pandemic
Strains Type Production
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Approved Ages
Daiichi-Sankyo, Japan 2010 Seasonal A/California/7/2009
(H1N1)
A/Victoria/210/2009
(H3N2)
B/Brisbane/60/2008
(B)
Inactivated Eggs
Denka  Japan 2006 Pandemic A/Vietnam/1194/2004 Inactivated Eggs
Denka  Seiken, Japan Inﬂuenza
Seiken HA?
2010–11 Seasonal A/California/16/2009
(H1N1)
A/Perch/210/2009
(H3N2)
B/Brisbane/60/2008
(B)
Inactivated Eggs
Dynavax  ? 2010 Pandemic M2e and NP
conjugated to
oligonucelotide
Recombinant No data
Fort  Ltd Russia Ultrix Seasonal A/New
Caledonia/20/99
(H1N1)
A/Wisconsin/67/2005
(H3N2)
B/Malaysia/2506/2004
Inactivated Ok for 6 yrs+
(earlier?)
Fraunhofer  US 2011 Pandemic HAC1 Recombinant N. benthamiana
plant
Green  Cross
Corporation
Korea GC FLU inj
(single dose
vial)
2013–14 Seasonal A/California/7/2009
reassortant virus
NYMC X-181 (H1N1)
A/Texas/50/2012
reassortant virus
NYMC X-223A
(H3N2)
B/Massachusetts/02/2012
reassortant virus
NYMC Bx-51B
Inactivated Eggs 6 mos+
Green  Cross
Corporation
Korea GC FLU Multi inj. 2013–14 Seasonal A/California/7/2009
reassortant virus
NYMC X-181 (H1N1)
A/Texas/50/2012
reassortant virus
NYMC X-223A
(H3N2)
B/Massachusetts/02/2012
reassortant virus
NYMC Bx-51B
Inactivated Eggs 6 mos+
Green  Cross
Corporation
Korea Green Flu-S Pandemic A/California/7/2009
NYMC
X-179A(H1N1)
Inactivated Eggs 6 mos+
Green  Hills
Biotech
Austria 2007–08 Pandemic A/New
Caledonia/20/99-
NS1
Live attenuated Vero cells
Green  Hills
Biotech|
Henogen
Austria|
Belgium
2009 Pandemic A/Vietnam/1203/2004-
NS1
Live attenuated Vero cells
GSK  Belgium Adjupanrix 2014 Pandemic A/VietNam/1194/2004
(H5N1) like strain
used (NIBRG-14)
Inactivated Eggs 18 yrs +
GSK  Germany Arepanrix 2010 Pandemic A/California/7/2009
(H1N1)v-like strain
(X-179A)
Inactivated Eggs 18 yrs +
GSK  UK Fluarix 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain used
(NIB-74xp) derived
from
A/Christchurch/16/2010
A/Texas/50/2012
(H3N2) derived
strain
used (NYMC X-233A)
B/Massachusetts/02/2012
derived strain used
(NYMC BX-51B)
Inactivated Eggs 6 mos+
GSK  US Fluarix
Quadravalent
2014–15 Seasonal A/Christchurch/16/2010
NIB-74XP (H1N1)
(an
A/California/7/2009-
like virus),
A/Texas/50/2012
Inactivated Eggs 3 yrs+NYMC X-223A
(H3N2),
B/Massachusetts/2/2012
NYMC BX-51B,
B/Brisbane/60/2008
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GSK UK Fluarix Tetra 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain used
(NIB-74xp) derived
from
A/Christchurch/16/2010
A/Texas/50/2012
(H3N2) derived
strains
used (NYMC X-223A)
B/Massachusetts/02/2012
derived strain used
(NYMC BX-51B)
(Yamagata lineage)
B/Brisbane/60/2008
(Victoria lineage)
Inactivated Eggs 3 yrs+
GSK  Canada FluLaval 2013–14 seasonal A/California/7/2009
(H1N1)-like strain:
A/California/7/2009
X-179A
A/Texas/50/2012
(H3N2)-like strain:
A/Texas/50/2012
X-223A
B/Massachusetts/2/2012-
like strain:
B/Massachusetts/2/2012
BX-51B
Inactivated Eggs 18 yrs+
GSK  US Flulaval
Quadravalent
2014–15 Seasonal A/California/7/2009
NYMC X-179A
(H1N1),
A/Texas/50/2012
NYMC X-223A
(H3N2),
B/Massachusetts/2/2012
NYMC BX-51B,
B/Brisbane/60/2008
Inactivated Eggs 3 yrs+
GSK  Canada FluLaval Tetra 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
virus
A/Texas/50/2012
(H3N2)-like virus
B/Massachusetts/2/2012-
like virus
B/Brisbane/60/2008-
like
virus
Inactivated Eggs
GSK  Belgium Pandemrix pandemic A/California/7/2009
(H1N1)v-like strain
(X-179A)
Inactivated Eggs 6 mos+
GSK  Belgium Prepandrix 2013-last
reviewed
Pre-pandemic A/Indonesia/05/2005
(H5N1) like strain
used
(PR8-IBCDC-RG2)
Inactivated Eggs 18 yrs+
GSK  Belgium Pumarix pandemic ‘A/Indonesia/05/2005
PR8-IBCDC-RG2’
(H5N1)
Inactivated Eggs 18 yrs+
Hokken,  Saitama, Japan 2005–06 Seasonal A/New
Caledonia/20/99
(H1N1)
A/New York/55/04
(H3N2)
B/hanghai/361/029
(B)
Inactivated Eggs
Hualan  Biological China 2009 Pandemic A/California/07/2009 Inactivated Eggs
Hualan  Biological China Inﬂuenza
Vaccine (split
virion)
2012 Seasonal A/California/7/2009
(H1N1)pdm09-like
virus
A/Victoria/361/
2011H3N2-like virus
B/Wisconsin/1/2010-
like
virus
Inactivated Eggs 3 yrs+
Immune  Targeting
Systems
UK 2010–11 Pandemic Six ﬂuorocarbon
modiﬁed peptides
that encapsulate
multiple CD4+ and
Peptide-based NoneCD8+ T cell epitopes
from nucleoprotein,
matrix and
polymerase 1 and 2
proteins
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Immunopreparat
Research
productive
association
Russia Inﬂuenza
Vaccine
Impfstoffwerk Germany 2010–11 Pandemic Modiﬁed Vaccinia
virus Ankara (MVA)
vector encoding NP
and  MI of strain
A/Panama/2007/99
Recombinant CEF
Instituto  Butantan Brazil 2010 Pandemic A/California/07/2009 Inactivated Eggs
Instituto  Butantan Brazil CEPAS
Also PI
from IB
2014
(southern
hemisphere)
Seasonal A/California/7/2009
(H1N1)pdm09
A/Texas/50/2012
B/Massachusetts/2/2012
Inactivated Eggs (ovos) 6 mos+
Janssen-Cilag  Ltd UK Viroﬂu 2013–14 Seasonal A/California/7/2009
(H1N1)pdm09-
derived strain used
(NYMC X-181)
A/Victoria/361/2011
(H3N2)-like strain
used (NYMC X-223)
derived from
A/Texas/50/2012
B/Massachusetts/2/2012-
derived strain used
(NYMC BX-51B)
Inactivated Eggs 6 mos+
Kaketsuken  Japan 2006 Pandemic A/Vietnam/1194/2004 Inactivated Eggs
Kaketsuken
Biologicals
Japan  Inﬂuenza HA
vaccine (in
japanese)
2005 Seasonal A/New
Caledonia/20/99
(H1N1)
A/New
York/55/2004
(H3N2)
B/Shanghai/361/2002
(B)
Inactivated Eggs?
Kitasato  Institute Japan 2006 Pandemic A/Vietnam/1194/2004 Inactivated Eggs
Lanzhou  Institute
of Biological
Products (LIBP)
China Inﬂuenza
LG  Life Sciences Korea 2004–5 Seasonal A/New
Caledonia/20/99
(H1N1)
A/Fujian/411/2002
(H3N2)
B/Shainghaia/361/2002
(B)
Inactivated Eggs
Liaoning  Tiancheng
Bio-pharmacy
Insitute Co. Ltd
China Inﬂuenza
MedImmune UK FLUENZ nasal
spray
suspension
2013–14 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain
A/Victoria/361/2011
(H3N2)-like strain
B/Massachusetts/2/2012-
like
strain
Live attenuated Eggs 24 mos–>18 yrs
MedImmune  UK Fluenz Tetra
nasal spray
suspension
2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-like
strain
A/Texas/50/2012
(H3N2)-like strain
B/Brisbane/60/2008
(Victoria
lineage)-like strain
B/Massachusetts/2/2012
(Yamagata
lineage)-like strain
Live attenuated Eggs 24 mos–>18 yrs
MedImmune  USA FluMist
Quadrivalent
2014–15 Seasonal A/California/7/2009
(H1N1)
A/Texas/50/2012
(H3N2)
B/Massachusetts/2/2012
(B/Yamagata/16/88
lineage)
B/Brisbane/60/2008
(B/Victoria/2/87
lineage)
Live attenuated Eggs 2–49 yrsMedImmune  USA Inﬂuenza A
(H1N1) 2009
monovalent
vaccine nasal
2010 Pandemic 
Microgen  Russia 2009–10 Pandemic A/California/7/2009
(H1N1)v
Live Eggs 2–49 yrs
A/California/07/2009 Live attenuated Eggs
F40 N.A. Halsey et al. / Vaccine 33 (2015) F1–F67
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Microgen Russia 2009–10 Pandemic A/California/07/2009 Inactivated Eggs
Microgen  Russia Grippol Seasonal changed yearly
according to
epidemic situation
and WHO
recommendations
Polymer-
subunit
6 mos+
Microgen  Russia INFLUENZA
VIRUS
VACCINE
Seasonal changed yearly
according to WHO
recommendations
Live, Dry Eggs 3 yrs+
Netherlands
Vaccine  Institute
Netherlands 2011 Pandemic A/Uruguay/716/2007
(H3N2))
Inactivated Eggs
NIH|Novartis  USA|Italy 2009–10 Pandemic A/California/07/2009 DNA Vaccine E. coli
NIH|Sanoﬁ  pasteur USA 2011–12 Seasonal 2011–2012 seasonal
strains
DNA Vaccine DNA
NIH|Sanoﬁ  pasteur USA 2010–11 Pandemic A/Indonesia/05/2005 DNA Vaccine E. coli
Nobilon
International
Netherlands  2009 Seasonal A/Brisbane/59/2007
(H1N1)
A/Brisbane/10/2007
(H3N2)
B/Florida/4/2006 (B)
Live attenuated MDCK cells
Novartis  Italy Aﬂunov Pre-pandemic A/turkey/Turkey/1/05
(H5N1)-like strain
(NIBRG-23)
Inactivated Eggs 18 yrs+
Novartis  US Agriﬂu 2013–14 Seasonal A/California/7/2009,
NYMC X-181 (H1N1)
A/Texas/50/2012,
NYMC X-223 (H3N2)
B/Massachusetts/2/2012
Inactivated Eggs 18 yrs+
Novartis  UK Agrippal 2014–15
Season
Seasonal A/California/7/2009
(H1N1)pdm09 –
derived strain used
(NYMC X-181
A/Texas/50/2012
(H3N2) – derived
strain used (NYMC
X-223)
B/Massachusetts/2/2012
– (wild type)
Inactivated Eggs 6 mos+
Novartis  Germany Celtura 2010 Pandemic A/California/7/2009
(H1N1)v-like strain
used (X-179A)
Inactivated MDCK 6 mos+
Novartis  Italy Flucelvax 2014–15 Seasonal A/Brisbane/10/2010
(H1N1) (an
A/California/7/2009
-like virus);
A/Texas/50/2012,
NYMC X-223A
(H3N2)
B/Massachusetts/2/2012
Inactivated MDCK 18 yrs+
Novartis  US Flucelvax 2014–15 Seasonal A/Brisbane/10/2010
(H1N1) (an
A/California/7/2009-
like virus)
A/Texas/50/2012,
NYMC X-223A
(H3N2)
B/Massachusetts/2/2012
Inactivated Madin Darby
Canine Kidney
(MDCK)
18 yrs+
Novartis  UK Fluvirin 2014–15 Seasonal A/Christchurch/16/2010,
NIB-74 (H1N1) (an
A/California/7/2009-
like virus);
A/Texas/50/2012,
NYMC X-223
(H3N2);
B/Massachusetts/2/2012,
NYMC BX-51B
Inactivated Eggs 4 yrs
Novartis  UK Fluvirin H1N1 Pandemic A/California/7/2009
(H1N1)v-like virus
Inactivated Eggs 4 yrs+
Novartis  Italy Focetria Pandemic A/California/7/2009
(H1N1)v like strain
(X-181)
Inactivated Eggs 6 mos+
Novartis  Italy Foclivia Pandemic A/Vietnam/1194/2004
(H5N1)
Inactivated Eggs 18 yrs+
Novartis  Germany Optaﬂu 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09 – like
strain used
A/Brisbane/10/2010
wild type
Inactivated MDCK cells 18 yrs+A/Texas/50/2012
(H3N2) – derived
strain
used (NYMC X-223A)
B/Massachusetts/2/2012
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Novartis Italy Prepandemic
Inﬂuenza
vaccine (H5N1)
Pre-pandemic A/Vietnam/1194/2004
(H5N1)-like strain
(NIBRG-14)
Inactivated Eggs 18 yrs+
Novavax  US 2009 Pandemic A/California/04/2009
(VLP consisting of HA,
NA  and M1)
Recombinant Sf9 insect eggs
Novavax  US 2005 Pandemic A/chicken/Hong
Kong/G9/97
Live attenuated Eggs
NTpharma  LLC Russia AdeVac-Flu
(intranasal)
Seasonal Recombinant
Omninvest,  Hungary Fluval AB 2012–13 Seasonal A/California/7/2009
(H1N1) origin, NYMC
X-179A reassortant
strain
Victoria/361/2011
(H3N2) derived IVR-165
reassortant strain
B/Wisconsin/1/2010-like
B/Hubei-
Wujiagang/158/2009
Inactivated Eggs 3 yrs+
Omnivest  Hungary Fluval P 2009 Pandemic A/California/07/2009 Inactivated Eggs
Pax  Vax US 2011 Pandemic A/Vietnam/1194/2004 Live
Ad4-vectored
vaccine
MRC5 cells
Petrovax  Russia Grippol
Grippol Plus
Grippol Neo
2008–09 seasonal A/Brisbane/59/2007
(H1N1) -like virus;
A/Brisbane/10/2007
(H3N2) -like virus;
B/Florida/4/2006-like
virus.
Inactivated MDCK cells 6 mos+
Pﬁzer  Limited UK Enzira 2014–15 Seasonal A/California/7/2009
(H1N1) pdm09 – like
strain
(A/California/7/2009,
NYMC X-181)
A/Texas/50/2012 (H3N2)
–  like strain
(A/Texas/50/2012, NYMC
X-223)
B/Massachusetts/2/2012
– like strain
(B/Massachusetts/2/2012,
NYMC BX-51B
Inactivated Eggs 5 yrs+
Pharmaceutical
Organization
Thailand  2012 Pandemic A/California/07/2009 Live attenuated Eggs
PowderJect
Vaccines
US  No data Pandemic A/Panama/2007/99
(H3N2)
DNA vaccine
PowderMed  UK 2007 Seasonal A/New Caledonia/20/99
(H1N1)
A/Panama/2007/99
(H3N2)
B/Jiangsu/10/2003()B)
DNA vaccine E. coli
Protein  Sciences US 2010–11 Pandemic A/Indonesia/05/2005 Recombinant SF9 insect cells
Protein  Sciences, USA Flublok 2014–15 Seasonal A/California/7/2009
(H1N1)
A/Texas/50/2012 (H3N2)
B/Massachusetts/2/2012
Recombinant Serum-free
medium
composed of
chemically-
deﬁned lipids,
vitamins, amino
acids, and
mineral salts
18–49 yrs
Research  Foundation
for Microb Dis of
Osaka Univ
Japan 2009 Pandemic A/California/07/2009 Inactivated Eggs
RIBSP  Khazakhstan 2010–11 Pandemic A/California/07/2009 Inactivated Eggs
Sanoﬁ  Pasteur US Fluzone 2014–15 Seasonal A/California/07/2009
X-179A (H1N1)
A/Texas/50/2012 X-223A
(H3N2)
B/Massachusetts/02/2012
(B  Yamagata lineage)
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur US Fluzone 2014–15 Seasonal A/California/07/2009 Inactivated Eggs 65 yrs+
High-Dose X-179A (H1N1)
A/Texas/50/2012 X-11
223A  (H3N2
B/Massachusetts/02/2012
(B Yamagata lineage)
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Sanoﬁ Pasteur US Fluzone
Intradermal
2014–15 Seasonal A/California/07/2009
X-179A (H1N1)
A/Texas/50/2012 X-223A
(H3N2)
B/Massachusetts/02/2012
(B  Yamagata lineage)
Inactivated Eggs 18–64 yrs
Sanoﬁ  Pasteur US Fluzone single
dose
2009–10 Seasonal A/Brisbane/59/2007,
IVR-148 (H1N1)
A/Uruguay/716/2007,
NYMC X-175C (an
A/Brisbane/10/2007-like
virus) (H3N2)
B/Brisbane/60/2008
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur US Fluzone®
Quadrivalent
2014–15 Seasonal A/California/07/2009
X-179A (H1N1)
A/Texas/50/2012 X-223A
(H3N2) (an
A/Victoria/361/2011-like
virus)
B/Massachusetts/02/2012
(B Yamagata lineage)
B/Brisbane/60/2008 (B
Victoria lineage
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur France IDﬂu 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-derived
strain used (NYMC
X-179A)
A/Victoria/361/2011
(H3N2)-like strain used
(NYMC X-223A) derived
from/Texas/50/2012
B/Massachusetts/02/2012
Inactivated Eggs 18–59 yrs
Sanoﬁ  Pasteur UK Inactivated
Inﬂuenza
Vaccine (Split
Virion) BP
2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-derived
strain used (NYMC
X-179A)
A/Texas/50/2012
(H3N2)-derived strain
used  (NYMC X-223A)
B/Massachusetts/2/2012
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur US Inﬂuenza A
(H1N1) 2009
monovalent
vaccine – single
dose vial
Pandemic A/California/07/2009
(H1N1) v-like virus
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur US Inﬂuenza A
(H1N1) 2009
monovalent
vaccine-
multidose vial
Pandemic A/California/07/2009
(H1N1) v-like virus
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur France Intanza 2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-derived
strain used (NYMC
X-179A
A/Victoria/361/2011
(H3N2)-like strain used
(NYMC X-223A) derived
from A/Texas/50/2012
B/Massachusetts/02/2012
Inactivated Eggs 18–59 yrs
Sanoﬁ  Pasteur UK INTANZA 9
micro-
gram/strain
suspension for
injection
2014–15 seasonal A/California/7/2009
(H1N1)pdm09-derived
strain used (NYMC
X-179A)
A/Texas/50/2012
(H3N2)-derived strain
used  (NYMC X-223A)
B/Massachusetts/2/2012
Inactivated Eggs 18–59 yrs
Sanoﬁ  Pasteur France Panenza Pandemic A/California/7/2009
(H1N1)v-like strain
(NYMC X-179A)
Inactivated Eggs 9 yrs+
Sanoﬁ  Pasteur France Vaxigrip 2010–11 Seasonal A/California/7/2009
(H1N1) – derived strain
used NYMC X-179A
Inactivated Eggs 6 mos+A/Perth/16/2009 (H3N2)
–  like strain used NYMC
X-187 derived from
A/Victoria/210/2009
B/Brisbane/60/2008
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Manufacturer Manf Country Vaccine Date Seasonal/
Pandemic
Strains Type Production
Meth
Approved Ages
Sanoﬁ Pasteur New Zealand Vaxigrip Dated Jan 2013 Seasonal A/California/7/2009
NYMC X-179A
(A/California/7/2009
[H1N1]pdm09 –
like),
A/Victoria/361/2011
IVR-165
(A/Victoria/361/2011
[H3N2] – like), and
B/Hubei-
Wujiagang/158/2009
NYMC BX-39
(B/Wisconsin/1/2010
– like)
Inactivated Eggs 6 mos+
Sanoﬁ  Pasteur China Vaxigrip (china) Inactivated 6–35 mos
Sanoﬁ  Pasteur MSD
Limited
UK INTANZA 15
micro-
gram/strain
suspension for
injection
2014–15 Seasonal A/California/7/2009
(H1N1)pdm09-
derived strain used
(NYMC X-179A)
A/Texas/50/2012
(H3N2)-derived
strain
used (NYMC X-223A)
B/Massachusetts/2/2012
Inactivated Eggs 60 yrs+
SEEK  UK 2011 Pandemic Unknown Recombinant Synthetic
Serum  Institute
of India
India NASOVAC – 5
dose vial
Pandemic A/17/California/2009/38 Live Attenuated Eggs 3 yrs+
Serum  Institute
of India
India NASOVAC-S 2014 Southern
Hemisphere
Seasonal A(H1N1) Strain –
A/17/California/2009/38
(H1N1)
A(H3N2) Strain –
A/17/Texas/2012/30
(H3N2)
B  Strain –
B/60/Massachusetts/
2012/10
Live Attenuated Eggs 3 yrs+
Shanghai  Institute
of Biological
Products (SIBP)
China 2009–10 Pandemic A/California/07/2009 Inactivated Eggs
Sinovac  Kexing
Biological
Product Co., Ltd
China AnFluTM 2010 Seasonal A/California/7/2009
A/Victoria/210/2009
B/Brisbane/60/2008
Inactivated Chicken embryo 6 mos+
Sinovac  Kexing
Biological
Product Co., Ltd
China Panﬂu Pandemic A/Vietnam/1194/
2004(H5N1)
Inactivated Chicken embryo 18 yrs+
Sinovac  Kexing
Biological
Product Co., Ltd
China Panﬂu.1 Pandemic H1N1 Inactivated Chicken embryo 3 yrs+
Solvay
Pharmaceuticals
Netherlands  2007–8 Seasonal A/Solomon
Islands/3/2006
(H1N1)
A/Wisconsin/67/2005
(H3N2)
B/Malaysia/2506/2004
(B)
Inactivated Eggs
Torlak  Institute Serbia and
Montenegro
Vaccinum
Inﬂuenzae
Seasonal Inactivated Eggs
Vabiotech  Vietnam 2010–11 Pandemic A/Vietnam/1194/2004 Inactivated Primary monkey
kidney cells
Vaxinnate  Corp US 2009–10 Pandemic HA globular head
three formats of
VAX128 (A, B, C)
Recombinant E. coli
Vical  Incorp US 2008 Pandemic A/Vietnam/1203/2004
for H5; seasonal
H1N1 or H3N2 for
DNA vaccineNP and M2
Zhejiang  Tianyuan -
BioPharmaceutical
Co. Ltd
China Inﬂuenza Inactivated
Zydus  India? Vaxiﬂu-S 2010 Pandemic A/California/7/2009 Inactivated Egg 18 yrs+
F44
 
N
.A
.
 H
alsey
 et
 al.
 /
 V
accine
 33
 (2015)
 F1–F67
Appendix 4. Epidemiological Evidence for Association between Inﬂuenza Vaccines and Febrile Seizures by Year
Autho r 
Yea r 
Coun try 
Influenza 
Season (s
) 
& 
Age 
group 
Stud y type  Vacc ine type 
Dose  
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interva l) 
Number or 
proportion  of febril e 
con vulsion s 
Primary risk  Estimate (95 % Con fidence  
interva l) 
Total  time of Adve rse  
Eve nt Mon itoring  aft er 
vaccination   
Time aft er vacc ination 
AE no ted 
Marine  
1976 
Eng land  
1972 
9mos-
2Yrs 
Cli nical trial  Who le cell  
MIV  
340 cc a (IM) 
500 cc a (SC) 
rh 42 deificeps toN detaniccav 31/1 detaniccav 31/9 s.    Fevers within 6-12  Hrs.   
Feb ril e seizure 7 Hrs.   
12-28  mos 
9/16  vacc ina ted   
1/19  con trols 
2/16  vacc ina ted  0/19  
con trols 
3-6 Yrs. 
Wrigh t 
1976 
US
1973 
1-6 Yrs. 
Cli nical trial  Who le cell  
MIV 
250 cca1  
(0.25 mL) 
2/29  vacc ina ted   
0/4 con trols 
0/29  vacc ina ted  
0/4 con trols 
  .srh 42 deificeps toN Fever 6-12  Hrs.   
Feb ril e seizure 6.5 Hrs.   
Who le cell  
MIV 
12/40  
TIV 
21/40  
Spli t-virus 
Bernstein 
1982 
US 
1978-
1980 
6-36  mos 
Cli nical trial  Who le cell  
Split   
3.5 mg  
(0.25  mL) 
MIV 
6/37  
 TIV  
0/37  
 .srH 84-6 deificeps toN detaniccav 77/0 Not  spe cified  
Feldman  
1985 
US
Not 
spe cified   
1-7 Yrs. 
Rando mize
d con trolled  
trial 
LAIV  
0.5mL 
Who le cell  
MIV  
8 μg  
(0.25  mL) 
LAIV H1N1 0/29  
LAIV H3N2 3/28  
MIV H3N2 8/24  
Placebo  0/30  
LAIV H1N1 0/29   
LAIV H3N2 0/28   
MIV H3N2 1/24  
Placebo  0/30  
  syad 6 VIAL deificeps toN
MIV 6-12  hrs.   
Most f evers within 24  
Hrs. 
Feb ril e seizure within 6 
days 
Fran ce 
2004 
US
1993-
1999 
<18  Yrs. 
Self-
con trolled  
case series 
not spe cified   1,094 /128 ,679  
vacc ina ted  
81/128 ,679  
vacc ina ted  
 41-1 yaD deificeps toN Feb ril e seizure within 14  
days  
Con trol windo w: 15 -28  
days be fore and  aft er 
vacc ina tion   
Nolan  
2008 
US, 
Australi a
2000-
2002 
12-15  
mos 
Rando mize
d con trolled  
trial 
LAIV   
0.5 mL 
MMR+Varicell a+LAI
V 417 /422  
LAIV  
211/412  
MMR+Varicell a+LAIV 
0/422  
MMR+Varicell a  
0/411   
LAIV  
1/412  
 tnerrucnoc retfa syad 14 deificeps toN
vacc ine s and  10  da ys 
aft er LAIV 
Time of  Feb ril e seizure 
occ urren ce not  spe cified  
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Autho r 
Yea r 
Coun try 
Influenza 
Season (s
) 
& 
Age 
group
Stud y type Vacc ine type 
Dose
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interva l) 
Number or 
proportion  of febril e 
con vulsions
Primary risk  Estimate (95 % Con fidence  
interva l)
Total  time of Adve rse  
Eve nt Mon itoring  aft er 
vaccination   
Time aft er vacc ination 
AE no ted
Breiman  
2009 
Asia,  S. 
America
2002 
6-36  mos 
Rando mize
d con trolled  
trial 
LAIV  
0.2 mL 
LAIV + OPV   
Dose 1: 237 /818  
Placebo  + OPV  
234/826   
LAIV 228 /814  
1/2,503 t otal 
vacc ina ted  
 deificeps toN  .syad 11 deificeps toN
Hazard Ratio  
Fever Febrile Seizures 
Dose1:  0.52  (0.06 -
4.56 )  
 1.17  (0.36 -3.86 )  
Good man  
2005 
US
2002-
2004 
6-23  mos 
Case-
con trol 
TIV  Not  spe cified  Not  spe cified  
Dose2:  0.64  (0.15 -
2.74 ) 
 1.026  (0.19 -
5.56 ) 
42 da ys.    Not  spe cified  
Hambidge  
2006 
US
1991-
2003 
6-23  mos 
Retrospe cti
ve coho rt,  
self-
con trolled  
case series 
TIV  Not  spe cified   Risk  windo w: 22  
Con trol windo w: 12  
seizures 
Total vacc ina ted  
45,356  
Feb ril e Seizure 
Matched  OR:  1.36  (0.63 -2.97 ) 
Con comitant MM R excluded  
14 da ys  21 Feb ril e seizures 
occurred after day 3 
post-vacc ina tion.   
Con trol windo w: 15 -28  
days be fore and  aft er 
vacc ina tion . 
LAIV+MM
R  
Placeb
o + 
MMR  
Dose 1: 
523/806  
Dose 
1: 
229/40
6 
Lum
2010 
Mostly 
Europe  & 
Asia
2002-
2003 
11-24  
mos 
Rando mize
d con trolled  
trial 
LAIV  
0.2 mL 
Dose 2: 
195/765  
Dose 
2: 
100/38
3 
LAIV+MMR  1/765  
Plac ebo + MMR  1/38 3
  syad 82 deificeps toN Feb ril e seizure occ urred  
3 mon ths aft er 
vacc ina tion  
LAIV 
 0.2 mL 
TIV 
<35  
mos 
>36 
mos 
Belshe
2007 
US, 
Europe , 
ME,  Asia
2004 
6-59  mos 
Rando mize
d con trolled  
trial 
0.25  
mL 
0.5 
mL 
LAIV 219 /3,916  
TIV 78 /3,936  
LAIV 0/3,916  
TIV 2/3,936  
 syad 2 nihtiw reveF  deificeps toN deificeps toN
Kavada s
2008 
Canad a
1991-
2005 
Chil dren  
Active 
surveillan ce 
  1 Feb ril e seizure 
aft er Fluzone ® 
(Aven tis) in 1991  
 elirbeF  deificeps toN deificeps toN deificeps toN seizures occ urred  
1 da y aft er vacc ine . 
TIV 
<3 
Yrs 
>3 
Yrs 
Baxter
2010 
US
2006-
2007 
0.5-18  
Yrs. 
Rando mize
d con trolled  
trial 
15 μg 
0.25  
mL 
15μg 
0.5 
mL 
6 mo to <3 yea rs: 
Flua rix® 16 .4% 
(12 .7-20 .8)  
2.9% (1.4-5.3)**  
Fluzone ® 11 .0% 
(7.9-14 .7)   
1% (0.3-2.9)**  
All  age s: 
Flua rix® 1/2,081   
Fluzone ® 0/1,173  
  .syad 82 deificeps toN Feb ril e seizures occ urred  
4 da ys aft er 2nd  do se.   
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Autho r 
Yea r 
Coun try 
Influenza 
Season (s
) 
& 
Age 
group
Stud y type Vacc ine type 
Dose
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interva l) 
Number or 
proportion  of febril e 
con vulsions
Primary risk  Estimate (95 % Con fidence  
interva l)
Total  time of Adve rse  
Eve nt Mon itoring  aft er 
vaccination   
Time aft er vacc ination 
AE no ted
6-11  mos 12 -23  mos TIV 
0.25
ml 
0.5 
ml 
0.25
ml 
0.5 
ml 
Dose
1 
2/65   2/61   7/63   3/63  
Skowron s
ki
2011 
Canad a
2008 
6-23  mos 
Rando mize
d con trolled  
trial 
Dose 
2 
16/ 
65 
1/ 
61 
20/ 
61 
14/ 
63 
  deificeps toN syad 01 deificeps toN 252/0
  0.25  
ml 
0.5 
ml 
Dos
e 1 
44/ 
184 
75/ 
183  
Nolan
2010 
Australi a
2009 
0.5-9 Yrs. 
Rando mize
d con trolled  
trial 
pA/H1N1 no  
adjuvant   
0.25  mL 
(15μg) 0.50  
mL (30μg) Dos
e 2 
32/ 
176 
24/ 
168 
1 FS in 18  mon th-old 
with con curren t 
pneumon ia 
 derrucco eruzies elirbeF  .syad 12 deificeps toN
20 da ys aft er 15μg 
vacc ine  
Stavrou lo
poulos
2010 
Gree ce
2009 
Adu lts 
Prospe ctive 
coho rt 
pA/H1N1 
AS03 
adjuvan t 
0.5 mL 
1/110  vacc ina ted   
1/42  con trols 
0/110  vacc ina ted   
0/42  con trols 
No sign ificant  diff eren ce in risk  of f ever 
between  dialysis pa tien ts and  con trols 
Not  spe cified   Not  spe cified  
Nordin
2013 
US
2002-
2009 
14-49  Yrs. 
Old 
Women  
Retrospe cti
ve coho rt 
TIV 13 /75 ,906  
vacc ina ted   
227/147 ,992  
unvacc ina ted  
1/75 ,906  vacc ina ted   
0/147 ,992  
unvacc ina ted   
No sign ificant  diff eren ce be tween  
vacc ina ted  and  un vacc ina ted  
42 da ys  Not  spe cified  
Tenn is
2011 
US
2007-
2009 
<60  mos 
Retrospe cti
ve coho rt 
24 deificeps toN 735/1 VIAL deificeps toN VIT ,VIAL  da ys  Not  spe cified  
Nazareth
2013 
UK 
2009
>9 mos
Prospe ctive 
coho rt 
pA/H1N1 
AS03 
adjuvan t 
<5 Yrs.  9/55   
5-17  Yrs. 11 /63  
od tsal retfa syad 102 deificeps toN 053/1 sraey 9< se.    Fever repo rted  within 7 
days of  vacc ine  
Lambe rt
2013 
Australi a
2009 
0.5-18  
Yrs. 
Cli nical trial  TIV 
0.25  mL (15  
μg) 0.5 mL 
(15  μg) 
>6 mos - <3 Yrs. 
Dose 1: 29 /710  
Dose 2: 18 /710  
>3-9 Yrs. 
Dose 1: 19 /880  
Dose 2: 10 /880  
 tsal retfa syad 081 deificeps toN 679,1/1
vacc ine   
Feb ril e seizure da y 1 
aft er vacc ina tion . 
Stowe
2011 
UK
2000-
2010 
<10  Yrs. 
With 
history of 
at  lea st  1 
con vulsio
n 
Active 
surveillan ce
; Self-
con trolled  
case series 
TIV,   
pA/H1N1 
AS03 
adjuvan t 
Not  spe cified   2 weeks  pre-vacc ine:   
TIV 32 /2,858   
MIV 13 /1,895  
0-7 da ys po st 
vacc ine  
TIV 19 /2,858  do ses 
MIV 17 /1,895  do ses  
IRR  7 da ys po st 
Mono valent  H1N1:  0.99  (0.61 -1.60 )  
Dose 1 TIV:  0.89  (0.53 -1.52 ) 
0-7 da ys po st  vacc ine  
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Autho r 
Yea r 
Coun try 
Influenza 
Season (s
) 
& 
Age 
group
Stud y type Vacc ine type 
Dose
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interval) 
Number or 
proportion  of febril e 
con vulsions
Primary risk  Estimate (95 % Con fidence  
interva l)
Total  time of Adve rse  
Eve nt Mon itoring  aft er 
vaccination   
Time aft er vacc ination 
AE no ted
Domacho
wsk e
2012 
US
2009-
2010 
3-17 Yrs. 
Rando mize
d con trolled  
trial 
TIV
0.5 mL (15  
μg)
3-4 Yrs.   
Vacc ina ted  14 /294  
4.8% (2.6-7.9)  
Con trol 8/281  
2.9% (1.2-5.6%) 
  
5-8 Yrs.   
Vacc ina ted  15 /387   
3.9% (2.2-6.3)  
Control 17/377 
4.5% (2.6-7.1) 
9-17 Yrs. 
Vaccinated 12/362 
3.3% (1.7-5.7) 
Control 8/368  
2.2% (0.9-4.2) 
Vacc ina ted  1/1,055  
Con trol 0/1,061  
 deificeps toN syad 081 deificeps toN
6 to <9 yea rs with 
AS03 ad juvan ted  
Fever 34 .6-50 .0%;   
Langley, 
Reich
2012 
Canad a
2009-
2010 
0.5-9 Yrs. 
Rando mize
d con trolled  
trial 
pA/H1N1 
AS03a: 3.75  
μg AS03b:  1.9 
μg No 
adjuvant:  
7.5 or 15  μg 
Fever >39 .0°C  
3.75  μg AS03  
adjuvan ted  vacc ine   
6 mos to 5 years  
8.0-18 .2%  
6 to <9 yea rs 11 .1% 
Adjuvant  vacc ine  
2/259   
No ad juvant  0/127   
  .raey 1 deificeps toN Feb ril e seizure on  da y 
105 and  266  aft er 2nd  
dose. 
Armstrong
2011 
Australi a
2008-
2010
0.5-5 Yrs.
Passive 
Surveillan ce
,  repo rts of 
FS, 
Retrospe cti
ve Coho rt 
TIV 
<3 Yrs.   
0.25  mL (7.5 
μg)  
4 Yrs.   
0.5 mL (15  
μg) 
Fluvax® 118/209 
Influvac® 19 /110   
62/18,816 
vacc ina tion s 
Fluvax® OR of Fever 5.1 (2.9-9.2)  
Overall  Risk  of  Feb ril e seizures:   
3.3/  1,000  do ses (2.6-3.2) 
OR of  Feb ril e seizures in 2010  compa red  
to 2008: 44  (6-894 )  
Sign ificant  Feb ril e Adverse Event  with 
Fluvax® OR 8.9 (3.1-25 .7)  
72 Hrs.   62 Febrile seizures within 
72 hou rs (most f irst 
dose) 
Blyth
2011 
Australi a
2010 
<5 Yrs. 
Retrospe cti
ve coho rt 
TIV
<3 Yrs.   
0.25  mL 
(7.5μg) 
>3 Yrs.   
0.5 mL (15  
μg)
tiw eruzies elirbeF deificeps toN deifitnedi SF 83 hin 72  
hours 
Not  spe cified  
Leeb
2011 
Australi a
2010 
>18  Yrs. 
Retrospe cti
ve survey 
TIV Fluvax® 4/156  
Influvac® 4/127  
Fluvax® 0/156   
Influvac® 0/127  
Fluvax® Adjusted  OR of f ever 1.63  (0.32 -
8.2) 
72 Hrs.  Not  spe cified  
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Autho r 
Yea r 
Coun try
Influenza 
Season (s
) 
& 
Age 
group
Stud y type Vacc ine type 
Dose
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interval) 
Number or 
proportion  of febril e 
con vulsions
Primary risk  Estimate (95 % Con fidence  
interva l)
Total  time of Adve rse  
Event Monitoring after 
vaccination   
Time aft er vacc ination 
AE no ted
Petousis-
Harris
2011 
New 
Zea land  
2010
<5 Yrs.
Retrospe cti
ve survey 
TIV  
15 μg
Fluvax® 33/104  
Vaxigrip® 3/267 
Fluvax® 1/104      
Vaxigrip® 0/267 
Fluvax® RR  of f ever 4.33  (2.4-7.7) 24  hou rs  Not  specified  
Van  
Buynder
2012 
Canada 
2010
6-59 mos
Prospective 
survey 
TIV 
<3 yrs 0.25 
mL >3 yrs 0.5 
mL
 3 deificeps toN detaniccav 066/0 detaniccav 066/65 days Not specified 
McEvoy
2012 
Australia 
(Perth) 
2010 
Adults 
Not 
specified 
TIV Fluvax® 51/2,019 
Other 2/226 
 deificeps toN sruoh 84 deificeps toN 542,2/0
Mofleh
2012 
Afghanista
n 
2010
Adults
Retrospecti
ve survey
pA/H1N1 N deificeps toN detaniccav 063/3 detaniccav 063/441 ot specified Not specified 
Petousis-
Harris
2012 
New 
Zea land  
2010-
2011 
0.5-8 Yrs. 
Retrospecti
ve survey
TIV
15μg
Fluvax® 242/865  
Vaxigrip® 233/2,571  
Influvac® 39 /204    
Flua rix® 22 /438  
Fluvax® 3/865 
doses; Vaxigrip® 
0/2,571; I nfluvac® 
0/204 doses, 
Flua rix® 0/438  do ses 
Fluvax® Risk of Febrile seizure 35/ 
10,000 doses in children 6 mos to 8 years 
within 24  hou rs of   
Not  spe cified   Not  spe cified  
Tse 
2012 
US
2010-
2011 
Not 
specified 
Active 
surveillan ce
, Self-
con trolled  
case series
TIV Not  spe cified  25  FS in risk  interval  
22 FS in con trol 
interval  
among  206 ,174  
chil dren  6-59  mos 
and 384 ,098  5-17  
Yrs. 
Unad justed IRR f or FS in risk  windo w 
 4.0 (2.1-6.2).   
IRR  ad justed f or PCV13  same da y  
2.5 (1.2-4.7) 
Risk window: 0-1 days 
post  vacc ina tion  
Control window: 14-20 
days aft er vacc ina tion  
Wood 
2012 
Australi a
2010-
2011 
0.5-5 Yrs.
Coho rt TIV 
0.5 mL (15 
μg)  
pA/H1N1 no 
adjuvan t 
0.25  mL (7.25  
μg) or 
0.5 mL (15  
μg)  
66/333  vacc ina ted   0/333  RR f evers with CSL Fluvax® compa red t o 
othe rs 6.5 (3.1-13 .9) 
Within 48  hou rs.  Not  spe cified  
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Autho r 
Yea r 
Coun try 
Influenza 
Season (s
) 
& 
Age 
group
Stud y type Vacc ine type 
Dose
Number or 
proportion  of 
febril e episodes  
(95 % Con fidence  
interva l) 
Number or 
proportion  of febril e 
con vulsions
Primary risk  Estimate (95 % Con fidence  
interva l)
Total  time of Adve rse  
Eve nt Mon itoring  aft er 
vaccination   
Time aft er vacc ination 
AE no ted
Domacho
wsk e 
2013 
US, 
Europe , 
Philipp ine
s
2010-
2011
0.5-17  
Yrs.
Rando mize
d con trolled  
trial 
QIV,  TIV
0.5 mL
6-35  mos  
20% with QIV  
3-5 yea rs  
12% with QIV  
10% with TIV-Vic  
10% with TIV-Yam  
6-17  Yrs.   
<10 % all  vacc ine  
type s 
6-35  mos  
2/277  with QIV  
3-17  yea rs  
0/915  with QIV  
0/912  with TIV-Vic 
0/911  with TIV-Yam 
 som 6 deificeps toN Febrile seizure on day 16 
and 98   
Greenbe r
g 
2014 
US
2010-
2011
0.5-9 Yrs.
Rando mize
d con trolled  
trial 
QIV,  TIV 
<3 Yrs.  0.25  
mL  
>3 Yrs. 
0.5 mL (15  
μg) 
Not  spe cified   QIV 0/2,892   
Licen sed  TIV 1/734   
(11  mon th old) 
Unli cen sed  TIV 1 
/721  
(4 yea r old) 
 .srH 8 eruzies elirbeF  .som 6 deificeps toN
and 1 da y aft er. 
Langley, 
Sche ifele 
2012 
Canad a
2010-
2011
12-59  
mos
Prospe ctive 
coho rt 
TIV 
<3 Yrs.  0.25  
mL >3 Yrs. 
0.5 mL
Dose 1:   
10/207  on  da y 0-1  
19/207  on  da y 0-6 
 deificeps toN .som 6 deificeps toN 702/0
Dose 1 
Adjuvan ted  vacc ine   
+ placebo  310 /1,356  
15 feb ril e con vulsion s 
Adjuvan ted  + 
placebo  6/1,356  
2 Doses of 
Adjuvan ted  vacc ine   
300/1,336  
6 mos to <6 yea rs 
19.0% (16 .9-21 .2) 
2 do ses of 
Adjuvan ted  vacc ine  
4/1,336  
Nolan  
2014 
S. 
America, 
Australi a, 
Asia
2010-
2011
0.5-10  
Yrs.
Rando mize
d con trolled  
trial 
pA/H1N1 
AS03 1.9 μg 
No ad juvant   
<3 Yrs.   
0.25  mL(7.5 
μg) >3 Yrs. 
0.5 ml (15  μg) 
No ad juvan t 
176/1,327  
No ad juvan t 
5/1,327  
   raey 1 deificeps toN Feb ril e seizure on  da y 
42. 
Stock well 
2014  
US
2011-
2012
6-23  mos
Prospe ctive 
coho rt 
TIV  TIV and  PCV13  
 64 /170,   
TIV 12 /159,   
PCV13  8/84  
0/530  chil dren   Adjusted  RR f ever TIV and  PCV13  vs TIV 
alone  2.69  (1.3-5.6) 
7 da ys  Not  spe cified  
Halasa 
2014 
US
2010-
2012
6-35  mos
Rando mize
d con trolled  
trial 
TIV 
0.25  mL(7.5 
μg) 0.5 mL 
(15  μg) 
toN deificeps toN deificeps toN 342/0 deificeps toN  spe cified  
** High fever.
1-cca: chick cell agglutinating units; S. America: South America; MIV: monovalent; TIV-Vic: TIV-B/Victoria; TIV-Yam: TIV-B/Yamagata; MIV: Monovalent inactivated inﬂuenza vaccine; TIV: Trivalent inactivated inﬂuenza vaccine;
QIV:  Quadrivalent inactivated inﬂuenza vaccine; LAIV: Live attenuated inﬂuenza vaccine; IM:  Intramuscular; SC: Subcutaenous; FS: Febrile Seizure; OR: Odds Ratio; IRR: Incidence rate ratio; Mos: months; OPV: oral polio vaccine;
Yrs:  Years; ED: Emergency Department.
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ppendix 5. Epidemiological Evidence for Association between Inﬂuenza Vaccines and Guillain-Barré Syndrome by Inﬂuenza
eason
First author Pub year Study type Inﬂuenza
season(s)
Country Type of vaccine # of cases in
each group
Primary risk
estimate (95%
conﬁdence
interval)
Finding in
children
1 Schonberger 1979 Retrospective
cohort
1976–77 US mH1N1 363 GBS cases
within 6 wks
after vaccination
RR: 9.2
(8.2–10.3)
NA
2  Johnson 1982 Retrospective
cohort
1976–77 US Not speciﬁed 98 cases Incidence not
higher than
previous years
NA
3  Hurwitz 1981 Retrospective
cohort
1978–79 US Not speciﬁed 12 GBS cases
within 8 wks
after
vaccination, 393
unvaccinated
RR: 1.4 (0.7–2.7) NA
4  Kaplan 1982 Prospective
cohort
1979–80 US TIV 7 GBS cases
vaccinated, 412
unvaccinated
(1979–80); 12
cases
vaccinated, 347
unvaccinated
(1980–81)
RR: 0.6
(0.45–1.32)
1979–80; 1.4
(0.8–1.76)
1980–81
NA
5  Roscelli 1991 Retrospective
cohort
1980–88 US Not speciﬁed 289 GBS cases No temporal or
seasonal
differences
NA
6  Stowe 2009 Self-controlled
case series
1990–05 UK Not speciﬁed 12 GBS cases
within 90 days
after vaccination
IRR: 0.76
(0.41–1.40)
NA
7  Hughes 2006 Self-controlled
case series
1992–00 UK Not speciﬁed 3 GBS cases
within 42 days
after
vaccination, 225
cases
unvaccinated
RR: 0.99
(0.32–3.12)
NA
8  Lasky 1998 Retrospective
cohort
1992–94 US Not speciﬁed 19 cases
vaccinated
within 6 wks
prior to GBS
onset, 148
non-vaccine-
associated
cases
RR: 1.7 (1.0–2.8) NA
9  Juurlink 2006 Self-controlled
case series
2000–01 Canada Not speciﬁed 51 GBS cases
within 2–7 wks
after
vaccination, 141
in control period
between 26 and
43 wks
IRR: 1.45
(1.05–1.99)
NA
10  Baxter 2013 Self-controlled
case series
1995–06 US TIV 18 cases
vaccinated
within 6 wks
prior to GBS
onset, 92 cases
vaccinated
within prior 9
months
OR: 1.1 (0.4–3.1) NA
11  Burwen 2010 Self-controlled
case series
2000–01 US TIV 84 GBS cases
within 6 wks
after
vaccination, 80
in control period
of wks 9–14
IRR: 1.04
(0.76–1.43)
NA
12  Greene 2010 Retrospective
cohort
2005–08 US TIV 12, 17, 23 GBS
cases within 42
days after
vaccination (by
year), compared
RR: 0.83, 1.13,
1.37 (by year, no
Cis  provided)
NAto 14.4, 15.1,
16.7 expected
cases based on
historical risk
periods
N
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First author Pub year Study type Inﬂuenza
season(s)
Country Type of vaccine # of cases in
each group
Primary risk
estimate (95%
conﬁdence
interval)
Finding in
children
13 Ho 2012 Retrospective
cohort
2008–09 Taiwan Inactivated, split
non adjuvanted
17 GBS cases
vaccinated, 12
unvaccinated (1
year of
follow-up)
OR:  1.64
(0.77–3.49)
NA
14  Dieleman 2011 Case–control 2009–10 Denmark,
France,
Netherlands,
Sweden UK
mH1N1 (AS03-
adjuvanted)
104 GBS cases
each to 1+
controls
OR: 1.0 (0.3–2.7) 9 children with
GBS included,
no  risk estimate
provided
15  Salmon 2013 Self-controlled
case series,
meta-analysis
2009–10  US mH1N1 54 GBS cases
within 42 days
after
vaccination, 23
within 50–91
days
IRR: 2.35
(1.42–4.01)
2.33
(0.65–10.46)
16  Dodd 2013 Self-controlled
case series,
meta-analysis
2009–10  Australia,
Canada, China,
Denmark,
Finland,
Netherlands,
Singapore,
Spain, UK, US
Variable –
adjuvanted and
non-adjuvanted
risk interval
within 42 days
after vaccination
IRR: pooled 2.86
(1.88–4.34);
meta-analytic
2.42 (1.58–3.72)
Trend of
increasing risk
with increasing
age;  <19 = 0.73
(0.16–3.46)
17  Huang 2013 Self-controlled
case series
2009–10 Taiwan TIV with and
without
adjuvant
5 GBS cases
within 42 days
after
vaccination, 1
unvaccinated
IRR: 3.81
(0.43–33.85)
NA
18  Prestel 2014 Self-controlled
case series
2009–10 Germany mH1N1 (AS03-
adjuvanted) and
seasonal
18  GBS cases in
risk period of
5–42 days after
vaccination, 11
in control period
of 43–150 days
IRR: 2.96
(106–8.25)
1  case in risk
window for
child <10, no
cases in
comparison
window
19  Grimaldi-
Bensouda
2011 Case–control 2007–10 France Not speciﬁed 145 GBS cases to
1080 controls
OR: 1.22
(0.45–3.32)
NA
20  Galeotti 2013 Case–control 2010–11 Italy Inactivated,
mostly
non-adjuvanted
140 GBS cases to
308  controls
OR: 3.8
(1.3–10.5)
NA
21  Greene 2013 Self-controlled
case series
2009–11 US MIV/TIV 18 GBS cases
among 1.27
million 2009–10
MIV and 2.8
million 2010–11
TIV
OR: 1.54
(0.59–3.99)
NA
22  Kwong 2013 Self-controlled
case series
1993–2011 Canada Non-adjuvanted
TIV
69 GBS cases
within 6 wks of
vaccination, 251
during control
interval of 9–42
wks
IRR: 1.52
(1.17–1.99)
1.66  (0.46–6.03)
23  McCarthy 2013 Self-controlled
case series
2009–11 US H1N1, 2009–10
TIV, 2010–11
TIV
6  GBS cases
within 42 days
of vaccination, 3
in comparison
window of
43–84
days(H1N1); 11
cases within 42
days of
vaccination, 7
cases in
comparison
window
(2009–10 TIV);
14 cases within
42 days of
vaccination, 14
days in
comparison
window
(2010–11 TIV)
IRR: 2.0
(0.50–8.0)
H1N1; 1.57
(0.61–4.05)
2009–10 TIV;
1.00 (0.45–2.23)
2010–11 TIV
NA
24  Kawai 2014 Retrospective
cohort
2012–13 US Non-adjuvanted
TIV and LAIV
14 GBS cases
within 42 days
after
RR: 0.5 (0.3–0.9)
in TIV; LAIV one
case in risk and
NAvaccination, 102
in historical
control group
none in control
window
ote: There are additional publications which include subsets of the data published from the US studies in 1976–77 ([216], line 1) and 2009–10 ([217],  line 15) and consequently
hese  studies are not listed in Table.
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ppendix 6. Epidemiological Evidence for Association between Inﬂuenza Vaccines and Multiple Sclerosis by Study Type
First author Pub year Study type Inﬂuenza
season(s)
Country Type of Vaccine # of cases in
each group
Primary risk
estimate (95%
conﬁdence
interval)
Finding in
children
Incident or
relapse
1 DeStefano 2003 Case–control Not speciﬁed US Not speciﬁed 73 cases, 177
controls
OR: 0.7 (0.5–1.1)
ever vaccinated
before MS index
date vs not
NA Incident
2  Hernán 2004 Case–control Not speciﬁed UK Not speciﬁed Vaccinated: 10
cases, 153
controls.
Reference: 153
cases, 1508
controls.
OR: 1.0 (0.5–2.0)
vaccinated
within 3 yrs
before MS index
date vs not
NA Incident
3  Ramagopalan 2009 Case–control Not speciﬁed Canada Not speciﬁed 14362 cases,
7671 controls
OR: 1.02
(0.96–1.09)
vaccinated vs
not, adjusted for
age and sex
NA Incident
4  Bardage 2011 Retrospective
cohort
2009–2010 Sweden Pandemic
A/H1N1, AS03
3795 cases HR: 0.93
(0.68–1.26)
vaccinated vs
not, adjusted for
age,  sex, SES,
healthcare
consumption
Included large
numbers of
children but
results not
stratiﬁed by age
Incident
5  Ho 2012 Retrospective
cohort
2008–2009 Taiwan Unadjuvanted
TIV
8 cases in
persons aged
65+ yrs
Adjusted OR:
0.35 (0.07–1.77)
vaccinated
within 1 yr
before vs not
NA Incident
6  Persson 2014 Prospective
cohort
2009–2010 Sweden Pandemic
A/H1N1, AS03
1003 Adjusted OR:
1.04 (0.95–1.15)
Included large
numbers of
children but
results not
stratiﬁed by age
Incident
7  Myers 1977 Randomized
controlled trial
Not speciﬁed US Whole BIV 33 vaccinated,
33 placebo, 22
no injection
controls
Relapse rate per
patient year: 0.5
vaccinated, 0.5
placebo, 0.7
untreated
control
NA Relapse
8  Bamford 1978 Randomized
controlled trial
1976–1977 US Bivalent swine
ﬂu
65 vaccinated
and 62 controls
No differneces
in neurological
symptoms or
reoccurance by
group
NA Relapse
9  Miller 1997 Randomized
controlled trial
1993 US Seasonal 49 vaccinated
and 54 controls
Annual rate:
0.45 vaccinated,
0.22 placebo; no
statistically
signiﬁant
difference
NA Relapse
10  Mokhtarian 1997 Randomized
controlled trial
1993–1994 US TIV 11 vaccinated
and contrors
MS relapse and
Extended
Disability Status
Score not
different
between groups
NA Relapse
11  Confavreux 2001 Case-crossover 1993–1997 France, Spain,
Switzerland
Not speciﬁed 23 vaccinated in
yr  before relapse
RR: 1.08
(0.37–3.10)
vaccinated
within 2 months
before relapse vs
control period
NA Relapse
12  Auriel 2011 Cohort 2009–2010 Israel Seasonal and
pandemic
A/H1N1
24 vaccinated
with seasonal
and H1N1, 14
seasonal only,
11 H1N1 only,
No new
neurological
symptoms in
any vaccinated
persons;
NA Relapse52 not
vaccinated
Extended
Disability Status
Score not
different
between groups
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Appendix 7. Epidemiological Evidence for Association between Inﬂuenza Vaccines and Narcolepsy by Country
First author Pub year Country Inﬂuenza
season(s)
Type Vaccine Adjuvant Population size # of cases Age group Study type Primary risk
estimate (95%
conﬁdence
interval)
Nohynek 2012 Finland 2009–2010 pA/H1N1 Pandemrix AS03 5.3 million 67 4–19 yrs Retrospective
cohort
IRR: 12.7
(6.1–30.8) within
8 months of
vaccine vs
unvaccinated
Partinen 2012 Finland 2002–2010 pA/H1N1 Pandemrix AS03 not speciﬁed 54 (50
vaccinated)
<17 Modiﬁed cohort IRR: 17 (no CI or p)
2010 vs
2002–2009
MPA 2011 Sweden 2009–2010 pA/H1N1 Pandemrix AS03 57% Swedish
pop
81  (69
vaccinated)
<19 yrs Retrospective
cohort
IRR: 6.6 (3.1–14.5)
vaccinated vs not
Szakács 2013 Sweden 2000–2010 pA/H1N1 Pandemrix AS03 20% Swedish
pop
36  2–17 yrs Modiﬁed cohort IRR: 25
(p < 0.000001)
during vaccination
period vs before
Persson 2014 Sweden 2009–2011 pA/H1N1 Pandemrix AS03 61% Swedish
pop
126  ≤20 yrs Prospective
cohort
HR: 2.92
(1.78–4.79)
vaccinated vs not
O’Flanagan 2014 Ireland 2009–2010 pA/H1N1 Pandemrix AS03 906,280 24 (19
vaccinated)
<20 yrs Retrospective
cohort
IRR: 13.9
(5.2–37.2)
vaccinated vs not
Miller 2013 England 2009 pA/H1N1  Pandemrix AS03 Not
speciﬁed
75 4–18 yrs Case-coverage OR: 16.2
(3.1–84.5)
vaccinated within
6 months before
vs not
Self-controlled
case series
IRR: 9.9 (2.1–47.9)
within 3–6
months of vaccine
vs control period
Winstone  2014 England 2008–2011 pA/H1N1 Pandemrix AS03 16 hospitals 75 (11
vaccinated)
3–18 yrs Retrospective
cohort
not speciﬁed
Dauvilliers 2013 France 2005+ pA/H1N1 Pandemrix
or Panenza
AS03 or
none
Not
speciﬁed
59 cases vs
135 controls
<18 yrs Matched
case–control
OR: 6.5 (2.1–19.9)
vaccinated vs not
18+  yrs OR: 4.7 (1.6–13.9)
vaccinated vs not
Heier 2013 Norway 2009–2010 pA/H1N1  Pandemrix AS03 470,000
vaccinated
58 vaccinated 4–19 yrs Retrospective
cohort
Minimum IR:
10/100,000 within
1 year of vaccine
NA  NA NA approx. 470,000
not
5 not IR: 0.5–1/100,000
unvaccinated
McCarthy 2013 US 2009–2010 pA/H1N1 Not
speciﬁed
Not
speciﬁed
312,914 doses 2 (risk), 19
(comp)
≤24 yrs Self-
controlled
case series
IRR: 0.53
(0.12–2.27) within
90 days of vaccine
vs historical comp
225,343  doses 23 (risk), 215
(comp)
≥25 yrs IRR: 0.95
(0.62–1.46) within
90 days of vaccine
vs historical comp
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First author Pub year Country Inﬂuenza
season(s)
Type Vaccine Adjuvant Population size #  of cases Age group Study type Primary risk
estimate (95%
conﬁdence
interval)
Duffy 2014 US 2009–2010 pA/H1N1 pdm09
strain
Not
speciﬁed
650,995 0 within 180
days
<30 yrs Retrospective
cohort
0 observed
compared to 6.52
expected from
published IR
estimates
2010–2011 seasonal  870,530 2 within 180
days
2 observed
compared to 8.83
expected from
published IR
estimates
Montplaisir 2014 Canada 2009–2010 pA/H1N1 Arepanrix AS03 Quebec:
7,817,449
12 (5
vaccinated)
.5–20 yrs Retrospective
cohort
IRR: 6.39
(1.60–23.38)
vaccinated vs not
8  Self-controlled
case series
IRR: 2.96
(0.71–12.39)
within 16 weeks
of vaccine vs not
8  (6 vaccinated) Case–control OR: 3.21
(0.37–90.37)
Tsai 2011 >25 countries Until 7/10 pA/H1N1 Focetria MF59 23.26 million
doses
0  All ages Retrospective
cohort
not speciﬁed
115  trials Not speciﬁed All Novartis
inﬂuenza
vaccines
79,004 0 Retrospective
cohort
not speciﬁed
Wijnans 2013 Sweden 2000–2010 Vaccine not
part of
analysis
9 million 60 after, 60
before
5–19 yrs Retrospective
cohort
IRR: 7.5 (5.2–10.7)
after 9/09 vs
before 4/09
Finland  .5 million 67 after, 25
before
IRR: 6.4 (4.2–9.7)
after 9/09 vs
before 4/09
Denmark  5.5 million 20 after, 70
before
IRR: 1.9 (1.1–3.1)
after 9/09 vs
before 4/09
Netherlands  1 million 1 after, 2 before IRR: 5.7 (0.6–54)
after 9/09 vs
before 4/09
UK  3.5 million 4 after, 46
before
IRR: 0.9 (0.3–2.5)
after 9/09 vs
before 4/09
Italy  6 million 2 after, 11
before
IRR: 1.1 (0.2–4.9)
after 9/09 vs
before 4/09
ECDC 2012 Sweden and
Finland
2009–2010 pA/H1N1 Pandemrix AS03 Not
speciﬁed
4 cases, 23
controls
≤18 Case–control OR:  15.8
(1.6–inﬁnity) 8–42
days after vaccine
29  cases, 214
controls
OR: 11.4
(1.9–inﬁnity)
43–180  days after
vaccine
Denmark,
Netherlands,
UK,  Italy
and Norway
1 case, 3
controls
OR: 0.6 (0.0–19.7)
8–42 days after
vaccine
8  cases, 11
controls
OR: 9.5 (1.1–461)
43–180 days after
vaccine
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Appendix 8. Epidemiological Evidence for Association between LAIV and Adverse Events
First author Pub year Country Study years Age Study type Vaccine
manufacturer
(name of
vaccine)
Number of
doses studied
Size of study
groups
Time window
studied
Fever and local
reactions
Systemic
reactions
Asthma and
Wheezing
Rudenko 1993 Russia 1989–1991 7–14 yrs Randomized
controlled trial
Russian 1 >100/group Not speciﬁed 0.6% (2/323)
LAIV, 0.7%
(2/278) placebo,
1.8% IIV (5/271
in 7–10 yrs,
8/435 in 11–14
yrs)
Not speciﬁed Not speciﬁed
Slepushkin 1993 Russia 1987–1988 8–15 yrs Randomized
controlled trial
IVSP, Leningrad 2, 4 weeks apart 345 (97 LAIV) 4 days Fever: 2/95
LAIV, 0/78
placebo (Dose 2)
Not speciﬁed Not speciﬁed
Edwards 1994 USA 1985–1990 1–65 yrs Randomized
controlled trial
not speciﬁed Not speciﬁed 5210 Not speciﬁed Redness: 8.3%
placebo, 10.5%
IIV; Induration:
7.1% placebo,
12.1% IIV;
Tenderness: 36%
placebo, 51.1%
IIV (p < 0.00005)
Rhinorrhea:
26.2% LAIV,
19.8% control
(p < 0.00005);
Lethargy: 21.7%
LAIV,18.4% IIV,
16.7% placebo
(p < 0.00005 vs
LAIV); Sore
throat: 20.5%
LAIV, 9.8%
placebo
(p < 0.05);
Myalgia: 15.3%
LAIV (p < 0.05 vs
placebo), 14.1%
IIV, 13.3%
placebo;
Headache: LAIV
22.6% (p < 0.005
vs placebo),
20.7% IIV, 19.7%
placebo; Cough
and GI: no
difference.
Not speciﬁed
Swierkosz 1994 USA Not speciﬁed 2–22 months Controlled trial L. Potash 3, 2 months
apart
17 LAIV, 5
placebo
11 days Fever: 3/17
vaccine, 0/5
placebo (Dose 1)
Cough: 1/17
vaccinees, 3/5
placebos;
Rhinorrhea:
9/17 vaccinees
Not speciﬁed
Gruber  1996 USA 1991 6–18 months Controlled trial Wyeth-Ayerst 1 182 10 days Fever: 5/44
H1N1, 13/45
H3N2, 12/47
bivalent, 10/44
control
Cough: 23/44
H1N1, 23/45
H3N2, 19/47
bivalent, 24/44
control;
Rhinorrhea:
32/44 H1N1,
35/45 H3N2,
35/37 bivalent,
30/44 control
Not speciﬁed
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First author Pub year Country Study years Age Study type Vaccine
manufacturer
(name of
vaccine)
Number of
doses studied
Size of study
groups
Time window
studied
Fever and local
reactions
Systemic
reactions
Asthma and
Wheezing
Rudenko 1996 Russia,
Cuba,
Khazakstan
1986–1991 3–14 yrs Randomized
controlled trial
not speciﬁed 2, 21–28 days
apart
521 LAIV-L, 545
placebo
7 days Fever: no
difference
Cough and
Rhinorrhea: no
difference
Not speciﬁed
Belshe 1998 USA 1995–96 15––71 months Randomized
controlled trial
Aviron 1 vs 2  1314 (2  dose),
288  (1 dose); 2:1
LAIV to placebo
10 days Fever: 15%
vaccine, 11%
placebo
(p = 0.05) (day 2
–  6.5% vs 1.6%
p  < 0.001);
Rhinorrhea: 58%
vaccine, 47%
placebo
(p < 0.001);
Lethargy: 16%
vaccine, 12%
placebo
(p = 0.06)
Not speciﬁed
King, Jr. 2001 USA Not speciﬁed 1–17 yrs Randomized
controlled trial
Aviron 2 24 HIV+, 25
HIV−
not speciﬁed Fever: no
difference
Cough: LAIV
30%, placebo
38%;
Rhinorrhea:
LAIV  39%,
placebo 21%;
Lethargy: LAIV
13%, placebo 0;
Irritability: LAIV
17% placebo
13%;
Not speciﬁed
Piedra 2002 USA 1996–2000 15–71 months Randomized
controlled trial
Aviron Not speciﬁed Yr 1: 1070 LAIV,
532 placebo
42 days (10
acute)
Fever: OR 5.23
(2.48–11.0) (Day
2) (Dose 1), no
difference other
days (Yr 1); OR
4.43
(1.02–19.28)
(Day 3) (Yr 2)
Rhinorrhea: OR
1.61 (1.3–1.99)
(Dose 1), 1.29
(1.02–1.65)
(Dose 2)
(highest days
2–3, persisted
day 8–9);
Lethargy: OR
2.91 (1.51–5.58)
(Day 2);
Irritability: OR
1.81 (1.15–2.85)
(Day 2); GI: OR
1.78 (1.05–3.01)
vomiting, OR 2.0
(1.10–3.65)
Not speciﬁed
Redding 2002 USA 1997–1998 9–17 yrs Randomized
controlled trial
not speciﬁed Not speciﬁed 24 with
asthma/group
7 days before,
28  days after
not speciﬁed not speciﬁed No difference
Bergen 2004 USA 1999–2000 1–18 yrs Randomized
controlled trial
MedImmune 2 in 1–8 yrs; 1  in
9–18 yrs
9689; 2:1 LAIV
to placebo 8.8%
previous
wheeze or
asthma. ***Used
90% CI (not 95).
42  days Not speciﬁed URI: 88.9
visits/1000
person-months
vaccine, 68.9
visits/1000
person-months
placebo in
18–35 month
olds.
RR 4.06 (90% CI
1.29–17.86) in
18–35 month
olds (7 of 16
with
pre-existing
asthma). In all
children with
h/o previous
wheeze, RR 1.11
(90%CI,
0.59–2.14).
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First author Pub year Country Study years Age Study type Vaccine
manufacturer
(name of
vaccine)
Number of
doses studied
Size of study
groups
Time window
studied
Fever and local
reactions
Systemic
reactions
Asthma and
Wheezing
Piedra 2005 USA 1997–2002 1.5–18 yrs Clinical trial MedImmune 1/yr 18,780 doses in
11,096 children
42 days (14
acute)
Not speciﬁed Not speciﬁed no increased
risk in visits in
0–14 days, 1.5–4
yrs had
increased
wheezing days
15–42 (RR 2.85;
1.01–8.03) (Yr
1) 10% with mild
asthma/RAD
Vesikari 2006 Finland 1999–2000 9–36 months Randomized
controlled trial
MedImmune 1 98 LAIV, 99
placebo
42 days (10
reactogenicity)
Fever: 51%
vaccine, 51%
placebo (>38C),
4% vs 10.4%
(>/=39.1), no
difference in
rates
Cough,
Rhinorrhea,
Lethargy,
Irritability, and
GI: no difference
not speciﬁed *1
conﬁrmed case
of vaccine virus
transmission
from vaccinee to
placebo
recipient.
Fleming 2006 13, mostly
Europe
2002–2003 6–17 yrs not speciﬁed Wyeth-Ayerst Not speciﬁed 1114 LAIV, 1115
TIV; all with
asthma
42 days (15
reactogenicity)
Fever: no
difference
Rhinorrhea:
66.2% LAIV,
52.5% TIV
(p < 0.0001);
Headache:
greater in LAIV
vs TIV; Cough,
Lethargy,
Irritability, and
GI: no difference
19.5% LAIV,
23.8% TIV
(p = 0.02) (15
days)
Ashkenazi 2006 9 in Europe 2002–2003 6–71 months
history of
recurrent RTI
Randomized
trial
Wyeth-Ayerst 2, 35 days apart LAIV 1101, TIV
1086; all with
RTI, 40%
wheezing, 23%
asthma
11 days (42
wheezing)
Fever: no
difference. Local
rxns: 31.6% TIV
(Dose 1), 28.9%
(Dose 2); Pain:
24.2% TIV (Dose
1), 23.3% (Dose
2).
Rhinorrhea:
68.3% LAIV,
55.1% TIV
(p < 0.0001)
(Dose 1), 52.1%
LAIV, 44.4% TIV
(p < 0.0001)
(Dose 2);
Decreased
appetite: LAIV
23.9%, TIV 19.8%
(p = 0.031) (Dose
2);  Cough,
Lethargy, and
Irritability: no
difference
no difference *
likely
documentation
of transmission
Belshe 2007 16: USA,
ME, Europe,
Asia
2004–2005 6–59 months Randomized
trial
MedImmune,
Aventis Pasteur
1 or 2 4179 LAIV, 4173
IIV
42 days Fever: 5.4%
LAIV, 2.0% TIV
(p < 0.001)
(>37.8C) (Day 2)
(Dose 1), no
difference (Dose
2)
Rhinorrhea: 57%
LAIV, 46.3% TIV
3.2% LAIV, 2.0%
IIV (<2 yrs)
(Dose 1)
Gaglani  2008 USA 1998–2002 1.5–18 yrs Reanalysis of
Piedra trial data
Aviron,
MedImmune
not speciﬁed 430–656/year;
all with asthma,
RAD or
wheezing
42 days not speciﬁed not speciﬁed Asthma/wheezing:
no increase in
health care
utilization in the
0–14 days or
0–42 period
after  vaccination
vs  reference
times
F58
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First author Pub year Country Study years Age Study type Vaccine
manufacturer
(name of
vaccine)
Number of
doses studied
Size of study
groups
Time window
studied
Fever and local
reactions
Systemic
reactions
Asthma and
Wheezing
Levin 2008 USA 2004–2005 5–18 yrs Randomized
controlled trial
MedImmune,
Aventis Pasteur
1 122 LAIV, 121
TIV
42 days Local rxns: 23%
TIV, 0% LAIV.
Pulmonary: LAI
32%, TIV 26%;
Nasopharyngeal:
52% LAIV, 31%
TIV; Abdominal:
16%  LAIV, 8% TIV;
Constitutional:
no  difference
Not speciﬁed
Neto 2009 S. Africa,
Brazil,
Argentina
2001–2003 6–36 months Randomized
controlled trial
MedImmune Not speciﬁed 3200; 2:2:1:1 11 days Fever: no
difference
Cough: 50.3%
LAIV, 58.2%
placebo
(p  < 0.004);
Rhinnorea,
Lethargy,
Irritability, and
GI: no difference
Not speciﬁed
Breiman 2009 7 in S.
America
and  Asia
2002 6–36 months Randomized
controlled trial
MedImmune
and  Wyeth
2 832 LAIV+OPV,
836
placebo+OPV,
835 LAIV
11 days Fever: no
difference in
rates between 3
groups
Rhinorrhea: 70%
LAIV+OPV, 62.7%
placebo+OPV,
67.2% LAIV alone
(p = 0.006) (Dose
1);  Lethargy:
14.7% LAIV+OPV,
17.3%
placebo+OPV,
12.4% LAIV alone
(p = 0.017) (Dose
1);
Not speciﬁed
Lum 2010 13, mostly
Europe and
Asia
2002–2003 11–24 months Randomized
controlled trial
MedImmune
and  Wyeth
2, MMR with 1st 819 LAIV, 414
Placebo
27 days Fever: 49.9%
LAIV,  41.7%
(p  < 0.001)
(>37.5C) (Dose
1), LAIV 0,
placebo 0.8%
(p = 0.035) (40C)
(Dose 2)
Rhinorrhea: LAIV
70.1%, placebo
51.6% (p < 0.001);
Decreased
appetite: 33.6%
LAIV, 27.7%
placebo
(p  = 0.036);
Not speciﬁed
Mallory  2010 USA 2009 2–17 yrs Randomized
controlled trial
MedImmune 2 260  LAIV, 65
placebo
15 days (8 fever) Fever: 1.5%
LAIV,  1.5%
placebo (≥38.3)
Cough,
Rhinorrhea,
Lethargy: no
difference
Not speciﬁed
Tennis 2011 USA 2007–2009 2–5 yrs Retrospective
cohort
not speciﬁed Not speciﬁed 633 yr1, 2412
yr2  asthma and
wheezing; 12,
89
immunocomp.
42 days Not speciﬁed Not speciﬁed Not speciﬁed no
increase in
hospitalizations
LAIV vs TIV
Carr 2011 USA 2008–2009 2–21 yrs Randomized
controlled trial
not speciﬁed Not speciﬁed 28 LAIV, 27 TIV 28 days Fever: LAIV 0%,
TIV 7.4% (Dose
1)  (Days 0–10),
3.6% LAIV, 14.8%
TIV (Days 0–28).
Local rxns:
14.8% TIV (Days
0–10), 18.5%
(Days 0–28).
Cough: LAIV 7.1%,
TIV 18.5% (Days
0–10), 10.7%
LAIV, 18.5% TIV
(Days 0–28)
(Dose  1);
Rhinorrhea:
35.7% LAIV, 33.3%
TIV (Days 0–10),
42.9% LAIV, 33.3%
TIV (Days 0–28)
(Dose 1);
Irritability: 10.7%
LAIV, 3.7% TIV.
Not speciﬁed
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First author Pub year Country Study years Age Study type Vaccine
manufacturer
(name of
vaccine)
Number of
doses studied
Size of study
groups
Time window
studied
Fever and local
reactions
Systemic
reactions
Asthma and
Wheezing
Halasa 2011 USA 2005–2007 5–17 yrs Randomized
controlled trial
MedImmune 1 10 LAIV, 10
placebo
42 days Fever: 11% LAIV,
10% placebo
(≥37.8C) (Days
0–10)
Cough: 11% LAIV,
10% placebo
(Days 0–10);
Rhinorrhea: 78%
LAIV, 20% placebo
(p = 0.02) (Days
0–10)
Not speciﬁed
Tennis 2012 USA 2009–2010 2–5 yrs Retrospective
cohort
not speciﬁed Not speciﬁed 3457 asthma,
5821  wheezing,
361
immunocomp.
42 days Not speciﬁed Not speciﬁed Not speciﬁed
No  increase in
hospitalizations
LAIV vs TIV
Block 2012 USA 2009–2010 2–17 yrs Randomized
controlled trial
MedImmune 2 in 2–8 yrs; 1 in
9–17 yrs
1385 QLAIV, 464
T/LAIV
B-Yamagata,
463-T/LAIV
B-Victoria
10 days Fever: 5.1%
QLAIV, 3.1%
TLAIV (p = 0.04)
(T>  38) (2–8
yrs), no
difference (T>
38.5), QLAIV
1.2%, TLAIV 0.3%
(T>39.0C)
Irritability: no
difference
Not speciﬁed
Baxter 2012 USA 2003–2008 5–17 yrs Prospective
cohort
MedImmune 1 53369 LAIV,
48683 TIV doses
in 43702; 53366
unvaccinated
42 days Not speciﬁed Not speciﬁed Lower in LAIV vs
TIV
Toback 2013 USA 2007–2010 24–59 months Prospective
cohort
not speciﬁed Not speciﬁed 28226 LAIV,
27937 TIV,
25981
unvaccinated
42 days Not speciﬁed Not speciﬁed Hospitalization
(180 days) lower
in LAIV vs TIV
Kulkarni 2013 India 2009 ≥3 yrs Retrospective
surveillance
Serum Institute
of India
1 7565 7 days based on
recall 1 year
later
Cough: 0.05%;
Runny nose:
0.32%; Stuffy
nose: 0.03%;
Sneezing: 0.11%
0.03%
Boikos 2014 Canada 2012–2013 2–18 yrs Prospective
cohort Self
controlled
MedImmune 1 (2 in 2
subjects)
168 children
with CF
28 days Fever: 38% at
risk, 9% not, RR
4.27 (2.54–7.18)
Cough: 23% at
risk, 13% not, RR
1.77 (1.1–2.86);
Runny nose: 33%
at risk D0–6; 44%
at risk D0–28,
17%  not, RR 2.64
(1.81–3.86);
Nasal congestion:
40% at risk, 14%
not, RR 2.91
(1.91–4.45); Ab
pain: 20% at risk,
4% not, RR 4.86
(2.22–10.65);
Vomiting: 14% at
risk, 2% not, RR
7.67
(2.35–25.05); also
signiﬁcant for
diarrhea (13 vs
3%) and nausea
(13 vs 5%).
Wheezing: 8% at
risk, 2% not
(1.26–14.93)
F accine
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